¡@

Âå®v¸s-¸­°ê°¶Âå®v
²{¥ô¡G
ªL¤fªø©°¨àµ£¹L±Ó®ð³Ý¤¤¤ß¥D¥ô
ªø©°¤j¾Ç¡þªL¤fªø©°¨àµ£Âå¾Ç¤¤¤ß§U²z±Ð±Â¯Å¥DªvÂå®v
¥xÆW¨àµ£®ð(±ó)³Ý¤§¤Í·|²z¨Æ
¥xÆW¨àµ£¹L±Ó®ð³Ý¤Î§K¬Ì¾Ç·|²z¨Æ
¬ü°ê¹L±Ó®ð³Ý§K¬Ì¾Ç·|International Fellowº[¨È¤Ó¦a°Ï©e­û·|©e­û
¼Ú¬w¹L±Ó¤ÎÁ{§É§K¬Ì¾Ç·|·|­û
¥xÆW¨àµ£¹L±Ó®ð³Ý¤Î§K¬Ì¾Ç·|±M¬ìÂå®v
¤¤µØ¥Á°ê§K¬Ì¾Ç·|±M¬ìÂå®v
¤¤µØ¥Á°ê¤p¨à¬ì±M¬ìÂå®v
¾ú¥ô
­^°ê«n¦w´¶¹y§K¬ÌÃIJz¬ì¬ã¨s­û
±Mªø¡G
®ð³Ý¶Eªv»P±Ð¨|¡AÀ¦¥®¨à³Ý»ï¡A¹L±Ó¯g¨¾ªv»P¿zÀË¡A¹L±Ó©Ê»óª¢¡AëC³Â¯l

¡@


¡iÂå¸ô¤ß±o¡j

¹L±Ó¨à±`¨£°ÝÃDÄÀºÃ

®ð³Ý¤§©I§l¹D­«¼Ò²Õ¤Æ
¥Õ¤T²m¯ÀªýÂ_¾¯
Ä_Ä_¡u«¦¡v¤£°±~®ð³Ýªº©~®a·ÓÅ@
¹ï¨àµ£®ð³Ýªº¥t¤@ºØ»{ÃÑ
¨àµ£®ð³ÝªvÀø¤§¹êÃÒÂå¾Ç
¦p¦ó¥¿½T¦YÃÄ
¥®¨à²Ó¤ä®ðºÞª¢¤ÎªÍª¢
Baby¥´©I¬O®ð³Ýªº«e¥ü¡H
²§¦ì©Ê¥Ö½§ª¢
²¾°£«Ç¤ºªº¹L±Ó­ì
®ð³ÝªvÀøªº²{ª¬»PÁͶÕ
­^­Ûªì©]
AAAAI 60¶g¦~¼y---¤¦¦ò¬ö¦æ
¡@

Survey of the Clinical Practice of Physicians in
the Management of Asthma in Taiwan


Allergens and Allergic Diseases in Children
¡@

Survey of asthma care in Taiwan: a comparison of asthma
specialists and general practitioners

¡@


¹L±Ó¨à±`¨£°ÝÃDÄÀºÃ

ªø©°¨àµ£¹L±Ó®ð³Ý­·Àã¬ì ¸­°ê°¶ Âå®v

¤£»Ý±´¨s²`¼hªº­ì¦]¡A¨àµ£¹L±Ó®ð³Ýªº²±¦æ²v¤é¯q¼W°ª½T¬O¤£ª§ªº¨Æ¹ê¡C·í®aªø¥b©]Å¥¨ì¦Û¤vªºÄ_¨©«y¤£°±¬Æ¦Ü©I§l§xÃø®É¡A¨ººØ¨­¤ßªº·Î¼õµ´«D¥~¤H¯à·Q¹³¡C­YÂå¥Í§P©w¤pªB¤Íªº¤[«y«K¬O®ð³Ý¡A°£¤F¤ß¦sºÃ´b¥~¡A±N¨Óªºªø´Á§Ü¾Ô§óÅý¤H¤O¤£±q¤ß¡C¬°¤F¦Û¤vªº¤p«Äªº°·±d¡A¦UºØ¤f¦Õ¬Û¶Çªº¥P¤¦§®ÃĤ]³£Ä@´M¨D¹Á¸Õ¡CµM¦Ó¹ï¹L±Ó®ð³Ýªº¤@ª¾¥b¸Ñ¡A¤Ï¦Ó¬O³y¦¨®ð³Ý¤£©ö±±¨îªº­ì¦]¤§¤@¡C¦b¦¹´£¥X¤@¨Ç¦bªù¶E¤¤±`¨£ªºªº°ÝÃD¡A²¦³º¹ï®ð³Ý¦³§ó¥¿½Tªº»{ÃÑ¡AªvÀø¤Wµ´¹ï¯à¨Æ¥b¥\­¿¡C¤U¦C´X­Ó°ÝÃD¦bªù¶E®É±`³Q°Ý¤Î¡A¤]¬O¹ï®ð³Ý¯fÀ³¦³ªº»{ÃÑ¡A¦b¦¹µy§@»¡©ú

 

1.    ­n¥ÎªÅ®ð²M²b¾÷ÁÙ¬O°£Àã¾÷¶Ü¡H

²  ¾A·íªº¬Û¹ïÀã«×¤£¶È¤Hı±oµÎ¾A¤]¯à´î¤Ö¹Ð蟎ªº¥Í¦s¡A´î¤Ö¹Ð蟎ªº¦s¦b¦ÛµM´î¤Ö¹L±Ó­ì±µÄ²ªº¾÷·|¡A«K¯à¹w¨¾¹L±Ó¯gª¬ªº²£¥Í¡C¥Ñ©ó¹Ð蟎¥­®É¨Ã¤£·|¨ì³B­¸´­¡A¦]¦¹­Y¹Ð蟎¤£­¸´­®ÉªÅ®ð²M²b¾÷ªº®ÄªG¨Ã¤£¤j¡C¦ý¬OªÅ®ð²M²b¾÷¹ïÃdª«ªº¥Ö®h©Î¤G¤â·Ïµ¥¤Þ°_®ð³Ýªº¹L±Ó­ì©Î¨ë¿Eª«¬O¦³¹LÂoªº®ÄªG¡C

2.    »Ý­n¨Ï¥Î¨¾蟎¹ì¨ã¶Ü¡H

²  ¦³³ø§i«ü¥X¨¾¹Ð蟎¹ì¨ã¯à¦³®Ä¹jµ´¹Ð蟎ªº­¸´­¤Î§l¤J¡A¦ý¤@¯ë¦Ó¨¥»ù®æ¨Ã¤£«K©y¡C¦]¦¹¸û¸gÀ٤覡«K¬O¦Ü¤Ö¹j¨â¬P´Á±`´«¬~§É³æ³Q®Mµ¥¡C¬~«á¯à¯M°®©ÎÅΰ®¬Ò¯à±þ¦º¹Ð蟎¡C

3.    ®ð³Ý¨à­þ¨Ç­¹ª«¤£¯à¦Y¡H¯à¤£¯à¦Y¦B¡H

²  °£¤F¾á¤ß®ð³Ýµo§@¥~¡A¨àµ£ªº¦¨ªø¤]»Ý§¡¿ÅªºÀç¾i¡C¦]¦¹°£«D¬YºØ­¹ª«·|¹ï¤pªB¤Í²£¥Í©úÅ㪺¹L±Ó¤ÏÀ³¡A§_«h¤£»Ý§O¸T­¹¡C¬ã¨sÅã¥Ü¬ù¤T¤À¤§¤@ªº¤pªB¤Í³Ü¦B¤ô·|¦³©I§l¹D±Ó·P¤ÏÀ³¡A¤]ªí¥Ü³oºØ¤ÏÀ³¦]¤H¦Ó²§¡A¦]¦¹¤£»Ý§¹¥þ¸T¤î¡C

4.    §lÃþ©T¾J·|¤ë«GÁy¡Aªø¤£°ª¡H

²  ªvÀøºC©Ê®ð³Ýªº¤@­Ó­«­n¤è¦¡«K¬O§l¤JÃþ©T¾J¡AµM¨ä´c¦W¬L¹ü¡A»D¤§²ö¤£¦âÅÜ¡CµM¦Ó±j½Õ¨ä¬°§l¤J©ÊÃþ©T¾J¡A»P¤@¯ë¤fªAªºÃþ©T¾J¾¯¶q¬Û®t·¥¤j¡C¥t¥~¥ç¦³¤j«¬¥Bªø´Á«ÈÆ[ªº¬ã¨sÅã¥Üªø´Á§l¤JÃþ©TÃþ©T¾J¨Ã¤£¼vÅT¨­°ª¡A·íµM¤£·|¦³¤ë«GÁy©Î¤ô¤ûªÓ¡C¦ý§l¤JÃþ©T¾J¤Ï¦Ó®ð³Ý¯gª¬§óí©w¡Aí©w«á¦ÛµM¤£·|±`¦YÃĩάݯf¡C

5.    ªø´Á¥ÎÃÄ·|¤£·|¦³°Æ§@¥Î¡H

²  ªvÀø®ð³Ý¯fÁöµM»Ý­n®É¶¡¦ý¤£»Ý­nªø´Á¦YÃÄ¡A¦]¦¹¤£·|¶Ë¨x¶ËµÇ¡C¨Ï¥Î§l¤J©ÊÃĪ«ªº¾¯¶q·¥§C¡A¤]¤£·|¦³¥ô¦ó¼vÅT°·±dªº°Æ§@¥Î¡C¦ý¹ï®ð³Ý·|¦³¥¿­±À°§U¡C

6.    ¥i¥H¥Î¤¤ÃĨӪvÀø«O¾i®ð³Ý¶Ü¡H¸Á½¦¡A¥VÂήL¯ó¦³®Ä¶Ü¡H

²  ¤¤Ãijդjºë²`¡A¬y¶Ç¤d¦~¦Û¦³¨ä»ù­È¡AµM¦Ó¥i±¤¯Ê¥F¬ì¾ÇÃÒ¾Ú¡C¦Ó¦èÃĥΩó¤HÅ饲¬O¸g¥Ñ¤ÏÂÐÅçÃÒ«á¤~¯àÀ³¥Î¡C³ø³¹Âø»x³ø¾É¤§¤¤ÃĩηsÃĨӪvÀø®ð³Ýµ¥µ¥¡A¦³¨Ç¥uÀ³¥Î©ó°Êª«¡A©|¥¼À³¥Î©ó¤HÅé¡A¤]¤£ª¾¹ï¤HÅ骺¼vÅT¡A¦]¦¹¸ÑŪ¤W­n¤p¤ß¡C

 

¹ï©ó®ð³Ýªº»{Ãѵ´¤£¬O¥H¤W´X­Ó°ÝÃD´N¯à§¹¥þ²[»\¡A¹ï©ó®ð³ÝªºªvÀø¤]µ´¤£¬O¥u¾aÂå¥Íªº¥ÎÃÄ¡A¦Ó§ó»Ý»P¨àµ£¹L±Ó±M¬ìÂå®v·¾³q¡C§ó¤F¸Ñ®ð³Ýªº­P¯f¦]¤l¡A¤F¸Ñ¦Û¤vªº¤pªB¤Íªº¥ÎÃı¡§Î¤ÎÃĪ«¯S©Ê¡C®ð³Ý¬O¤@ºØºC©Ê¯e¯f¡AªvÀø¤Wµ´¹ï»Ý­n®É¶¡¤Î­@¤ß¡A¥u¦³§ó»{ÃÑ®ð³Ý¡A¤~¤£¦Ü©óÅå·W¥¢±¹¡A¤]¤~¯àÅý¨àµ£¦­¤é²æÂ÷®ð³Ýªº³±¼v¡C


¡@

¡@

®ð³Ý¤§©I§l¹D­«¼Ò²Õ¤Æ
¡@

ªL¤fªø©°¨àµ£Âå°|
¨àµ£¹L±Ó®ð³Ý­·Àã¬ì ¸­°ê°¶Âå®v
¡@


¦b¹L¥h¼Æ¤Q¦~¨Ó®ð³Ý¤@ª½³Q»{¬°¬O¤@ºØ¥i°f©Êªº©I§l¹D¹L«×¤ÏÀ³¡A¤]´N¬OÁaµMµo§@®ÉªÍ¥\¯à¨ü¼vÅT¦ýµo§@«á¨äªÍ¥\¯à¤´·|«ì´_¥¿±`ª¬ºA¡C¦b1960¦~¥N¡A®ð³Ý³Q»{¬°¥u¬O©I§l¹Dªº¦¬ÁY©Ò³y¦¨ªº¯e¯f¡A¦]¦¹¦b¨Ï¥ÎªºÃĪ«¤WµÛ­«©ó¤ä®ðºÞÂX±i¾¯©Î¯ùÆPÃþªºÃĪ«¡C¦Ó¦b¹ï®ð³Ýªº­P¯f¾÷Â঳§ó¦hªº¤F¸Ñ«á¡Aµo²{¨ä¥»½è¤D¬O¤@ºØµoª¢ªº¤ÏÀ³¡A¦]¦¹ª½¨ì²{¤µ¡A§l¤J©ÊªºÃþ©T¾J¤´¬O¥Ø«eªvÀøªº¥D¬y¡A¥D­n¬O°ò¥»¸Ñ¨M¦]©I§l¹Dµoª¢¦Ó¾É­Pªº®ð³ÝÁ{§É¯gª¬¡CµM¦Ó¦b­ô¥»«¢®Úªº¤@¶µ¬ã¨s¤¤µo²{¦³6.25%ªº®ð³Ý¯f¤H¦b15¦~ªºªø´Á°lÂÜ«á¡A¨äªÍ¥\¯à¦³©úÅ㪺³vº¥¤U­°ªºÁͶÕ1¡C¦³¨Ç¯f¤H§Y¨Ï¥Îªø´Áªº§l¤J©ÊÃþ©T¾JªvÀø¡A¨ä©I§l¹D¤´§e²{«ùÄò©Êªº¹L«×±Ó·Pªí²{¡COsward et al.¥ç´£¥X³ø§i»¡©ú¦b¨àµ£´Á«K¶}©l¦³¤ÏÂÐ¥B«ùÄò©Êªº®ð³Ý¯gª¬ªº¯f¤H¡Aª½¨ì¤¤¦~¨äªÍ¥\¯à¤´¥¼¯à«ì´_¥¿±`2¡C¥Ñ³o¨Ç³ø§iÅã¥Ü®ð³Ý¦ü¥G¦³¨ä¤£¥i°fªº¥»½è¡C¦]¦¹®ð³ÝÀ³¤£¥u¬O©I§l¹D¦¬ÁY©Îµoª¢¦Ó¤w¡Aªñ´X¦~©I§l¹D­«¼Ò²Õ¤ÆªºÆ[©À¤]º¥º¥³Q´£¥X°Q½×¡A¦Ó¥B¦b³y¦¨®ð³Ýªº¯f²z¥Í²z¾Ç¤W§êºtµÛ¤@©wªº¨¤¦â¡A¤]¬O¥¼¨Ó¦bªvÀø®ð³Ý¤W»Ýª`­«ªº²{¶H¡C

­«¼Ò²Õ¤Æ
©Ò¿×ªº­«¼Ò²Õ¤Æ¬O«ü¦b¤@¯}Ãaªº¹Lµ{«á­«·s²Õ´«ì´_­ì»ª©ÎªÌ¤£§¹¥þ¦^´_­ìª¬¡C¦b©I§l¹D«hªí²{¦bµoª¢¤ÏÀ³«á©Î¦P®É¡A°ò½è(matrix)¥Í¦¨©Î¯}Ãa¤§¶¡ªº¤@ºØ°ÊºA¥­¿Å¡A¤]´N¬O©I§l¹D²Õ´¥¿±`ªº­««Ø©Î¬O¯f²z¤Wªº­×¸É¡C¦b¯f²z¾Ç¤WªºÅܤƤW®ð³Ýªº©I§l¹D­«¼Ò²Õ¤Æ«hªí²{¥Xªí¥Ö²Ó­M¤U¼hÅÖºû¤Æ(subepithelial fibrosis)¡AªMª¬²Ó­M¼W´Þ( goblet cell metaplasia)¡A©I§l¹D¥­·Æ¦ÙªÎ«p(smooth muscle hypertrophy)¡A¦ÙÅÖºû¥À²Ó­M¼W¥Í(myofibroblast hyperplasia)¡Aµ²½l²Õ´¨I¿n¡A¦åºÞ¼W¥Íµ¥µ¥¡C³o¨Ç¹Lµ{¥i¯à¬O¦UºØ¹L±Ó­ì©Î«D¹L±Ó­ìªº¨ë¿E«á¾É­Pµoª¢¤ÏÀ³Ä~¦Ó­«¼Ò²Õ¤Æ¡CµM¦Ó¤]¥i¯à¬O¨ë¿E«á¦P®É¤Þ°_µoª¢¤Î­«¼Ò²Õ¤Æªº¤ÏÀ³¡C¨âªÌ¤§¶¡ªº¦]ªGÃö«Y¤´¤£²M·¡¡C

­«¼Ò²Õ¤Æ»PÁ{§É¬ÛÃö
¬ã¨sµo²{©I§l¹DºÞ¾Àªº«p«×»P®ð³ÝÄY­«µ{«×¤Î©I§l¹Dªý¶ëµ{«×§e¥¿¬ÛÃö¡C­«¼Ò²Õ¤Æ©óÁ{§É¤W«á¥i¤Þ°_®ðºÞ¾À¼W«p¡A¦Ó®ðºÞ¾À¼W«pªºªí²{¥ç¨£©ó¦UºØ¤£¦PÄY­«µ{«×ªº®ð³Ý¯f¤H3¡CChetta et al.µo²{¦b»´¡A¤¤¤Î­««×ªº®ð³Ý¨ä®ðºÞªí¥Ö²Ó­M¤Uªºµ²½l²Õ´¥ç¦³¤£¦Pµ{«×ªº¨I¿n4¡C§Q¥Î°ª¸ÑªR«×¹q¸£Â_¼h(high-resolution computed tomography)ªºÀˬd¦b¨àµ£®ð³Ý¤]¥iµo²{¦³®ðºÞ¾À¼W«p¡AªÍ®ð¸~¤ÎªÍ¶ò³´ªº²{¶H¡A¤]¶¡±µÃÒ©ú¨àµ£´Á®ð³Ý¥ç¦³­«¼Ò²Õ¤Æªºªí²{5¡C¤]´N¬O®ðºÞªººôª¬°ò©³½¤(reticular basement membrane)»P­«¼Ò²Õ¤Æ¤ÎÁ{§Éªí²{ªº½T¦³Ãö«Y¡C

­«¼Ò²Õ¤Æªº¤¶½è
¾ã­Ó­«¼Ò²Õ¤Æªº¹Lµ{¦³³\¦h¤¶½èªº°Ñ»P¡A¦UºØ¤¶½è©¼¦¹²o¨îªº°ÊºA¥­¿Å³y¦¨³Ì«áªº¯f²zÅܤơCµM¦Ó²¦³º¬O¤@·sªºÆ[©À¡A¦]¦¹¤´¥¼¦³¤@²M·¡¦Ó§¹¾ãªº¾÷Âà¨Ó¸ÑÄÀ¾ã­Ó¹Lµ{¡C¥t¤@§xÃø¦b©ó®ðºÞ²Õ´¤Á¤ù¨Ã¤£©ö±o¡A¥H¤Î¦b®É¶¡ÂIªº¿ï¾Ü¤W¥ç¬O»Ý¦Ò¶qªº¦]¯À¡C§ó¹N½×®ð³Ý¨àµ£ªº²Õ´¤Á¤ù§ó¬O¤£©öÀò±o¡CTransforming growth factor-£](TGF-£]) ¦b®ð³Ý­«¼Ò²Õ¤Æ¬O¤@­«­n¦]¤l¡A¨ä¥i¨ë¿EÅÖºû¥À²Ó­M¥Íªø¦ý§í¨îªí¥Ö²Ó­M¼W¥Í6¡C°ò©³½¤«p«×¶V«p¡AÅÖºû¥À²Ó­M¶V¦h¡A¯e¯fÄY­««×¶V¼F®`¡A«hTGF-£]ªºªí²{¤]¶V©úÅã7¡CEpidermal growth factor(EGF) ¤]¥i¨ë¿E©I§l¹D¥­·Æ¦Ù¤Îªí¥Ö²Ó­M¼W¥Í¡A¤]¥i¼W¥[fibronectinªº¦X¦¨¡C¹ï®ðºÞ¾Àªº²Õ´¤Á¤ù§Q¥Î§K¬Ì²Õ´¤Æ¾Ç¬V¦â¥iµo²{EGF¤Î¨ä±µ¨üÅéepidermal growth factor receptor (EGFR)¦bªí¥Ö²Ó­M¡A°ò©³½¤¡A®ðºÞ½uÅé²Ó­M¤W¦³«D±`©úÅ㪺§e¦âªí²{¡A¥çªí¥Ü¨ä¹ï­«¼Ò²Õ¤Æ¦³¤@©wµ{«×ªº°Ñ»P8¡C¦ÓEGFR¥ç¥i¦b®ð³Ý¯f¤H¦]¯f¦Ó³Q¯}Ãaªºªí¥Ö²Ó­M¤Î«¬ºA§¹¾ãªºªí¥Ö²Ó­M¤W¦³©úÅ㪺ªí²{¡A¦Óªí²{ªºµ{«×»P°ò©³½¤¤Uªºµ²½l²Õ´ªº«p«×¦³¥¿¬ÛÃö9,10¡C¦b¹êÅç«Ç¤¤§Q¥Î¤H¤u¤è¦¡±N°ö¾iªº³æ¼hªí¥Ö²Ó­M¯}Ãa¡A¥iµo²{EGF¥[³t²Ó­M­×´_¡F¦Ó¥[¤JEGFRªº§í¨î¾¯«h§í¨îEGFªº­×¸É§@¥Î¡A¦¹±¡ªp¤UTGF-£]ªº¼Æ¶q¤]µo²{¼W¥[9¡C

¥t¥~matrix metalloproteinase (MMP)¤Îmatrix matalloproteinase inhibitor (TIMP)¤§¶¡ªº°ÊºA¥­¿Å¤]¬OÅÖºû¤Æ¹Lµ{ªº­«­n¦]¯À¡C¦b­«¼Ò²Õ¤Æªº¹Lµ{¤¤MMP¥i¥H¯}Ãa°ò©³½¤¤Î²Ó­M¥~°ò½è(extracellular matrix)¡A¬Û¤Ïªº¡ATIMP´X¥G¥i¥H§í¨î©Ò¦³MMPªº¬¡©Ê¡C¦b®ð³Ý«æ©Êµo§@®É¡A¯f¤Hªº®ðºÞ¨R¬~²G¤¤¥iµo²{¤j¶qªºMMP-911¡A¦P®É¦b®ðºÞ²Õ´¤Á¤ù¤¤µo²{MMP¤]©Mªí¥Ö²Õ´¤UªºÅÖºû¤Æ¤ÎFEV1¤U­°¦³Ãö12¡CMMP»PTIMP¤§¶¡ªº¤£¥­¿Å«K·|³y¦¨©I§l¹Dµ²ºcªº§ïÅÜ¡C¥t¥~¤]µo²{¨Ç®ð³Ý¯f¤H¦å²M¤¤ªºMMP-9/TIMPªº¤ñ­È­Y§C«h¹ïÃþ©T¾Jªº¤ÏÀ³¤£¨Î¡A¤]Åã¥Ü®ðºÞªºÅÖºû¤Æ¬O©úÅ㪺13¡C

Elastase¤Î£\1-antitrypsin «h¬O¥t¤@²Õ¤¶½è¨Óºû«ù²Ó­M¥~°ò½èªº¥­¿Å¡C¹ï®ð³Ý¯f¤H°µ»¤µo·ð²G¸ÕÅç¥i´ú¨ì¨âªÌªº¼Æ­È¬Ò¼W°ª¡C¦Ó¥Belastaseªºµ{«×¶V°ª«h®ð¹D¯U¯¶µ{«×¶V©úÅã14¡C·íµM¤åÄm¤W¤´¦³³\¦h¤¶½è¥i¯à°Ñ»P­«¼Ò²Õ¤Æªº¹Lµ{¡A¤]ÃÒ©ú¦¹¹Lµ{ªº½ÆÂø©Ê¡C

­«¼Ò²Õ¤Æ»Pµoª¢¤ÏÀ³
¦h¦~¨Ó®ð³Ý¤@ª½³Q»{¬°¬O¤@ºØ¥i°f©Êªº¯gª¬¡AµM¦Ó¦³¤@³¡¤Àªº¯f¤HÁöµMÁ{§É¤WµL¯gª¬¡A¦ý¬Oªº½T¤´¦³ÃÒ¾ÚÅã¥Ü¨ä©I§l¹D¬O¯U¯¶ªº¡C®ð³Ýµo§@®É³y¦¨©I§l¹Dªí¥Ö²Ó­M­é¸¨¤Î¤@³s¦êµoª¢¤ÏÀ³¡C¦ý¤]¦P®É¤Þ°_­×´_¤Î­«¼Ò²Õ¤Æªº¹Lµ{15¡CLaprise et al.´£¥X®ðºÞ¦³¹L«×±Ó·P¤ÏÀ³¦ýµLÁ{§É®ð³Ý¯gª¬ªº¯f¤H®ðºÞ¤Á¤ù«K¦³ªí¥Ö¤UÅÖºû¤Æªº²{¶H¡A¦ý«á¨Ó¤~¯u¥¿µo¥Í®ð³Ý16¡C¥t¥~¦b·s¶EÂ_¬°®ð³Ý¯f¤H¤Î±w¦³®ð³Ý¦h¦~ªº¨â²Õ¯f¤Hªº®ðºÞ¤Á¤ùµo²{¨Æ¹ê¤W¤GªÌªí¥Ö¤UÅÖºû¤Æªºµ{«×¬O®t¤£¦hªº17¡C¥Ñ©ó®ð³Ý¨àµ£ªº®ðºÞ¤Á¤ù·¥ÃøÀò±o¡A¦b¥®¨à¶È¦³ªºªº¤Á¤ù³ø§i¤]µo²{±N¨Óµo®i¬°®ð³Ýªº¨àµ£¡A¦b¥®¨à®É«K¦³ªí¥Ö¤UÅÖºû¤Æªº²{¶H¡A¾½¥ì¬õ©Ê²Ó­Mªº¬V¦â¤]¸û¦h18¡C³o¨ÇÃÒ¾Ú¤]ªí¥Ü­«¼Ò²Õ¤Æ¤]³\¦­¤wµo¥Í¡C

­«¼Ò²Õ¤Æ»PÃþ©T¾J
§l¤J©ÊÃþ©T¾J¤´¬O¥Ø«eªvÀø®ð³Ýªº¥D¬yÃĪ«¡C³\¦hªº¬ã¨s³£ÃÒ©ú¨ä¦b¯f²z¤W¥i´î§Cµoª¢¤ÏÀ³¡AÁ{§É¤W¤]§ïµ½¯gª¬¡C¶V¦­¨Ï¥Î§l¤J©ÊÃþ©T¾JªvÀø·U«á¤]¶V¦n19¡C¦ý¨ä¬O§_¯à§ïÅÜ®ðºÞ­«¼Ò²Õ¤Æªº²{¶H¦Ü¥Ø«e«h¥¼¦³©w½×¡C¦³¬ã¨sÅã¥Ü§l¤J©ÊÃþ©T¾J¥i´î§Cªí¥Ö¤U¸`½l²Õ´ªº¨I¿n¤Î°ò½èªº¼W«p20,21¡C¥t¥~ªº¬ã¨s³ø§i«hªí¥Ü¤£¯à´î§C°ò½èªº«p«×22,23¡C

Á`µ²
®ðºÞ¾À«p«×ªº¼W¥[¡A²Ó­M¥~°ò½èªº§ïÅܪº½T·|³y¦¨®ðºÞªº¹L«×±Ó·P¤ÏÀ³¡C¦ý¤]¤£¬O©Ò¦³ªº­«¼Ò²Õ¤Æªº¯f²zÅܤƳ£¤@©w·|¦³Á{§É¤Wªº·N¸q¡C¹ï©ó®ð³Ý¤§­«¼Ò²Õ¤Æ¬O§_¥i°f¡H¦h¦­·|µo¥Í¡H­þ¤@Ãþ®ð³Ý¯f¤H·|ªí²{¥X­«¼Ò²Õ¤Æ¡H¬O§_¦³¤@Àˬd¯à¥Nªí­«¼Ò²Õ¤Æªºµ{«×¡H¤´¦³¤Ó¦hªÅ¶¡¤]¤´»Ý®É¶¡¶i¤@¨BÂç²M³o¨ÇÆ[©À¡A¤]¤~¯à§ó¶i¨B¤F¸Ñ¼vÅT¤HÃþ¥Í¬¡¬Æ¼@ªº®ð³Ý¡A¦Ó´£¥X§ó¦³®ÄªºªvÀø¤è¦¡¡C

References
1. Lange, P, Parner, J, Vestbo, J, Schnohr, P, Jensen, G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339:1194-1200, 1998
2. Oswald H, Phelan P, Lanigan A, et al. Childhood asthma and lung function in mid-adult life. Ped Pulmonl 23:14-20, 1997
3. Niimi A., Matsumoto H., Amitani R. et al. Airway wall thickness in asthma assessed by computed tomography. Am J Respir Crit Care Med 162:1518-23, 2000
4. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airway remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 111:852-7, 1997
5. Carnimeo N, Mappa L, Guidi G, Nigro A, Silletti M. Computed lung tomography in pediatric asthma. Chest 118:198s, 2000
6. Vignola AM, Chanez P, Chiappara G, Gafliardo R, Bonsignore G, Bousquet J. Growth factors in the remodeling of asthma. Allergy Clini Immunol Int 10:149-53, 1998
7. Vignola AM, Chanez P, Chiappara G, Merendino A, Pace E, Rizzo A. la Rocca AM, Bellia V, Bonsignore G, Bousquet J. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. American Journal of Respiratory & Critical Care Medicine. 156:591-9, 1997
8. Amishima M, Munakata M, Nasuhara Y, Sato A, Takahashi T, Homma Y, Kawasaki Y. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am J Respir Crit Care Med 157:1907-12, 1998
9. Puddicombe SM. Polosa R. Richter A. Krishna MT. Howarth PH. Holgate ST. Davies DE. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB Journal. 14:1362-74, 2000 Jul
10. Davies D, Polosa R, Puddicombe S, Richter A, Holgate S. The epidermal growth factor receptor and its ligand family: their potential role in repair and remodeling in asthma. Allergy 54:771-83, 1999
11. Mautino G, Henriquet C, Jaaffuel D, Bouequet J, Capony F. Tissue inhibitor of metalloproteinase-1 levels in BAL fluid from asthmatics. Am J Respir Crit Care Med 160:324-30, 1999
12. Hoshino M, Nakamura Y, Sim J, Shimojo J, Isogai S. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 102:783-8, 1998
13. Bosse M, Chakir J, Rouabhia M, Boulet LP, Audette M, Laviolette M. Serum matrix metalloprteinase-p:tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 159:596-602,1999
14. Vignola AAM, Bonanno A, Mirabella A, Riccobono L, Mirabella F, Profita M, Bella V, Bousquet J, Bonsinore G. Increased levels of elastase and £\1-antitrypsin in sputum of asthmatic patients. Am J Respir Crit Care Med 157:505-11, 1998
15. Latinen A, karjalainen EM, Altrajaa A, Latinen LA. Histopathologic features of early and progressive asthma. J Allergy Clin Immunol 105:S509-13, 2000
16. Laprise C, Laviolette M, Boulet M, Boulet LP. Asymptomatic airway hyperresponsiveness: relationships with airway inflammation and remodeling. Eur Respir J 14:63-73, 1999
17. Boulet LP, Turcotte H, Laviolette M, Naud F, Bernier ML, Martel S, Chakir J. Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Am J Respir Crit Care Med 162:1308-13, 2000
18. Pohunek P, Roche WR, Turzikova J. Kudrmann J, Warner JO. Eosinophilic inflammation in the bronchial mucosa of children with bronchial asthma. Eur Respir J 10:160(S), 1997
19. Selrooss O, Pietinalho A, Lofroos AB, Riska H. Effect of early vs. late intervention with inhaled corticosteroids in asthma. Chest 108:1228-34, 1995
20. Hoshino M, Takahashi M, Takai Y, Sim JJ. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 104:356-63,1999
21. Olivieri DA, Chetta M, Del Donno G, Bertorelli A, Casalani A, Pesci R, Testi A. Effect of short-term treatment with low-dose inhaled Fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 155:1864-71
22. Jeffery PJ, Godfrey RW, Adelroth E, Nelson F, Rogers A, Hohansson SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: a quantitative light and electron microscopic study. Am Rev Respir Dis: 145: 890-9, 1992
23. Saetta M, Mawstrelli P, Turato G, Mapp CE, Milani G, Pivirotto F, Fabbri LM, Stefano AD. Airway wall remodeling after cessation of exposure to isocyanates in sensitized asthmatic subjects. Am J Respir Crit Care Med 151:489-94,1995




¡@

¥Õ¤T²m¯ÀªýÂ_¾¯ 

ªø©°¨àµ£¹L±Ó®ð³Ý­·Àã¬ì

¸­°ê°¶Âå®v

2002¦~¥@¬É®ð³Ý±M®a®Ú¾Ú·sªº¬ã¨sÃÒ¾Ú¦@¦P´£¥X®ð³ÝªvÀø·Ç«hGINA (Global Initiative for Asthma) guidelines¥H¤Î¡u¬ü°ê°ê®a¤ßªÍ¦å²G²Õ´¡v(NHLBI)¤]µoªí¤FªvÀø®ð³Ýªº«ü¼Ð¡A¨ä¤¤§l¤J©ÊÃþ©T¾J¤´¬O¦U¦~ÄÖ¼hªvÀø¤¤­««×¥H¤W®ð³Ýªº­º¿ïÃĪ«¡C²³¦hÃÒ¾Ú¤]Åã¥Ü¨äªº½T¥i§ïµ½®ð³Ý¯gª¬¡CµM¦Ó¨­¬°®aªø´Nºâ¯à¿í±qÂåÅñ¡A¤]¤F¸Ñ§l¤J©ÊÃþ©T¾Jªº­«­n¥~¡A¨C¤Ñ­n»P¤pªB¤Í¾Ä¾Ô¨Ï¥Î§l¤J©ÊÃĪ«¡A¬Û«H¤£¥X¤@¬P´Á«K±N§l¤J©ÊÃĪ«»P»²§U¾¹§ô¤§°ª»Õ¡A±ó¥Ò§ë­°¤F¡Cµ¥¨ì¦³¯gª¬¤~·|¦A§äÂå¥Í³B²z¡A©Îı±o¯f«ç­Ì¬Ý³£¤£·|¦n¡A¦¹ºØ±¡¸`¤@¦A­«ºt¡A¤]¬O©Ò¦³®aªø±`¹J¨ìªº¥Í¬¡ÃøÃD¡C¨ä¹ê¤£¬OÃĨS®Ä¡A¦Ó¬OÃĪ«¨Ï¥Î§Þ¥©¤W¤£ªñ¤H±¡¡A¹N½×¹ï©ó¦~¬ö¤p´Nºâ¦³²z¤]»¡¤£²Mªº¥®µ£¡A§ó¬OÃø¤W¥[Ãø¡C

¥Õ¤T²m¯ÀªýÂ_¾¯ºâ¬Oªñ´X¦~¨ÓªvÀø®ð³Ýªº¤@ºØ­²©R©ÊÃĪ«¡A¦o¤£¬OÃþ©T¾J¡A¤]¤£¬OÂX±i¾¯¡Aºâ¬O¤@ºØªø´Á«O¾iªº§Üµoª¢ÃĪ«¡C¦b¥xÆW¾A¦X¤pªB¤Í¨Ï¥Îªº¦¹ÃþÃĪ«¥u¦³¤@ºØ¡A°Ó«~¦W¬°¡uªY¬y¡v¡Cªø´Á¨Ï¥Î¨Ã¤£·|¤Þ°_°Æ§@¥Î¡A¬Æ¦Ü2·³¥H¤Wªº¤pªB¤Í«K¥i¥H¨Ï¥Î¡A¥i¨£¨ä¦w¥þ©Ê·¥°ª¡C¦]¬°¨ä¬°Äå®ç¤f¨ý¥B´X¥G¤J¤f§Y¤Æ¡A¹ê¦b¤£¹³¶Ç²ÎÃĪ«µ¹¤Hªº¨èª©¦L¶H¡A¦Ü¤Ö®aªø¤£¥Î¨C¤Ñ»P¤pªB¤Í³s«¡±aÄFªº¤Wºt§lÃĪ§¹Ü¾Ô¤F¡C·íµMÂåÅñ¿í±q©Ê¤ÎÃĪ«¨Ï¥Î°t¦X«×°ª¡A®ð³Ý¯gª¬¦ÛµM¯à¹F¨ì§ó¦nªº±±¨î¡C¹ï©ó»´«×ªº®ð³Ý¤S¤£°t¦X§lÃĪº¤pªB¤Í©Î³\¥i¥HÀ|¸Õ¥Î¦¹ÃÄ¡Aªº½T¦³¨äÀø®Ä¡C¦Ü©ó¸gÂå®vµû¦ô¬°¤¤­««×®ð³Ýªº¤pªB¤Í´N¤£¯à¥u¦Y¥Õ¤T²m¯ÀªýÂ_¾¯¦Ó¤£¥Î§l¤J©ÊÃþ©T¾J¤F¡A¬Æ¦Ü»Ý¤GªÌ¦X¨Ö¨Ï¥Î¤~¯à¹F¨ì±±¨î®ð³Ýªº¯gª¬¡C¤£¹L¬O§_¨C­Ó¤H³£­n¥Î¦¹ÃĨӱ±¨î®ð³Ý¯gª¬¤´»Ý±M·~Âå®v¨Ó§PÂ_¡A­Ë¤£¯à»{¬°Âå¥Í¤£¶}¦¹ÃÄ´N¸ò¤£¤W¼é¬y¡A©ÎªÌÂå¥Í¤£¥Î¸û°ª¶QªºÃĨӪvÀø®ð³Ý«K¬O¤£¦nªºÂå¥Í¡C·sªº¥Õ¤T²m¯ÀªýÂ_¾¯µ¹®ð³Ý¤pªB¤Í±a¨Ó·sªº§Æ±æ¡A¹ï©óÃĪ«ªº»{Ãѧó»Ý»P¨àµ£®ð³Ý±M¬ìÂå®v°Q½×¡C

 

 


¡@

Ä_Ä_¡u«¦¡v¤£°±~®ð³Ýªº©~®a·ÓÅ@

ªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý­·Àã¬ì ¸­°ê°¶Âå®v

 

¥Ñ©óÄ_Ä_®ð³Ý®×¨Ò³v¦~¼W¥[¡A¨Ï¶ý¶ý­Ì³£¤£´±»´©¿¡u®ð³Ý¡v³o­Ó¯e¯f¡CµM¦Ó¡A¨ì©³¤°»ò¬O®ð³Ý¡H¨ä»¤µoªº¯f¦]¬°¦ó¡H­Y®a¤¤¦³®ð³ÝÄ_Ä_¡A¶ý¶ý¦b©~®a·ÓÅ@¤WÀ³ª`·N­þ¨Ç¨Æ¶µ¡H¬°¦¹¡A¥»¥Z¯S³Xªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý­·Àã¬ì¸­°ê°¶¥DªvÂå®v¡A½Ð¥L»¡©ú®ð³Ý¦¨¦]¡A¥H¤Î¦b©~®a·ÓÅ@¤¤¡A¦³®ÄÁקK¹L±Ó­ì¨ë¿E©M«D¹L±Ó­ì·P¬Vªº¤èªk¡C

 

¦ó¿×¡u®ð³Ý¡v

¡u®ð³Ý¡v¡A²³æ¦a»¡¡A§Y¬O¡u¤ÏÂа}µo©Êªº©I§l¹Dªý¶ë¡v¡C¦­¦b¤G¡B¤T¤d¦~«e¤¤°ê¤åÄm¤¤§Y°O¸üµÛ¡u®ð³Ý¡v³o­Ó¯e¯f¡A¨äÁ{§É¯gª¬±`¬Oªø´ÁºC©Ê«y¹Â¡B«æ©Êµo§@®É«h·|©I§l«æ«P¡B©I§l§xÃø¡B¯Ý´e¡B©I§l®É·|µo¥X¡u«¦«¦¡vÁn¡B¼L®Bµo¥Õ¨Ã±a¦³¶À¦â©Î³z©úªº·ð¡A¦³®É¦ñ¦³»ó¤l©Î²´·ú¹L±ÓµoÄoªº¹L±Ó²{¶H¡C§Î¦¨³o¨Ç¯gª¬ªº¥D¦]¡A¬O¥Ñ©ó®ðºÞªº¥­·Æ¦Ù¦¬ÁY¡A¥[¤W®ðºÞ¤ºÂH½¤¸~µÈµoª¢¡A¨Ï±o·ð¼W¦h¡A®ðºÞºÞ®|Åܤp¡AªÅ®ð¶i¥X¤£©ö¡A©Ò¥H¤~¾É­P©I§l¤£¶¶ºZ¡A·P¨ì©I§l§xÃø¡A©I§l®Éµo¥X«¦«¦ªº³Ý»ïÁn¡C

 

Ä_Ä_®ð³Ýªº¦¨¦]

±´¨s³y¦¨Ä_Ä_®ð³Ýªº­ì¦]¥i¥Hµo²{¡A³y¦¨Ä_Ä_®ð³Ýªº­ì¦]«Ü¦h¡A¦ý³Ì¥D­n¤´»P¡u¿ò¶Ç¡v¦³Ãö¡C¦ó¥H¦p¦¹»¡¡H¥D­n¬O¦]¬°¬ù¤K¦¨¥ª¥kªº®ð³Ý¯fµ£¡A¨äµo¯f­ì¦]³£¬O¨ü¨ì¹L±Ó­ì©M«D¹L±Ó­ìªº¨ë¿E¦Ó»¤µo¡C¦]¦¹¡A¹ï©ó¿ò¶Ç¡u¹L±ÓÅé½è¡vªºÄ_Ä_¨Ó»¡¡A¨ä¿©±w®ð³Ý©Î¹L±Ó©Ê»óª¢¡B²§¦ì©Ê¥Ö½§ª¢ªº¾÷²v¡A´N»·¸û¤@¯ëÄ_Ä_¬°¤j¡C¨º»ò¡A¤°»ò¬O¡u¹L±Ó­ì¨ë¿E¡v¡B¤°»ò¬O¡u«D¹L±Ó­ì¨ë¿E¡v¡H²³æ¦a»¡¡G

 

¹L±Ó­ì¨ë¿E

©Ò¿×ªº¡u¹L±Ó­ì¡v¡A«üªº¬O¦Ç¹Ð¡B¹ÐÂÚ¡BÅðµß¡Bªá¯»¡B´Öµ¶¡A¥H¤ÎÃdª«¤ò®h¡BÁ­½¸¤Àªcª«µ¥¡AÄ_Ä_­Y§l¤J©Î¤£·V±µÄ²¨ì³o¨Ç¹L±Ó­ì¡A´N®e©ö¤Þµo®ð³Ý©Î¹L±Óªº¯gª¬¡C

 

«D¹L±Ó­ì¨ë¿E

¡u«D¹L±Ó­ì¨ë¿E¡v¡A¥H¡u©I§l¹D·P¬V¡v¬°³Ì±`¨£¡A¥ç§Y¡u·P«_¡v·|»¤µo®ð³Ýªºµo§@¡C¨ä¥L«D¹L±Ó­ì¦]¯À¡A¨Ò¦p¡G©u¸`ÂàÅÜ¡B±¡ºüÅܤơB§l¤J¤G¤â·Ï¡BªÅ®ð¦Ã¬Vµ¥¡A³£¬O¤ÞµoÄ_Ä_®ð³Ý­ì¦]¡C

 

Ä_Ä_®ð³Ýªº©~®a·ÓÅ@

®a¤¤Ä_Ä_­Y±w¦³®ð³Ý¡A·Q¥²¤÷¥À¤@©w¬O¬J¤ß¯k¤S¼~¼{¡C®Ú¾Úªø©°Âå°|¨àµ£¹L±Ó®ð³Ý­·Àã¬ì¸­°ê°¶¥DªvÂå®vªí¥Ü¡A¥Ñ©ó¤p«Äªº¦A¥Í¯à¤O¸û±j¡A©Ò¥H¡A§Y¨ÏÄ_Ä_¿©±w®ð³Ý¡A­Y¯à¤Î¦­ªvÀø°t¦X±M¬ìÂå®vªº¥ÎÃÄ«ü¥Ü¡A¦A¥[¤W©~®a·ÓÅU±o·í¡A70%¦Ü80%¥ª¥kªºÄ_Ä_¡A®ð³Ý¯gª¬¤j³£¯àÀò±o¤j´T§ïµ½¡A¥B¨ä«æ©Êµo§@ªº¦¸¼Æ¤]·|´î¤Ö¡A¬Æ¦Ü¦³¨ÇÄ_Ä_¦bªø¤j¦¨¤H«á¡A¤£·|¦A¦³¦¹¯gª¬´_µo¡C

 

¨º»ò¡A­Y®a¤¤¦³®ð³ÝÄ_Ä_¡A©~®a·ÓÅ@¤WÀ³¸Óª`·N­þ¨Ç¨Æ¶µ©O¡H¥H¤U´XÂI´£¨Ñ±z°µ¬°°Ñ¦Ò¡G

 

1.´î¤Ö¹L±Ó­ìªº¦s¦b»P¨ë¿E

­n¦³®Ä´î¤Ö¹L±Ó­ìªº¦s¦b¡A³Ì­«­nªº¬O«O«ù©~®aÀô¹Òªº°®²b»P½Ã¥Í¡A¦p¦¹¤~¯à§K©ó¨ü¹L±Ó­ìªº¨ë¿E¡C

¦b©~®aÀô¹Ò½Ã¥Í¤W¡A«Øij±zÀ³®É±`¬°Ä_Ä_´«¬~§É³æ¡B§É®M¡BªEÀY®Mµ¥¡A¨Ã©ó¥´±½®É¡A¨Ï¥ÎÀ㥬©Î¨¾ÂÚ©Ù¥¬À¿«ø¡A¥HÁקKÄ_Ä_§l¤J´­°_ªº¦Ç¹Ð¡A©Î±µÄ²¨ì®e©ö³y¦¨¹L±Óªº¹ÐÂÚ¡A»¤µo®ð³Ý¡C¥t¥~¡A­YÄ_Ä_¬°¹L±ÓÅé½è¡A«hÀ³¾¨¶qÁקK¹}¾iÃdª«¡A¥H¨¾ªg¬VÃdª«ªº¥Ö®h¡AÁקK¨Ï¥Î¥¬»s¨Fµo¡B¦a´à¡Bµ¡Ã®¡A¤£­nª±µ³¤òª±¨ãµ¥¡A¹w¨¾¹L±Ó­ìªº±µÄ²¤]¬OªvÀø®ð³Ý­«­nªº¤@Àô¡C

 

2.ÁקK­¹¥Î·|¤Þ°_¹L±Óªº­¹ª«

¤@¯ë¨Ó»¡¡A¤HÅ餧©Ò¥H·|¹ï¬Y¨Ç­¹ª«¹L±Ó¡A¥D­n¬O¦]¹ï©ó³o¨Ç­¹ª«¤¤©Ò§tªº¬YºØ³J¥Õ½è¹L±Ó¡CÁöµM³æ¯Â¥Ñ¶¼­¹¦Ó¤Þ°_ªº®ð³Ý¯gª¬¨Ã¤£±`¨£¡A¦ý¶ý¶ý¥­¤éÆ[¹îÄ_Ä_­Y·|¦]¦Y¤F¬YºØ­¹ª«¦Ó¦³¤@¨Ç¹L±Óªí²{¡AÀ³¾¨¶qÁקKÅýÄ_Ä_¦Y¨ì³oÃþ­¹ª«¡C­Y¬O¶ý¶ý¤£ª¾¹DÄ_Ä_Åé½è¡A®e©ö¹ï­þ¨ÇºØÃþ­¹ª«©ÎªF¦è²£¥Í¹L±Óªº¸Ü¡A«Øij¶ý¶ý¤£§«¥ý±aÄ_Ä_¦ÜÂå°|°µ¡u¹L±Óµû¦ô´ú¸Õ¡v¡A¥H¤F¸ÑÄ_Ä_Åé½è¡A¨ÃÅ¥±qÂå®v«Øij¡A¤©¥H¹w¨¾¡C

 

3.¨Ï¥Î°£Àã¾¹©ÎªÅ®ð²M²b¾÷

¥Ñ©ó¥xÆWªº®ð­Ô·Å¼ö¼éÀã¡A«D±`¾A¦X¹ÐÂڥͪø¡A¦]¦¹¡A¹ÐÂÚ¥i»¡¬O¥xÆW³Ì±`¨£ªº¹L±Ó­ì¡C­Y·Q§í¨î¹ÐÂڥͪø¡A³Ì¦nªº¤èªk´N¬O±N¬Û¹ï·Ã«×±±¨î¦b50¦Ü60¤§¶¡¡A¤£¶È¯à¨Ï¤H·PıµÎ²n¡A¤]¯à¦³®Ä§í¨î¹ÐÂÚ´F¥Í¡A¦Ó­n§¹µ½¦a±±¨î¬Û¹ï·Ã«×¡A´N¥²¶·¨Ï¥Î°£Àã¾÷¡C

·íµM¡A°£¤F¦³®Ä±±¨î·Ã«×¥~¡A°®²b²M·sªºªÅ®ð¡A¤]¬O¨¾¤î®ð³Ýµo¥Íªº­«­n¦]¯À¡C¥Ñ©ó¤£¦nªºªÅ®ð¡Bªo·Ï¡BżªÅ®ðµ¥¡A³£¬O»¤µo®ð³Ýªº­ì¦]¡A¦]¦¹¡A­Y¯à±N°£Àã¾÷»PªÅ®ð²M²b¾÷¤@¦P·f°t¨Ï¥Î¡A¤£¦ý¯à§í¨î¹ÐÂÚ´þªø¡A¤]¯à´î¤Ö¹L±Ó­ì¡A­°§C®ð³Ýªºµo¥Í¡C

 

4.´î¤Ö«D¹L±Ó­ìªº·P¬V»P¨ë¿E

¥Ñ©ó¬K¡B¬î¤§»Ú¡A©Î¬y¦æ©Ê·P«_²±¦æ´Á¶¡¡A³£¬O®ð³Ý¯fªº¦nµo®É´Á¡A¦]¦¹¡A¦b´î¤Ö«D¹L±Ó­ìªº·P¬V¤W¡A³Ì­«­nªº´N¬OÁקK©ó³o¨Ç®É´Á±aÄ_Ä_¥X¤J¤½¦@³õ©Ò¡A¥H¨¾Ä_Ä_ªº©I§l¹D¨ü¨ì·P¬V¡A»¤µo®ð³Ý¡C¥t¥~¡A¥­®ÉÀ³¾¨¶qÅýÄ_Ä_ªº±¡ºü«O«ù¥­Ã­¡A¨ÃÅýÄ_Ä_¾A·í¦a°µ¹B°Ê¡A³£¦³§U©ó´î¤Ö®ð³Ýµo¥Í¡C

5.¨Ì·ÓÂå®v«ü¥ÜªAÃÄ

¡uÃÄ¡v¯àªv¤H¡A¤]·|®`¤H¡C©Ò¥H¡A¦b¨Ï¥Î§l¤J©Ê©Î¤fªAÃĪ«¤W¡A³Ì¦nÀ³¿í´`Âå®v«ü¥Ü«á¦AªA¥Î¡A¤d¸U¤£¥i¦Û¦æ¶Ã¥ÎÃľ¯©ÎÅ¥«H°¾¤è¡A¥H§KÄ_Ä_¨ü¨ì¶Ë®`¡C

¡u®ð³Ý¡v¦b¤p¨àÂå¾Ç¬ìªº»â°ì¤W¡A¬O¤@ºØ±`¨£¥BºC©Ê¤£©öªv¡ªº¯e¯f¡A®a¤¤­Y¦³®ð³Ý¨à¡A¤÷¥À´N»Ýªá§ó¦hºë¤O¥h·ÓÅUÄ_Ä_¡C©Ò¥H¡A°£¤F§Q¥Î¤W­z¤èªk¨Ó­°§C»¤µo®ð³Ýªº¦]¯À¥~¡A¤÷¥À­Y¹îıÄ_Ä_¦³¸g±`«y¹Â¡B¤[«y¤£Â¡ªº±¡§Î¡A´NÀ³»°ºò±aÄ_Ä_¦ÜÂå°|¡A½Ð¤p¨à¬ì±M¬ìÂå®v¶EÂ_¡A¦]¬°¡A³o«Ü¥i¯à¬OÄ_Ä_¿©±w®ð³Ýªº«e¥ü¡A­Y¯à¤Î¦­µo²{¡B¤Î¦­ªvÀø¡A«h¤£¶È¥iÁקKÄ_Ä_¿©±w®ð³Ý¡A¥B¨äªv¡ªº¾÷²v¤]¶V°ª¡C


¡@

¡@

¹ï¨àµ£®ð³Ýªº¥t¤@ºØ»{ÃÑ

ªø©°¨àµ£Âå°| ¨àµ£¹L±Ó®ð³Ý­·Àã¬ì ¸­°ê°¶Âå®v

 

²³©Ò¶gª¾¡A¨àµ£®ð³Ýªº²±¦æ²v»P¤é­Ñ¼W¡A§xÂZµÛ³\¦h¤pªB¤Í¤Î®aªø¡AµM¦Ó¹ï®ð³Ýªº»{ÃѤιï¤pªB¤Íªº·ÓÅU«o¥¼¯à¦³§ó¥¿½Tªº»{ª¾¡A¤Ï¦Ó³y¦¨·ÓÅU¤Wªºª¼ÂI¡A¤]®ø¯Ó³\¦hª÷¿ú»Pºë¤O¡C

³\¦h®aªø¤@Å¥Âå®v¶EÂ_¦Û¤vªº¤p«Ä±w¦³®ð³Ý®É«K¦p¦P¿©±w¤Fµ´¯g¯ë¤£¸T´d±q¤¤¨Ó¥B¤£ª¾©Ò±¹¡C®ð³Ý¥»½è¤W¬O©I§l¹DªººC©Êµoª¢¤ÏÀ³¡AµM¦ÓÁ{§É¤W¨àµ£®ð³Ý¨Ã«D¤£ªv¤§¯g¡Aµ´¤j³¡¤À¬O¥iªv·Uªº¡A­«­nªº¬O­n¦³­@¤ß¥B¿í´`Âå®vªº³B¤è»P«Øij¡A²¦³ºªvÀø®É¶¡ªºªøµu¦]¤H¦Ó²§¡A¦ý¨M¤£¹³·P«_¯ë¥u­n3¦Ü5¤Ñ«K¥i´_­ì¡C¤×¨ä§ó»Ý¦­´ÁªvÀø¡A¥H´î¤Öµo§@ªº¾÷·|¡C¥Ñ©ó®ð³Ýµo§@®É¤£¶È®aªø¼~¤ß¡A¦bªÍ³¡²Õ´§ó¦]µoª¢¦Ó«á·|³y¦¨¤£¥i°fªºÅÖºû¤Æ¡A­Y¤ÏÂЪºµo§@¡AÅÖºû¤Æµ{«×«h·|§ó¼F®`§ó¼sªx¡A±N¨Óªø¤j§ó¥i¯à¼vÅTªÍ³¡ªºª¬ºA¤Î¥\¯à¡A¦]¦¹¤Î¦­ªvÀø¬O·¥­«­nªº¡C¥Ø«e¥Î¨Ó¹w¨¾«O¾iªºÃĪ«¬O§l¤J©ÊÃĪ«¡A¥]¬A§l¤J©ÊÃþ©T¾J¤Î«DÃþ©T¾Jµ¥¡AµM¦Ó¥u­n¤@Å¥¨ìÃþ©T¾J®aªø«K°hÁפTªÙ¡A²`©È¼vÅTµo¨|©Î¦³¥ô¦óªº°Æ§@¥Î¦Ó¤£´±µ¹¤pªB¤Í¨Ï¥Î¡AµM¦Ó­Y¤£¥Î«o®e©ö¨Ï®ð³Ý¤ÏÂеo§@¡A¹ï¨àµ£±o¥Í²z¤Î¤ß²z¼vÅT§ó¤j¡C¦b¦¹±j½Õ§l¤J©ÊÃĪ«¬O¥Ø«eªvÀø®ð³Ýªº¥D¬y¡A¨Ã«D­n¨Ì¿à¨ä¤@½ú¤l¡A¦Ó¬Oµø¤pªB¤Íªº§ïµ½µ{«×»PÂå®v°Q½×¨Ó½Õ¾ã¨ä¨Ï¥Î¾¯¶q¤ÎÀW²v¡Aª¬ªpí©w«á«hº¥º¥´î¶q¦Ó°±ÃÄ¡CÅv¿Å¨ä§Q®`±o¥¢¡Aµ´¹ï§Q¦h©ó¹ú¡A¤Á¤Å¦]¼O¼o­¹¡C

®a¤¤­Y¦³®ð³Ý¨à¥Í¬¡¤WÃø§K¨ü¼vÅT¡A¥Xªù¥þ°ÆªZ¸ËÀ¹¤f¸n¡A¤S¬O¤£¯à¹B°Ê¡A¤S¬O¤£¯à¦YÁ¦±ø¡A¤£¯à¦Y¦B¡K¡A¦b¤pªB¤Íªº¦Õ¤¤¥Rº¡¤F§i»|¦¡ªº¸T¥O¡AÅý¤@Áû·Q­¸ªº¤ßÀH®É¨ü¨ì¸TÀD¡A¦Û¤v¤]³Q¼ÐÅÒ¬°¡u¹L±Ó¨à¡v©Î¡u®ð³Ý¨à¡v¡C¨ä¹ê­n¤pªB¤Í¤£¶]¤£¸õ¬O¤£¤Ó¥i¯àªº¡A¾A«×ªº¹B°Ê¬O­È±o¹ªÀyªº¡A¥­®É¨Ï¥Î«O¾iªº§l¤J©ÊÃĪ«¤]¥i´î¤Ö¹B°Ê»¤µo®ð³Ýªº¥i¯à¡A¦P®É¥R¤À¤F¸Ñ­Y¦]¹B°Ê»¤µo³Ý»ïªº³B¸m¤è¦¡¡A´NÅý¤pªB¤Íµo´§¨ä¤Ñ©Ê¡A¤]¤£¦Ü¤ß²z¥Ã»·»X¤W¤@¼h³±Åµ¡C¦Ü©ó¦]­¹ª«¤Þ°_®ð³Ýªº¯gª¬¨Ã¤£±`¨£¡A¤]¨Ã«D¨C­Ó®ð³Ý¤pªB¤Í¦Y¦B«K·|®ð³Ý©Î«y¹Â¡A¦]¦¹¥i¹Á¸Õ¦Y¤@ÂI¡A­Y©úÅ㦳¯gª¬«hÀ³ÁקK¡A­YµL¯gª¬«h¦b®aªøªººÊ·þ¤U¦ó§«Åý´ç¨Ç¦Û¥Ñ¡C¹ï©ó¸ûÀ´¨Æªº¤p«Ä¡A·íµM¤]¤£À³¦Û»{¬°¦³®ð³Ý¦ÓÁŧK³\¦h¾Ç®Õªº¬¡°Ê©Î¥H¦¹¬°ÂǤf¦Ó°kÁ×À³ºÉªº¸q°È¡A¦Ó¦b¦P¾«¶¡¾AÀ³¤£¨}¡CÂå®v¡A®aªø¡A¦Ñ®v¤Î¤pªB¤Í¦h¤èªº·¾³q¡A¤~¤£·|¼vÅT¨ä¤ß²z¼h­±ªºµo®i¡C

´CÅé¸ê°T¤é¯qµo¹F¡Aºô»Úºô¸ô¤]µL»·¥±©¡¡A¥R¥¸µÛ¦UºØ¦ü¬O¦Ó«D©ÎÂ_³¹¨ú¸qªºÂåÃĸê°T©Î¼s§i¡A®aªø·R¨à¤ß¤Á¤]ÂǥѦUºØ¸ê°TºÞ¹D¹M³X¦WÂå¡A´M¨D¦W¶QÃħ÷°¾¤è¡A¥u¨D¯àªv·U®ð³Ý¡C¦b±µ¦¬¨ì¦UºØ¦³Ãö¹L±Ó®ð³Ýªº¸ê°T®É¡A®aªø»Ýª`·N¥B¦Û§Ú¬Ù«äªº¬O³o¨ÇÂåÃÄ·sª¾¬O§_¬°ÃÄ«~¼s§i©Î¸Ø¤j¤£¹ê?Àø®Ä¦³µL¬ì¾Ç®Ú¾Ú?¬O§_¤w¥Î©ó¤HÃþÁÙ¬O¤´¦b°Êª«¹êÅ綥¬q?¦]¬°°Êª«¹êÅ窺¦¨¥\¨Ã¤£¥Nªí¾A¥Î©ó¤HÅé¤W¡A´Nºâ¹ï¤HÅ馳®Ä¤]¨Ã«D¾A¥Î¨C­Ó¦~ÄÖ¼h©Î¨C­Ó­ÓÅé¡C¹ï©ó©ÒÀò±oªº¸ê°TÀ³»P±M¬ìÂå®v¦A§@¶i¤@¨Bªº°Q½×»P¤F¸Ñ¡A¦Ó¤£¬O³d©ÇÂå®v¤£¥Î·sÃĩηsªºªvÀø¤è¦¡¡C

¥H¤W´XÂI¹ïÃĪ«¨Ï¥Îªº»{ª¾¡A¹ï®ð³Ý¤pªB¤Íªº¤ß²z¼h­±¡A¤Î¹ï´CÅ骺¼f·VºA«×§Æ±æ»P®aªø¦@«j¡C


¡@

¡@

¨àµ£®ð³ÝªvÀø¤§¹êÃÒÂå¾Ç

ªø©°¨àµ£Âå°|

¨àµ£¹L±Ó®ð³Ý­·Àã¬ì¥DªvÂå®v   ¸­°ê°¶

 

¯f¨Ò

³o¬O¤@­Ó5·³ªº¨k«Ä¥Ñ¶ý¶ý±a¨Ó¨à¬ì«æ¶E¡A¥D¶D¨ä«y¹Â¤w5¤Ñ¦ý¤@¤Ñ¥H¨Ó«h©I§l§xÃø¡C¯f¤H³Ìªñ5¤Ñ«K¶}©l«y¹Â¡A±ß¤W¤]¦]«y¹Â¦ÓµLªk¦¨¯v¡A®É±`«y¿ô¡A¦­¤W°_§É§ó¬O«yªº¼F®`¡A³Ìªñ¤@¤Ñ¬Æ¦Ü«y¨ì³sÁ¿¸Ü³£Â_Â_ÄòÄò¡A¨«´X¨B¸ô³£­n¥ð®§¡C®Ú¾Ú¶ý¶ýªº³¯­z¡A¯f¤H¥­®É«K«Ü®e©ö·P«_¡A¤Ñ®ð¤@ÅÜ´N«y¹Â¬y»ó¤ô¡A·P«_¤]³£­n¦Y«Ü¤[ªºÃĤ~·|¦n¡A·P«_ÄY­«®ÉÁÙ·|¦³¡y«¦«¦¡zªº³Ý»ïÁn¡F¥­®É·|¦]¹B°Ê©Î¿E¯P°Ê§@¦Ó«y¹Â¡C¥t¥~¦­¤W°_§É´N³sÄò¥´¼QÀ¡¡A²´·ú¤]±`Äo±`´|¡C²z¾ÇÀˬd¥i¬Ý¨ì¨k«Ä¦]¨Ï¥Î»²§U©Ê¦Ù¦×¦³¨Ç¯Ý°©¤W¥W³´¡AÅ¥¶E¥iÅ¥¨ì¨â°¼ªÍ³¡©úÅ㪺³Ý»ïÁn¡A©I§l³t²v¬ù¨C¤ÀÄÁ40¦¸¡A¤ß¸õ¬ù¨C¤ÀÄÁ110¦¸¡A¨S¦³µo¿N¡A¨ä¾lªº²z¾ÇÀˬd¤j­P¥¿±`¡Cªì¨B¶EÂ_¬°«æ©Ê®ð³Ýµo§@¡A¦]¦¹°¨¤W©I¥s©I§lªvÀø¬ìÅ@¤hµ¹¤©Bricanyl inhalation¡C©I§lªvÀø¬ìÅ@¤h°Ý¬O­nAtrovent¥[BricanylÁÙ¬O¥u­nBricaynl ´N¦n¡HÅ@¤h¤p©j¤]°Ý­n¤£­nª`®gÂIºwµ¹Aminophylline¡H¦Ò¼{«áÁÙ¬O¨M©w¥uµ¹Bricanyl inhalation¡C¯f¤H¹ïBricanyl §l¤Jªº¤ÏÀ³´¶³q¡A®Ú¾Ú¾Çªø«ü¾É¡A¹j20¤ÀÄÁ¦A§l¤@¦¸¡A§l§¹2¦¸«á¯f¤H±¡ªp§ïµ½¡A¦]¦¹¶}¥ßPrednisolone¡ABerotec¤fªAÃĪ«¦^®a¡A¨ÃÅñ¨ä¦^ªù¶Eªø´Á°lÂܪvÀø¡C¯f¤H¦^ªù¶E«á®Ú¾Ú¯f¤Hªº¯f¥v¤ÎÄY­«µ{«×¶}©l±µ¨ü§l¤J«¬Ãþ©T¾JªºªvÀø¡A¨Ã±Ð¾É¨ä¥¿½Tªº¨Ï¥Î¤è¦¡¡C§Ú­ÌÂǥѳo­Ó¯f¨Òªº¤Þ¾É§Q¥Î¹êÃÒÂå¾ÇªºÆ[ÂI¨Ó¶i¤@¨B¤F¸Ñ¦b®ð³ÝªvÀø¤W¤@¨Ç­È±o°Q½×ªº¦a¤è¡A¼fµø¥­®É¦]´`ªº³B¸m¤è¦¡¬O§_±o·í¡C¥H¤U¤]±N¤À¦¨«æ©Ê³B²z¤ÎºC©ÊªvÀø¤À§OÄÄ­z¡C

    ªvÀø®ð³Ý¦³³\¦h¦@³qªº·Ç«h¡AµM¦Ó³o¨Ç·Ç«hªº²£¥Í¤]³£»Ý­n¦³¹êÅçÃÒ¾Ú¨Ó¤ä«ù¡C³o¨ÇÃÒ¾Ú¤j­P¥i°µ¥H¤U¤ÀÃþ¡J

Level I¡R¦Ü¤Ö¦³¤@­Ó¥HÀH¾÷¨ú¼Ë©Ò°µªºÁ{§É¸ÕÅçÀò±oªºÃÒ¾Ú¤ä«ù

Level II¡R¦Ü¤Ö¦³¤@­Ó¥H¥@¥N©Ê(cohort)©Î¯f¨Ò¹ï·Ó(case-control)ªº¹êÅç¤è¦¡¥B³]­pÄYÂÔªºÁ{§É¸ÕÅç©ÒÀò±oªºÃÒ¾Ú¤ä«ù

Level III¡R¸g¥Ñ³\¦h±M®a®Ú¾ÚÁ{§É¸gÅç¦@¦P°Q½×¦Ó±o¨Óªºµ²ªG

­Y¬°ªvÀø«Øij¤S¥i¦A²Ó¤À¬°¥H¤U¤ÀÃþ

A.    ¦³¥R¤ÀªºÃÒ¾Ú¤ä«ù¨Ã«Øij¦¹¶µ³B¸m

B.     ¦³¾A·íªºÃÒ¾Ú¤ä«ù¨Ã«Øij¦¹¶µ³B¸m

C.     µLÃÒ¾Ú¤ä«ù«Øij©Î¤£«Øij¦¹¶µ³B¸m

D.    ¦³¾A·íªºÃÒ¾Ú¤£¤ä«ù¥B¤£«Øij¦¹¶µ³B¸m

E.     ¦³¥R¤ÀÃÒ¾Ú¤£¤ä«ù¥B¤£«Øij¦¹¶µ³B¸m

 

«æ©Ê³B²z

µu®Ä«¬§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¡]£]2-agonist¡^¤´¬O¥Ø«e³B²z®ð³Ýµo§@ªº²Ä¤@½u¥ÎÃÄ¡A¤@¯ë§l¤J¼Æ¤ÀÄÁ¤º«K¦³§@¥Î¡A¦P®ÉÃĮĥiºû«ù3¦Ü4¤p®É¥ª¥k¡C¬Û¹ï©ó¤fªA©ÎÀR¯ßª`®gªº³~®|¡A§l¤J©Êªº¤è¦¡¯à¸û¦³®Äªº±NÃĪ«°e¶i®ðºÞ¦Ó¹F¨ìªvÀøªº®ÄªG¡C¦b«æ©Êµo§@®É§l¤Jµu®Ä«¬£]2-agonistÀW²v¶V±K¶°¡A¶V§Ö¹F¨ìªvÀø®ÄªG¡C¥H2²ÕÄY­«µ{«×¬Û¦üªº¨àµ£¤ñ¸û¡A¤@²Õ¨C¤@¤p®É§l salbutoml 0.15 mg/kg¦@3¦¸¡A¥t¤@²Õ¤@¶}©lµ¹¤©salbutoml 0.15mg/kg¤@¦¸¡A¤§«á¨C20¤ÀÄÁµ¹0.05mg/kg¦@6¦¸¡A¥HFEV1§@¬°µû¦ô¼Ð·Çµo²{2²Õ¹ï²Ä¤@¾¯§l¤J¦³¬Û¦üªº¤ÏÀ³¡A¦ý¸û±`§lÃĪº¤@²Õ¦b¤@¤p®É¤ºªÍ¥\¯à«ùÄò¶i¨B¡A¥t¤@²Õ«hªÍ¥\¯à¦b§l¤U¤@¾¯«e·|¦³¨Ç³\¤U­°¡CÁöµM2²Õ³Ì«áªºFEV1¨Ã¨S¦³®t§O¡A¦ý«æ©Ê´Á¸ûÀWÁc§l¤J£]2-agonist¥i«ùÄòºû«ùªÍ¥\¯àí©w¡]Level IA¡^¡C¥t¤@¬ã¨s«h¥Îsalbutoml 0.15 mg/kg¨C20¤ÀÄÁ§l¤J¤@¦¸»Psalbutoml 0.05 mg/kg¨C20¤ÀÄÁ§l¤J¤@¦¸¨Ó¤ñ¸û¡Aµo²{¸û°ª¾¯¶q¦³¸û¦nªº¤ÏÀ³¦ý°£¤F¤â§Ýªº°Æ§@¥Î¸û©úÅã¥~¨ä¾l¨ÃµL°Æ§@¥Î¡A¦]¦¹«æ©Ê´Á¥Î¸û°ª¾¯¶qªº£]2-agonist¥BÀWÁc§l¤J¬O¦³¸û¦nªº®ÄªG¡]Level IA¡^¡C

    ¯f¤H¦]®ð³Ý¨ì«æ¶E¤@¯ë¨Ï¥Î®ðÃú¦¡¡]nebulizer¡^§ë¤©¤ä®ðºÞÂX±i¾¯¡A¨Ï¥Î¦¹§l¤J¤è¦¡ªº¦n³B¬O²³æ¡A¨Ã¤£»Ý­n¯f¤Hªº°t¦X«K¥i§l¤JÃĪ«¡A¦ý¨Æ¹ê¤W¶i¤J®ðºÞªº¾¯¶q½T·¥¤Ö¡A¤j³¡¤ÀªºÃĪ«³£®ö¶O¤F¡C¨Ï¥Î©w¶q¼QÃú¾¯¡]metered dose inhaler¡^¥[¤W§lÃÄ»²§U¿µ¥ç¬O¥t¤@ºØ§l¤Jªº¤è¦¡¡C¥ÑºC©Ê®ð³Ýªº¬ã¨sµo²{¨Ï¥Î©w¶q¼QÃú¾¯¥[¤W§lÃÄ»²§U¿µ¤ñ¨Ï¥Înebulizer¦bªÍ¥\¯à§ïµ½¤è­±¦Ü¤Ö¦³¬Û¦P¬Æ¦Ü§ó¦nªº®ÄªG¡]Level IA¡^¡C¥ç¦³¨â¶µ³]­pÄY±Kªº¬ã¨s°w¹ï©ó«æ¶E¨Ï¥Înebulizer©Î©w¶q¼QÃú¾¯¥[¤W§lÃÄ»²§U¿µ§ë¤©¤ä®ðºÞÂX±i¾¯µo²{¹ï©ó§ïµ½®ð³Ý¯gª¬¡A´î¤Ö¦í°|¾÷²v¤Î¦y®p©I§l³t²v(peak expiratory flow rate)ªº§ïµ½¨ÃµL®t§O¡A¬Æ¦Ü¨Ï¥Î©w¶q¼QÃú¾¯¥[¤W§lÃÄ»²§U¿µªº¤@²Õªá¸û¤Öªº®É¶¡«K±o¨ì¬Û¦PªºªvÀø¡C¦]¦¹¦b«æ©Êµo§@®É¨Ã¤£¤@©w¥u¯à¥Înebulizerªº¤è¦¡¨Ï¥Î¡A¯à¤è«K¨Ï¥Î©w¶q¼QÃú¾¯¥[¤W§lÃÄ»²§U¿µ¤]¦³¬Û¦P®ÄªG¡C

«æ©Êµo§@®É¨Ï¥Î§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¬O¤½»{ªºªvÀø·Ç«h¡A¥[¤J§l¤J©Ê§ÜÁxÆP»s¾¯¥ç¬OÁ{§É¤W±`¥Îªº³B²z¤èªk¡C§l¤J©Ê§ÜÁxÆP»s¾¯¸û§l¤J©Ê¤ä®ðºÞÂX±i¾¯ªº°_©l§@¥Î®É¶¡¸ûºC¡A¦ý§@¥Î®É¶¡¸ûªø¡C¦ý¦X¨Ö¨Ï§l¤J©Ê§ÜÁxÆP»s¾¯¬O§_¦³§ó¦nªºªvÀø®ÄªG¡H¦b¤@¥æ¤e¤ÀªRªº¦^ÅU¤å³¹¤¤´£¨ì§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¥[¤W¤@¾¯ªº§l¤J©Ê§ÜÁxÆP»s¾¯¦b60¤ÀÄÁ«á¥i§ïµ½FEV1¡A¦ý½T¤£·|´î¤Ö¦í°|¾÷²v¡C¦ý­Y¥[§l¦h¾¯§l¤J©Ê§ÜÁxÆP»s¾¯«h¥i¥H´î¤Ö¦í°|¾÷²v¡C¥t¤@¶µ¬ã¨s¿ï¾Ü¤F480¦ì¦³¤¤­««×®ð³Ýªº¨àµ£¡A¹ï©ó­««×®ð³Ýªº¨àµ£¥[¤J§l¤J©Ê§ÜÁxÆP»s¾¯2¦¸«á¥i´î¤Ö¦í°|¾÷²v¡C¥t¤@¬ã¨s¤ñ¸û¹êÅç²Õ³sÄò§l¤J©Ê§ÜÁxÆP»s¾¯¥[¤W§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¤T¦¸»P¹ï·Ó²Õ¥u§l¤J¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¤ñ¸ûµo²{¦³¨Ï¥Î§l¤J©Ê§ÜÁxÆP»s¾¯Áö¥¼´î¤Ö¦í°|¾÷²v¦ý¥i¸û¦­¥Ñ«æ¶E¥X°|¡]Level IA¡^¡C¥Ñ³\¦h¬ã¨sÃÒ¾ÚÅã¥Ü¹ï©ó­««×®ð³Ý(predicted FEV1<55%)¦h¦¸¦X¨Ö¨Ï¥Î§l¤J©Ê§ÜÁxÆP»s¾¯¤Î§l¤J©Ê¤ä®ðºÞÂX±i¾¯©ó¦w¥þµL¸·¡A¥i§ïµ½ªÍ¥\¯à¡A¤]¥i´î¤Ö¦í°|¾÷²v¡C¦ý¹ï»´¤¤«×ªº®ð³Ýªº¨àµ£¥u¨Ï¥Î¤@¦¸§l¤J©Ê§ÜÁxÆP»s¾¯¨Ã¨S¦³Å㪺À°§U¡C

    ¹L¥h¯ùÆPÃþªºÃĪ«¦h¥Î¨Ó§@¬°²Ä¤@½u¥ÎÃÄ¡A¦ý¨ä«o®e©ö³y¦¨¸¡µh¡Aäú¤ß¡A¹Ã¦R¡A¤ß±ª¬Æ¦Ü¤ß«ß¤£¾ã¤Î©âµjµ¥°Æ§@¥Î¡A¦]¦¹¨Ï¥Î¤W­n®æ¥~¤p¤ß¡C¦³5½g¨Ï¥ÎÀH¾÷Âùª¼¹êÅç¤èªkªº¬ã¨s³ø§i³£¤£»{¦P»´¤¤«×ªº®ð³Ý«æ©Êµo§@ªº¯fµ£°£¤F§l¤JÂX±i¾¯¥~¦A¥[¤W¨Ï¥Îª`®g¯ùÆPÃþÃĪ«·|¦³§ó¦nªºªvÀø®ÄªG¡A¤]´N¬O¨Ã¤£·|§ïµ½ªÍ¥\¯à©ÎÁ{§É¯gª¬¡A¤]¤£·|´î¤Ö¦í°|¤Ñ¼Æ¡]Level IE¡^¡C¦Ó¹ï©ó­««×ªº®ð³Ýµo§@¥[¤W¯ùÆPªº½T¥i¥H¸û¦­§ïµ½ªÍ¥\¯à¤Î®ñ®ð¹¡©M¿@«×¡A¦ý©Ò¤Þ°_ªºäú¤ß¹Ã¦Rªº°Æ§@¥Î¤]ÀH¤§¼W¥[¡A¦P®É¨Ã¤£·|´î¤Ö¦í°|¤Ñ¼Æ¡C¦]¦¹¯ùÆP¨Ã«D§¹¥þ¤£¯à¥Î¡A¦ý¹ï©ó­««×«æ©Ê®ð³Ýµo§@¥B¹ï¨ä¥LªvÀø¤è¦¡¤ÏÀ³¤£¨Î®É¤´¥i¨Ï¥Î¡C

    ¥Ñ©ó¹ï®ð³Ý¤§¯f²z¥Í²z¾Ç¦³§ó²`¤Jªº¤F¸Ñ¡A§Üµoª¢®ÄªGÅãµÛªºÃþ©T¾J«K¬Û§Î­«­n¡C¥Ñ¦¨¤H®ð³Ýªº¸gÅç¡A³\¦h¬ã¨sÅã¥Ü«æ©Êµo§@®É¦­´Áµ¹¤©Ãþ©T¾J¥i´î¤Ö¦í°|²v¤Î´î¤Ö¦Aµo²v¡C¦Ó¨àµ£ªº¬ã¨s³ø§i¥çÅã¥Ü«æ©Êµo§@®É«Kµ¹¤©¤fªAÃþ©T¾Jªº¤@²Õ¨äªÍ¥\¯à¦³ÅãµÛ§ïµ½¤]´î¤Ö¦í°|¾÷²v¡A¦P®É©ó«æ¶E°±¯dªº®É¶¡¤]¸ûµu¡C¨Ï¥Î¦Ù¦×ª`®gÃþ©T¾J¥ç¦³¬Û¦Pªº®ÄªG¡]Level IA¡^¡C¦Ù¦×©ÎÀR¯ßª`®gÃþ©T¾J³£¦³¬Û¦Pªº®ÄªG¡C¥Ñ¥æ¤e¤ÀªRºî¦X¦U­Ó¬ã¨sµ²ªGµo²{Ãþ©T¾Jµ¹¤©ªº³~®|¹ï©ó§ïµ½ªÍ¥\¯àªº®ÄªG¬O¬Û·íªº¡C¥t¤@Âùª¼¬ã¨s¤ñ¸û©ó«æ¶E®É¤À§O§ë¤©¤fªA©ÎÀR¯ßª`®gÃþ©T¾J¡A¨â²ÕªºÁ{§É§ïµ½µ{«×©Î¦í°|²v¬ÒµL®t§O¡]Level IA¡^¡C¤@¯ëªº«Øij¾¯¶q¬°prednisolone 1-2 mg./kg/day¡A¦Ü©ó¨Ï¥Î¦h¤[¤´¥¼¦³©w½×¡A¤@¯ë¬°5¦Ü7¤Ñ¡A§Y¨Ï¨Ï¥Î10¤Ñ¤]¤£»Ý³v¦¸´î¶q¡C

 

 

Á`µ²

1.          ¹ï©ó¯Ê®ñªº¯f¤H®ñ®ðªº¨ÑÀ³¤´¬O­ºÀ³³B²zªº¨BÆJ¡]Level IIIB¡^¡C

2.          §l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¬Oºò«æ³B²zªº­º¿ï¥ÎÃÄ¡]Level IA¡^¡C

3.          ¹ï©ó­««×¯f¤H§l¤J©Ê§ÜÁxÆP»s¾¯¥i¥[¤J§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¦X¨Ö¨Ï¥Î¡]Level IB¡^¡C

4.          «æ©Êµo§@®É¥Î¯ùÆP¨Ã¤£·|§ïµ½¯gª¬¡A¦ý¥i¯à³y¦¨°Æ§@¥Î¡]Level ID¡^¡C

5.          ¦­´Á¨Ï¥ÎÃþ©T¾J¬O¥²­nªº¡]Level IA¡^¡C

 

ºC©Ê³B²z

¥Ø«eªvÀø®ð³Ýªº¥D¬y¤´¬O¥Î§l¤J©ÊÃþ©T¾J¡]Level IA¡^¡ACalpinµ¥¤H¤ÀªR¹L¥h20¦~¨Ó¨Ï¥ÎÂùª¼ÀH¾÷¹ï·Ó±±¨îªº¹êÅç¤èªk±´°Q§l¤J©ÊÃþ©T¾J¨ÓªvÀø¨àµ£®ð³Ýªº24½g¤å³¹¡A¾ã­Ó¥æ¤e¤ÀªRµ²ªGµo²{¥­§¡¨Ï¥Î§l¤J©ÊÃþ©T¾J8©P¥i§ïµ½Á{§É¯gª¬¡A´î¤Ö¨Ï¥Îºò«æµo§@®É¨Ï¥Î¤ä®ðºÞÂX±i¾¯ªº¾÷·|¡A´î¤Ö¨Ï¥Î¤fªAÃþ©T¾Jªº¾÷·|¡A¥H¤Î§ïµ½ªÍ¥\¯àµ¥¡C¨Ï¥Î§l¤J©ÊÃþ©T¾Jªø¹F¤@¦~ªº®ð³Ý¨àµ£ªº§ïµ½µ{«×¤]¸û¨Ï¥ÎSodium cromoglycateªº¤@²Õ®ÄªG¦n( Level IA)¡C¦b½T©w¶EÂ_¬°®ð³Ýªº¨àµ£¦­´Á¨Ï¥Î§l¤J©ÊÃþ©T¾J·|¤ñ¨S¦³¨Ï¥Îªº¤@²Õ¦³¸û¨ÎªºªvÀø®ÄªG¡C§Y¨Ï¦­¥ý¨S¦³¨Ï¥Î¤J©ÊÃþ©T¾J¦Ó«á¦A§ï¥Î¤§¡A¨ä³Ì«áªÍ¥\¯àªºªí²{¤]¤ñ¦­´Á«K¶}©l¨Ï¥Î§l¤J©ÊÃþ©T¾Jªº¤@²Õ®t(Level II)¡C

 

 

 

 

u  ¦³Ãö¨Ï¥Î§l¤J©ÊÃþ©T¾JªvÀø®ð³ÝªºÃÒ¾Ú

§l¤J©ÊÃþ©T¾J¬O¥Ø«eªvÀø®ð³Ý³Ì¦³®ÄªºÃĪ« (Level IA)

§l¤J©ÊÃþ©T¾J¥i§ïµ½®ð³Ýªº©I§l¹Dªý¶ë¤Î©I§l¹D±Ó·Pµ{«× (Level IA)

»P¨ä¥LªvÀø¤è¦¡¤ñ¸û§l¤J©ÊÃþ©T¾J¬O³Ì¸gÀÙ¥B¦³®ÄªºªvÀø(Level IA)

§Y¨Ï¤Ö¶qªº¤J©ÊÃþ©T¾J¤]¥i¯à³y¦¨¨Ç§½³¡ªº°Æ§@¥Î¦p¤fµÄÅðµß¤ÎÁn­µ¨F°×(Level IA)

¨Ï¥Î¾A·í¾¯¶qªº§l¤J©ÊÃþ©T¾J¥i±±¨î¤j³¡¤Àªº®ð³Ý¯gª¬¦ý¨Ã¤£·|¦³©úÅ㪺¨­Åé¤W¥ô¦ó°Æ§@¥Î (Level IA)

¦b­ì¨Ó¨Ï¥Î§l¤J©ÊÃþ©T¾J¥[¤Wªø®Ä«¬¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¤ñ¼W¥[¨â­¿¾¯¶qªº§l¤J©ÊÃþ©T¾JªºªvÀø®ÄªG¦n (Level IA)

From Evidence-based Asthma Management B.C. Decker 2001

 

¹ï©ó§l¤J©ÊÃþ©T¾J³Ì¬°¤j²³©ÒÃö¤ßªº²ö¹L©ó¬O§_¦³°Æ§@¥Î¡H¬O§_·|¼vÅT¨àµ£¦¨ªø¡H°w¹ï21¶µ¬ã¨sÁ`¦@810¦ì¨àµ£©Ò°µªº¥æ¤e¤ÀªRµo²{ªø´Á¨Ï¥Î§l¤J©ÊÃþ©T¾J¡]Beclomethasone dipropionate¡^ªvÀø®ð³Ý¯f¤£·|¼vÅT³Ì«á¨­°ª¡A¦P®É«Øij¨Ï¥Î¾A·í¾¯¶q(¤p©ó600 micrograms/day)ªºBeclomethasone dipropionate¨Ã¤£·|¼vÅT¥Íªø¡C¨ä¥Lªº¬ã¨s«hÃÒ©ú¨Ï¥Î¸û°ª¾¯¶qªº§l¤J©ÊBeclomethasone dipropionate·|¤ñ¨S¦³¨Ï¥Îªº¤@²Õ·|¼vÅT¦¨ªø³t«×¡]Level IA¡^¡C¤£¹LÁö¬O§l¤J©ÊÃþ©T¾J¦ý¤´¦³¤£¦PºØÃþ·s¬ãµoªº§l¤J©ÊÃþ©T¾J¡C¦Ü¤Ö¦³3¶µ¬ã¨sµo²{ªø´Á¨Ï¥Î§l¤J©ÊFluticasone propionate¨Ã¤£·|§í¨î¦¨ªø³t«×¡]Level IB¡^¡C¦b²³¦hªº¬ã¨s¤¤§l¤J©ÊÃþ©T¾J»P¥ÍªøªºÃö«Y³£¨Ï¥Îknemometry´ú¶q»Lªø¡A¦Ó¹ê»Ú¤W¨àµ£¦¨ªø¨Ã¤£¤@©w¬O§eí©w¥B¥­§¡ªº¦¨ªø¡A¦Ó¦³¥i¯à¤@¬q®É¶¡°±º¢¦Ó¥t¤@¬q®É¶¡§Ö³t¦¨ªø¡A¦Óknemometry¬O§_´N¯à¥Nªí¨àµ£¦¨ªøª¬ªp¤´»Ý¦Ò¼{¡C®ð³Ý¥i¯à·|­P©R¡A®ð³Ý±±¨î¤£¦n¤]·|¼vÅTµo¨|¡A¦b²³¦hÃÒ¾Ú¤ä«ù¨Ï¥Î¾A·í¾¯¶qªº§l¤J©ÊÃþ©T¾J¯à¦³®Ä±±¨î®ð³Ý¡C¤ñ¸û¨ä¥i¯à¼vÅT¥Íªøµo¨|¤Î®ð³Ý¯gª¬±±¨îªº­«­n©Ê¡A¤Î¦­¨Ï¥Î§l¤J©ÊÃþ©T¾JÀ³¬O¸û¦nªº¿ï¾Ü¡A¦Ó±±¨î®ð³Ýí©w¤]¹ï¨àµ£¦¨ªø¦³©Ò§U¯q¡C

   §l¤J©ÊCromolyn Sodium¬O¤@·¥¦w¥þªºÃĪ«¡C³\¦h¤j«¬ªºÀH¾÷Âùª¼¸ÕÅçÃÒ©ú¨ä¥i¸û¹ï·Ó²Õ¦³®Äªº±±¨îºC©Ê®ð³ÝªºÃ­©w¡A¦³®Äµ{«×¦Ü¤Ö©M¯ùÆPÃþ¬Û·í¡]Level IA¡^¡C¦ý¤]¦³³\¦hÃÒ¾ÚÃÒ¹ê¨äÁ{§É®ÄªG¸û§l¤J©ÊÃþ©T¾J®t¡C¦]¦¹¹ï©ó¾ÇÄ֨ൣ«Øij­Y±`¥Î¨ìµu®Ä«¬ÂX±i¾¯¨Ó±±¨î¤ÏÂеo§@ªº®ð³Ý¯gª¬®É¥i¥[¤Wªø´Á§l¤JCromolyn sodium¡A ¹j¤»¶g­Y®ÄªG¤´¤£¨Î¥i¦A¥[¤W§C¾¯¶q§l¤J©ÊÃþ©T¾J¡C¹ï©ó¾ÇÄÖ«eªº¨àµ£¨Ã¨S¦³«Ü¦nªº¬ã¨s¤ÎÃÒ¾Ú¤ä«ù¨ä®ÄªG¡A¦ý¤´¥i¾A¥Î¦p«e©Ò­z¾ÇÄÖ´Á¨àµ£½Õ¾ã¥ÎÃĪº¨BÆJ¡C

¡@¡@ªø®Ä«¬¤ä®ðºÞÂX±i¾¯ªºÃĮĥiºû«ù12¤p®É¥ª¥k¡C¬ã¨sµo²{¨C¤Ñ§l¤Jªø®Ä«¬¤ä®ðºÞÂX±i¾¯·|¤ñ¹ï·Ó²Õ§ó¦³¹w¨¾®ðºÞÁYªº±¡§Îµo¥Í¡C¬Æ¦Ü³sÄò¨Ï¥Î12­Ó¤ë¤]¯àºû«ù«Ü¦nªºªÍ¥\¯à¡A¨ÃµL¤@¯ëµu®Ä«¬¤ä®ðºÞÂX±i¾¯¦b¨Ï¥Î¤@¬q®É¶¡«á·|²£¥Í­@¨ü©Êªº±¡§Î¡C§Q¥ÎÀH¾÷Âùª¼¸ÕÅç°w¹ï»´«×®ð³Ýªº¨àµ£±N§l¤J©ÊÃþ©T¾J¡Aªø®Ä«¬¤ä®ðºÞÂX±i¾¯¤Î¦w¼¢¾¯¤À¦¨3²Õ¨Ï¥Î1¦~«áµo²{§l¤J©ÊÃþ©T¾J(Beclomethasone)¹ï®ð³Ý±Ó·P«×ªº§ïµ½³Ì¦n¡A¦ýµu´Á¤º¹ï¨­°ªªº¼vÅT¤]¬O3²Õ¤¤³Ì©úÅ㪺¡C¥t¤@¶µÃþ¦üªº¬ã¨s¤D°w¹ï¤¤­««×®ð³Ýªº¨àµ£§@¤ñ¸û¡A¦bªÍ¥\¯àªº§ïµ½¤´¬O§l¤J©ÊÃþ©T¾J¤@²Õ¦³³Ì¦nªº®ÄªG¡A¦P®É¤£«Øij³æ¿W¨Ï¥Î§l¤J©Êªø®Ä«¬¤ä®ðºÞÂX±i¾¯§@¬°®ð³Ýªºªø´Á±±¨îÃĪ«(Level IE)¡C¹ï©ó®ð³Ý¯gª¬±±¨î¤£¦n®É¡A¦X¨Öªø®Ä«¬¤ä®ðºÞÂX±i¾¯»P§l¤J©ÊÃþ©T¾J»P¼W¥[§l¤J©ÊÃþ©T¾J¾¯¶q¤ñ¸û¡A¤GªÌ¦³¬Û¦üªº®ÄªG(Level IA)¡C¥Ø«e¤´«Øij»P§l¤J©ÊÃþ©T¾J¦X¨Ö¨Ï¥Î(Level IA)¨ÓªvÀø®ð³Ý¡C¹ï©ó¦]¹B°Ê¦Ó»¤µoªº®ð³Ý¡A¹w¥ý¨Ï¥Îªø®Ä«¬¤ä®ðºÞÂX±i¾¯¦³¹w¨¾µo§@ªº¦n³B¡C¦ý¨ä¨Ã¤£¾A¥Î©ó«æ©Êµo§@®Éªººò«æ³B²z¥ÎÃÄ¡C

    ¥Õ¤T²m¯À½Õ¸`¾¯¬OªvÀø®ð³Ýªº·sÃÄ¡C¹ï©ó¤¤­««×®ð³Ýªº¯f¤H¥i§ïµ½ªÍ¥\¯à¡A´î¤Ö©]«y¡A´î¤Ö¨Ï¥Î¤fªAÃþ©T¾J©Îµu®Ä«¬¤ä®ðºÞÂX±i¾¯ªº¾÷·|¡C¹ï©ó¤w¨Ï¥Î§l¤J©ÊÃþ©T¾J¦ý®ð³Ý¼xª¬¤´±±¨î¤£¨Îªº¯f¤H¥[¤W¥Õ¤T²m¯À½Õ¸`¾¯ªº½T¦³¸û¦nªº§ïµ½(Level IA)¡C¥t¥~¹ï©ó¹B°Ê»¤µoªº®ð³Ý¥ç¦³ªvÀø®ÄªG(Level IA)¡CÁöµM¦X¨Ö§l¤J©ÊÃþ©T¾J¨Ï¥Î¦³¥[±jªº®ÄªG¡A¦ý¥Ñ©ó¨ÃµLªø´Á¨Ï¥Îªº¬ã¨sÃÒ¾Ú¡A¦]¦¹»Ý­n§ó¦hªº¤ñ¸û¬ã¨s¨ÓÃÒ©ú¨ä®ÄªG¡C

 

Á`µ²

1.          §l¤J©ÊÃþ©T¾J¬O³Ì¦³®Ä±±¨î®ð³ÝªºÃĪ«¡A¦ý¨Ï¥Î¤´¦]¤H½Õ¾ã¡]Level IA¡^¡C

2.          Inhaled Cromolyn («|¹F¥Ã¼Ö)¬O¦w¥þ©Ê³Ì°ªªºÃÄ¡A¦ý®ÄªG¸ûÃþ©T¾J®t¡]Level IC¡^¡C

3.          ªø®Ä«¬¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¥i´î¤ÖÃþ©T¾J¾¯¶q(Level IB)¡C

4.          ¥Õ¤T²m¯À½Õ¸`¾¯¥Î©ó»´«×®ð³Ý¡A´î¤Ö¹B°Ê»¤µo®ð³Ý¡A´î¤ÖÃþ©T¾J¨Ï¥Î¶q¡]Level IA¡^¡C

5.          ®ð³Ý½Ã±Ð­«­n©Ê¤é¼W¡]Level IB¡^¡C

6.          ¯ùÆP»ù®æ«K©y¡A¦ýÀ³¥Î¤W¦³­­¡]Level IC¡^¡C

7.          ÁקK¹L±Ó­ì¤Î¨ë¿Eª«±`³Q©¿²¤¦ý¤´­«­n¡]Level IB¡^

 

µ²½×

¥Ñ©ó¨àµ£®ð³Ý¯f¤é¯q¼W¦h¡AµLºÃ®ø¯Ó¤F³\¦hªÀ·|¦¨¥»¡C½Ã¥Í¸p¥ç°Ñ¦ÒGINA (Global Initiative for Asthma)²Õ´­q©w¤§¡i®ð³Ý«ü¤Þ¡j¤Î¬ü°ê°ê®a½Ã¥Í¬ã¨s°|»P¥@¬É½Ã¥Í²Õ´¦X½s¤§¡i®ð³Ý¶EÀø«ü¤Þ¡j¡A­q©w¦X¥G°ê¤Hªº¡i®ð³Ý¶EÀø«ü¤Þ¡j¡C¦Ó³o¨Ç«ü¤Þ¤¤¹ï©ó®ð³Ýªº³B¸m¤]³£¬O¨Ì¹êÃÒÂå¾Çªººë¯«¡A¨C­Ó¨BÆJªº¥ÎÃÄ¥²¶·¦³³\¦h¬ã¨sÃÒ¾Úªº¤ä«ù¡A¯à¦b¹ï¤HÅé¦w¥þªº«e´£¤U³Ì¦³®Äªº±±¨î®ð³Ý¡C¦Ü©ó«ü¤Þªº¸Ô²Ó¤º®e¦]½g´T¦³­­¡A¦b¦¹¤£¦h´y­z¡A¤]¥iµ¹ÂåÅ@¤H­û¤Î¤j²³¹ï®ð³Ý¦³§ó²M·¡ªº·§©À¡C¦Ü©ó¤]¦³³\¦h¥tÃþªº®ð³ÝªvÀø¤è¦¡¡A¦³®Ä»P§_¦bÁ¿¨DÃÒ¾ÚÀu¥ýªºÂå¾Ç»â°ì´N¥²¶·¾a¤ÏÂФÎÄYÂÔªº¹êÅç¤Î®É¶¡¨ÓÅçÃÒ¡C

 

 

°Ñ¦Ò®Ñ¥Ø

1.          Evidence-based Asthma Management. J Mark FitzGerald, P. Ernst, LP Boulet, PM O¡¦Byrne. B.C. Decker. 2001

2.          Evidence-based Pediatrics. William Feldman. B.C. Decker. 2000

3.          Evidence-based Pediatrics and Child Health. VA Moyer, EJ Elliot, RL Davis et al. BMJ Book. 2000

4.          ®ð³Ý¶EÀø«ü¤Þ¡C¦æ¬F°|½Ã¥Í¸p 89¦~1¤ë¥Xª©

¡@


¡@

¡@

¦p¦ó¥¿½T¦YÃÄ

 ªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý­·Àã¬ì¥DªvÂå®v

¸­°ê°¶ Âå®v

 

³Ìªñ¤@³s¦êªº¦Y¿ùÃÄ¡A¥´¿ù°wªº·s»DÁ`¬OÅý¤H¼~¤ßÊÝÊÝ¡A°£¤F§Æ±æÂå®v¯àÃĨì¯f°£¥~¡A²`©ÈÂå®v¶}¿ùÃÄ¡A©Î²£¥Í°Æ§@¥Î¡CÃĪ«¦³¤d¸UºØ¡A·sÃĪº¬ãµo¤W¥«§ó¬O¤é¦³©Ò»D¡AÁa¨Ï¬OÂåÃĬɮõ¤æ¤]¤£¯à¤F¸Ñ©Ò¦³ÃĪ«ªº§@¥Î©Î¥Îªk¡C¨ä¹êÃIJzª¾ÃÑÁöÁ}²`ÃøÀ´¡A¦ý¬O¨Ï¥ÎÃĪ«½T»P¤é±`¥Í¬¡®§®§¬ÛÃö¡A¦óªpÃĪ«¬O§@¥Î¦b¦Û¤v¨­¤W¡A¥u­nµy¥[ª`·N«K¥i¦h¤@¤À¦w¥þªº«O»Ù¡C´Nºâ¬Oºû¥L©RÃĤY¤]ºâ¬O¤@ºØÃĪ«¡A¦Y¦h¤F¤£·|§ó°·±d¡A¤Ï¦Ó·|¦³°Æ§@¥Î¡C

 

1.    »â¨ìÃĮɥý¬Ý²M·¡¬O§_®³¨ì¬O¦Û¤vªºÃÄ¡A¦³®É¦£¤¤¦³¿ù®³¨ì§O¤HªºÃÄ¡A©Ò¥H¥ý¹ï¹ï¬ÝÃijU¤W¬O§_¬O¦Û¤vªº¦W¦r¡C

2.    ¬Ý²M·¡ÃĪ«ªººØÃþ¡A²{¦b¦h®aÂå°|ÃijU¤W·|µù©úÃĪº¦¨¤À¤Î§@¥Î¡A¥ý½T©w¬O§_¬O¦X¥G¦Û¤vªº¯gª¬¡C¨Ò¦p©ú©ú¬O·P«_«y¹Â¡AÃijU¤¤«ç»ò¦³­°¦åÀ£ÃÄ¡H¦³¥ô¦ó¥ÎÃĺü{À³¦b¸ß°ÝÂå®v¸Ô±¡¡C

3.    ¦YÃÄ«e¬Ý²M·¡ÃijU¤Wªº»¡©ú¤Î¥Î¶q¥Îªkµ¥¡A¦³ªº¬O¶º«eªA¥Î¡A¦³ªº¶º«á¤~¦Y¡A³o¨Ç³W©wµL«D¬O§Æ±æÃĪ«¯àµo´§°µ¤jªº®ÄªG¡A¥H§K¼vÅTÃĪ«ªº§l¦¬¡C¨Ã¤£¬O¶º«á¦Y¤~¤£·|¶Ë­G¡C¤£¹L­Y»{¯u·ÓÂåÅñ¦YÃÄ¡A¤@¤Ñ¥i¯à­n¦Y¤Q¼Æ¦^ªºÃÄ¡A·|¦Y¨ìÀY¥Öµo³Â¡C¥i½Ð±ÐÂå®v¥i§_¥H¤@°_ªA¥Î¡C

4.    ¦³¨ÇÃĪ«¨Ã¤£¾A¦X¥[¤J¤û¥¤©ÎªG¥Ä¤¤¡A¤@¨Ó¥i¯à´î§CÀø®Ä¡A¦AªÌ¥i¯à§ó·|¤Þ°_°Æ§@¥Î¡C¤£¹L¤]¤£­n³x­^¶¯³á¡A¬°¤Fªí¥Ü«i´±¦Óª½±µ§]ÃÄ¡A­YÃĪ«¦b­¹¹D·»¤Æ¡A¤Ï¦Ó¥i¯à³y¦¨­¹¹Dµoª¢¡C©Ò¥H³Ì¦nÁÙ¬O²VµÛ¶}¤ô§]ªA¡C

5.    ¦³®É¤@¤Ñ­n¦Y¦n¦h¦¸ÃĩΤ@¦¸­n¦Y¦n¦hºØÃÄÁöµMı±o«D±`³Â·Ð¡A¦ý¤´«Øij¨Ì·Ó«ü¥ÜªA¥Î¡AÅýÃĪ«¹F¨ì³Ì¦nªºÃĮġA­YÂ_Â_ÄòÄò¦Y¤£¶ÈµLªkµo´§¨äÃĮġA¦³¨ÇÃĦp§Ü¥Í¯À§ó·|¦]¦¹³y¦¨§ÜÃÄ©Ê¡C

6.    ÃĪ«¤]©M­¹«~¤@¯ë¤]¦³«O¦s´Á­­¡A³£·|¼Ð¥Ü¦bÃIJ~©ÎªÅ²°¤W¡A¹L´Á¤F¤]¤£­nªA¥Î¡C

7.    ¦Û¤v¦Y¤F¦³®ÄªºÃĤ]¤£­n®³µ¹§O¤H¥Î¡A¦]¬°¨C­Ó¤Hªº¯f±¡¤ÎÅé½è¤£¨£±o¬Û¦P¡AÁÙ¬O­n¸gÂå®vªºµû¦ô¤Î³B¤è¤~¦n¡C

 

¥ÎÃĦw¥þ¤£¥u¬OÂå®vÃÄ®vªº³d¥ô¡A¦Û¤v§óª`·N¤]¦h¤@¤À«O»Ù¡C

¡@


¡@

¡@

¥®¨à²Ó¤ä®ðºÞª¢¤ÎªÍª¢

ªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý­·Àã¬ì¥DªvÂå®v

¸­°ê°¶Âå®v

 

    À¦¥®¨à³Ì±`¨£ªº©I§l¹D¯e¯f°£¤F¤@¯ëªº³ïÄVµoª¢¡B«y¹Â¡B¬y»ó¤ôµ¥¤W©I§l¹D·P¬V¥~«K¬O¤U©I§l¹D·P¬V¡A¨ä¤¤³Ì±`µo¥Íªº¬O©Ò¿×«æ©Ê²Ó¤ä®ðºÞª¢¡A³o¤]À¦¥®¨à¦í°|¬O³Ì±`¨£ªº­ì¦]¡C¥V©u¯f¬rÄøÄø±ý°Ê¡A²{¦b¥i¬O¦nµoªº©u¸`¡A®aªø¥i­n¦hª`·N¡C

 

    «æ©Ê¤ä®ðºÞª¢¥D­n¬O¦]¯f¬rªº·P¬V³y¦¨¡A³Ì±`¤Þ°_ªº­P¯f¯f¬r¬°©I§l¹D¿Ä¦X¯f¬r¡A¨ä¥L¦p°Æ¬y·P¯f¬r¡B¸¢¯f¬rµ¥¤]³£¥i¯à³y¦¨Ãþ¦üªº¯gª¬¡C¥D­n¬OÂǥѭ¸ªj¶Ç¬V¡A¦]¦¹®a¤¤­Y¦³¸û¤jªº¤pªB¤Í·P«_«K®e©ö¶Çµ¹¨ä¥Lªº¤pªB¤Í¡C³\¦h®aªø¯Ç´e¤pÀ¦¨à«OÅ@ªº«D±`¦n¡A¤]¨S¦³±a¥Xªù¡A¦Ó¥B®a¤¤¤]¥u¦³³o¤@­ÓÄ_¨©¡A«ç»òÁÙ·|³Q¶Ç¬V¡H¨ä¹ê®aªø¦b¥~¤u§@¡A¥X¤J¤½¦@³õ©Ò«K¦³¥i¯à³Q¶Ç¬V¡A¥u¬O³o¨Ç¯f¬r¨I¿n¦b§Ú­Ìªº»óµÄ©Î³ïÀY¡A¦ý¤j¤H¥i¯à¦­¦³©è§Ü¤O©Ò¥H¨S¦³ªí²{¥X¥ô¦ó¯gª¬¡A©Î¥u¬Oı±o³ïÄV©Ç©Çªº¦Ó¤w¡A¦ý´N¦³¥i¯à¦]¦¹¦Ó¶Ç¬Vµ¹¤pªB¤Í¡C·P¬Vªì´Á®É¤]³\¥u¬O¥´¼QÀ¡¡B¬y»ó¤ô¡Bµo¿Nµ¥»´·L¯gª¬¡Aº¥º¥¦a«K¥X²{©I§l«æ«P¡A©I§l®ÉÅ¥±o¨ì³Ý»ïÁn¡B·ðÁnµ¥¡A§ó¬ÆªÌ¥iÆ[¹î¨ì¤pªB¤Í»óÁlݵ°Ê©Î¦Ø°©¤U½t·|©úÅã¥W³´¡A³o³q±`ªí¥Ü¤pªB¤Í©I§l§xÃø¡A»Ý­n¥Î¨ì»²§U©Êªº©I§l¦Ù¦×¡C¦³®É®aªø¤â´x¶K¦b¨àµ£ªº­I³¡³£¥i·P¨ü¨ì·ð¦bªÍ³¡¤º®¶°Ê¡C¤pªB¤Í³o¼Ëªº¤£µÎªA¦ÛµM­¹¼¤­°§C¡Bļ°Ê¤£¦w¡BºÎ¯v¤£Ã­¤F¡C

 

    ³y¦¨³o¼ËªºÁ{§Éªí²{¥D­n¬O¤pªB¤Íªº¤p¤ä®ðºÞ¦]¯f¬r·P¬V¦Ó³y¦¨¤p¤ä®ðºÞµoª¢¸~µÈ¨Ã»W¿n·ð²G¡A¦]¦¹¦b­ì¥»´N«Ü¤pªº²Ó¤ä®ðºÞ¤Sµo¥Í¤Fªý¶ë¡A¦ÛµM³y¦¨©I§l«æ«P§xÃø¤F¡A¦Ó¦b¸û¤jªº¤pªB¤Í©Î¦¨¦~¤H¡A§Y¨Ï¦³·ð²G¡A¦ý¦]®ðºÞªººÞ®|º¥º¥¦¨¼ô¡B¼W¤j¡A¬Û¹ïªºªý¶ëªºµ{«×´N¤£·|¼vÅT¤Ó¤j¤F¡A©Ò¥H²Ó¤ä®ðºÞª¢³o­ÓÂå¾Ç¦WºÙ¥i»¡¬O¨â·³¥H¤U¨àµ£ªº±M§Q¡C

 

    ¤p«Ä±o¨ì²Ó¤ä®ðºÞª¢¡A¤£¶È¤pªB¤ÍÃø¨ü¡A¤÷¥À¥²©w¤]¾á¤ß¤S¤ß¯k¡A¥u¥i±¤¨ì¥Ø«e¬°¤î¨Ã¨S¦³¯S®Ä¨}¤è°w¹ï¦¹¯fªvÀø¡C¦]¬°¬O¯f¬r·P¬V¡A©Ò¥H§Ü¥Í¯À¬O­^¶¯µL¥ÎªZ¤§¦a¡A§Y¨Ï¦³·ð¡A¨ä¹êªA¥Î«y¹Â¤Æ·ðªºÃĮĪG¦³­­¡A³o®É¥Î¬y»ó¤ôªºÃĨӪvÀø¬y»ó¤ô¡A¦³®É¤Ï¦Ó·|Åý·ðÅÜÂH¸Y¦Ó¤£©ö±Æ¥X¡C¦Ó­n¤Æ·ð¥H§K·ð¿n¦b²Ó¤ä®ðºÞ¤¤¡A³Ì­«­nªº¡uÃÄ¡v¨ä¹ê¬O¡u¤ô¡v¡C¤pªB¤Í©I§l«æ«P¨ä¹êµL§Î¤¤¦b©I®ð®É«K©I¥X¤F³\¦h¤ô¥÷¡A¦A¥[¤W¦]¨­Å餣µÎªA­G¤f¤£¦n¡A¶i­¹ªº¶q¤]´î¤Ö¡A¤ô¥÷ªºÄá¨ú¦ÛµM¸òµÛ´î¤Ö¡A©Ò¥H¦bÃÒ¾ÚÂå¾Ç¤¤¡AªvÀø²Ó¤äºÞª¢³Ì­«­nªº¤èªk¬O¡u¸É¥R¤ô¡v¡C¦Ü©ó§l¤J¤ä®ðºÞÂX±i¾¯¨Ó§ïµ½³Ý»ïªº²{¶H¡A¨Æ¹ê¤WÀ°§Uªº®ÄªG¦³­­¡C­Y¦í°|¤@¯ë·|µ¹¤©Àã¼íªº®ñ®ð¥Î¥HÀ°§U¼íÀã²Ó¤ä®ðºÞ¤ºªº·ð¡F¦b®a¸Ì¥i§Q¥Î¯D«Ç¤º©ñ¼ö¤ô§Î¦¨ªº¤ô»]®ð¨ÓÀ°§U¤Æ·ð¡A¥t¥~¥i¥H±N¤pªB¤Í­w©ñ¦b¤j»L¤W¡A¨{¤l¹Ô­Ó¤p¤ò¤y§Î¦¨ÀY§C¸}°ªªº«º¶Õ¡A±N§Ú­Ìªº¤â´xÅs¥W§Î¦¨ªMª¬¡A¦©À»¤pªB¤Íªº­I³¡¡A¾A·í¥X¤O©ç·ð¨ÓÀ°§U¤pªB¤Í«y·ð¡C¤£¹L¤@¤è­±¤pªB¤Í¤£¨£±o°t¦X¡A®e©ö§á°Ê¡F¥t¤@¤è­±®aªø¤ß¯k¤£´±¥Î¤O©çÀ»´N¨S¦³®ÄªG¡A¨ä¹ê©ç·ð¥¿½T¤pªB¤Í¨Ã¤£·|¨ü¶Ë©Îµhªº¡C

 

    ¦Ü©óªÍª¢¬O«üªÍ¹ê½è¦]·P¬V²£¥Íªºµoª¢¤ÏÀ³¡A¤]´N¬O¤U©I§l¹Dªº²Ó¤p¤ä®ðºÞ¡AªÍªw¡AªÍªwÅnµ¥³£µoª¢¤F¡C¦P¼Ëªº¤]¬OÂǥѪŮ𤤪º­¸ªj¶Ç¬Vªº¡A¤£¹L¦b¤£¦Pªº¦~ÄÖ¼h¦³¥i¯à¦³¤£¦Pªº·P¬V·½¡CÁ{§É¤W­n¥Ñ·ð²G©Î¦å²G°ö¾i¥Xªv¯f²Óµßªº¾÷²v¨Ã¤£°ª¡A©Ò¥H¥u»Ý¥Ñ¯Ý³¡X¥ú¤ÎÁ{§É¯gª¬«K¥i¶EÂ_¡C¨Ò¦p¦b¤@­Ó¤ë¤j¥H¤Uªº·s¥Í¨àªÍª¢¦h¬OB±ÚÃì²yµß¬°¥D¡F¸û¤jªºÀ¦¨à©Î¨àµ£ÁÙ¬O¥H¯f¬r¤Þ°_ªºªÍª¢¬°¦h¡A¦Ü©ó²Óµß¤Þ°_ªº­n¦Ò¼{B«¬¶Ý¦å±ìµß©ÎªÍª¢Âù²yµß¡F¾ÇÄ֨ൣ°£¤FªÍª¢Âù²yµß¥~±`¨£¤@ºØºÙÅð¼ßµßªÍª¢¡A¨ä«D²Óµß¤]«D¯f¬r¡A¤@¯ë¯gª¬¨Ã¤£ÄY­«¡A©¹©¹¥i¤£ÃĦÓ¡¡C¦]¦¹Âå®v®Ú¾ÚÁ{§É¯gª¬©Î¥²­n®É©Ò·Óªº¯Ý³¡X¥ú¨Ó¤U¶EÂ_¡A­Y»{©w¬O¯f¬r©Ê·P¬V¨Ã¤£»Ý§Ü¥Í¯ÀªvÀø¡A¤]¤£¤@©w¦³¶À·ð´N¤@©w­nªA¥Î§Ü¥Í¯À¡C­Y§P©w¬O²Óµß©ÊªÍª¢«h·|®Ú¾Ú¤£¦Pªº¦~ÄÖ¼h¥i¯à·P¬VªºµßºØµ¹¤©¾A·íªº§Ü¥Í¯À¡C

 

    §Ü¥Í¯Àªºµ¹¤©¬O¨Ì·Ó¯fªp¤ÎµßºØ¦Ó¿ï¾Ü¡A©Ò¥H§Y¨Ï¶EÂ_¬°ªÍª¢­Y¬O¹³¯f¬r·P¬V¨Ã¤£»Ý§Ü¥Í¯ÀªvÀø¡A¤ôªº¸É¥R¤´¬O³Ì­«­n¡C­Y¬O²Óµß©ÊªÍª¢¤]¤£¥²ÄߩȧܥͯÀªº°Æ§@¥Î¡A¤@©wªºÀøµ{¨Ã¤£·|¶Ë¨x¶ËµÇªº¡A¾A·íªºªvÀø¤~¯àÃĨì¯f°£¡C¥t¥~«e­zªº©ç·ð¤Î¸É¥R¤ô¥÷¤´¬OªvÀøªº¤£¤Gªkªù¡C¦ý­Y¬OÂå®v§PÂ_¿ù»~¡A»~±N²Óµß©Ê·P¬V·í¦¨¯f¬r·P¬V¦Ó¨S¥Î§Ü¥Í¯À·|¤£·|©µ»~¯f±¡¡H©ÎªÌ°®¯Ü¥ý¦Y§Ü¥Í¯À¥H¨¾¸U¤@¡H¦p¦¹«K®e©ö³y¦¨§Ü¥Í¯ÀÀݥΡA©ö³y¦¨§ÜÃÄ©Ê¡C¦]¦¹Á{§É¶EÂ_»PªvÀø¬O¸gÅ窺²Ö¿n¡Aª¾ÃѪºÀ³¥Î¡A¤]¬O¤@ªùÃÀ³N¡A·íµM¤]¦³¨ä­·ÀI©Ê¡A¦ý¤]µ´¤£¯à¶Ãºj¥´³¾¡A±N©Ò¦³¥i¯àªº¥ÎÃĤ@°_µ¹¤©¡A¨º»ò¨C­Ó¤H«K³£¦¨ÃÄÅø¤l¤F¡C¤£¹L¤@¯ë²Óµß©ÊªÍª¢ªºÁ{§Éªí²{¸ûÄY­«¡A¯fµ{¶i¦æªº¸û§Ö¡A¤pªB¤Íªº¬¡°Ê¤OÅÜ®t¡C©Ò¥H¤p¨à¬ìÂå¥Íµû¦ô¤pªB¤Íªº¯f±¡¨Ã¤£¬O«ü¾aµo¿Nµ{«×¡A¤]´N¬O§Y¨Ïµo¿N¨ì40¢J¡A¤]¤£¤@©w¥Nªí¬OÄY­«·P¬V¡A¤pªB¤Íªº­¹¼¤¡Aºë¯«¡A¤Î¬¡°Ê¤O³£¬O­«­nªº°Ñ¦Ò«ü¼Ð¡CÁ|¨Ò¦Ó¨¥¡A¤pªB¤Íµo¿N«y¹Â¦³·ð¡A·Ó¤FX¥úµo²{©úÅã¥kªÍ¦³ªÍª¢¡A¦ý¬OÁÙ¬O¬¡Â۶øõ¡A¤£¤Ó¹³ÄY­«¥Í¯f¡A³o®ÉÁ{§É¤W·|¦Ò¼{¬OÅð¼ßµßªÍª¢¡A¤]³\¦Y¦Y¬õÅð¯ÀÃþªºÃÄ«K¥i§ïµ½¤F¡C

 

    ²Ó¤ä®ðºÞª¢©Î¯f¬r©ÊªÍª¢¬O¦ÛµM·|¦nªº¯f¡A§Ú­ÌªºªvÀø¬OÀ°§U¤pªB¤Íªº¦]¯gª¬±a¨Óªº¤£µÎªA¡AµM¦Ó³Ì²«K¥B³Ì¦³®ÄªºªvÀøÃĪ«¤£¬O«y¹ÂÃÄ¡B©Ä·ðÃÄ¡A¦Ó¬O¥­²HµL©_¥BÀH¤â¥i±oªº¡u¤ô¡v¤Î®aªøªº­@¤ß¤F¡C­Y¤£©¯·P¬V¨ì²Óµß©ÊªÍª¢´N¥²¶·¥[¤W§Ü¥Í¯À¬Æ¦Ü¦í°|¡C§¡¿ÅÀç¾i¡A®É±`¬~¤â¥i¥H´î¤Ö·P¬Vªº¾÷·|¡A¨ä¹ê¤pªB¤Í¨Ã¤£¯Ü®z¡A¨C¤@¦¸ªº·P¬V¤]³£¦bÁëÁå§Ú­Ìªº§K¬Ì¤O¡C

¡@


¡@

¡@

Baby¥´©I¬O®ð³Ýªº«e¥ü¡H

 

¤pÄ_Ä_ºÎı·|¥´©I¡A¬O¤£¬O»ó¶ë·P«_¤F¡H¨­¬°¤÷¥ÀÃø§Kºò±i¦ÛµM·|´M¨DÂåÀø¨ó§U¡C¤p¨à¬ìÂå®v¦b¬Ý¤p¯f¤H®É­º¥ý«K¬Oª`·N¦~ÄÖ¡A¦]¬°¤£¦P¦~ÄÖ¼h¦³¨ä¤£¦Pªº¦nµo¯e¯f¡A§Y¨Ï¦P¼Ë¬O¥´©Iªº¯gª¬¤]·|¦³¤£¦Pªº¦Ò¶q¡C

³\¦h·s¥Í¨à©ÎÀ¦¨à¦b³Ü¥¤©ÎºÎı®É±`·|¸û¤jªº»ó®§Án¡A¦n¹³¤p½Þªº¥sÁn¡AºÎı®É¬Æ¦Ü·|¥´©I¡Cªì¬°¤÷¥Àªº®aªø«K¾á¤ß¤pÄ_¨©·P«_¤F¡A²¦³º¥L­Ì¬Ý°_¨Ó¨º»òªº¼b®z¡A¨ì³B¨DÂå¦ý½TµLªk§ïµ½¯gª¬¡C¨ä¹ê­è¥X¥Íªº·s¥Í¨à¨ä¦ì©ó³ïÄV³¡¦ìªº¸¢¼ËÅé¡A©|¥¼§¹¥þ°h¤Æ¡A¦]¦¹¦b§l¥¤®É¡A©Î©]Áñ¤HÀR®É¡A¥i¯à·|Å¥¨ì¥´©IªºÁn­µ¡AµM¦Ó³o½T¬O¥¿±`ªº²{¶H¡A¦pªG·í¦¨·P«_ªvÀø¦ÛµM¬OÃĥ۪ɮġC©Ò¥H¤@¤è­±¥iÆ[¹î¤pªB¤Íªº©I§l³t²v¡A·s¥Í¨à¤£¤ñ¦¨¤H¡A¤@¯ë¤@¤ÀÄÁ©I§l26-28¤U¬O¥i±µ¨üªº¥¿±`½d³ò¡C¥t¥~¥iÆ[¹î¬O§_¦³»óÁlݵ°Ê©Î¦Ø°©¤U¥W³´µ¥©I§l«æ«Pªºªí²{¡C¨ä¹êÀ¦¥®¨à¥u­n¦Y±o¥¿±`¡BºÎ±o­»²¢¡A¤Q¤§¤K¤E³£¬O°·±dªºÄ_Ä_¡C

¦Ó¦pªG¬O¤@­Ó¦~¬ö¸û¤jªº¤pªB¤ÍºÎı®É·|¥´©I«K­n¦Ò¼{¨ì¦b»óµÄ©Î«|³ï¦³³¡¤Àªý¶ë¡A·íµM©I§l¤£¶¶ºZ¦ÛµM·|µo¥XÁn­µ¡C³Ì±`¨£ªº­ì¦]«K¬O©Ò¿×ªº·P«_¡AµM¦Ó³oÃþªº¯f¬r·P¬V©Ò³y¦¨ªº¥´©IÀ³¤£·|«ùÄò¤Ó¤[¡AÀHµÛ·P«_»ó¶ëªº¯gª¬¸Ñ°£²zÀ³®ø¥¢¡C¦pªG¨S¦³·P«_¦ýªø´Á¦³»ó¶ë©ÎºÎı¥´©Iªº±¡§Î«K­n¦Ò¼{¨ä¥L­ì¦]¡C¹L±Ó­Ë¬O¨ä¤¤±`¨£ªº¦]¯À¡C¦]¬°»ó¤lªº¹L±Ó¤ÏÀ³·|¼W¥[¤Àªcª«¡A¤]·|¨Ï»óÂH½¤¸~º¦¦Ó¼vÅT©I§l¹Dªº¶¶ºZ¡A·íµM´N·|¥´©I¤F¡C

¹L±Ó¯gª¬ªº²£¥Í©¹©¹¬O´`§Çº¥ªñªº¡A·s¥Í¨à¨Ã¤£·|¤@¥X¥Í«K¶}©l¦³®ð³Ý¯gª¬¡A§Y«K¬Oªí²{¥X©I§l«æ«P¬Æ¦Ü»´·L³Ý»ïÁn¤]¤£·|°¨¤W¦Ò¼{¦³®ð³Ý¯f¡CÀ¦¥®¨à¹L±Ó¯g©¹©¹¬O¥H¥Ö½§ªº¹L±Óªí²{¬°¥ý¡A©¹©¹·|¦bÁy¤W¡B¥|ªÏ©Î²ä¤lµ¥¸û©ö¥X¦½ªº¦a¤è¥X²{¬õ¯l¡A¤@¯ëºÙ¤§¬°Àã¯l©Î²§¦ì©Ê¥Ö½§ª¢¡Cº¥º¥ªº¥i¯à¦³»ó¤l¹L±Óªº¯gª¬«Kªí²{¥X¨Ó¤F¡A¦p¦­¤W°_§É®e©ö¥´¼QÀ¡¡A¦]»ó¤lÄo¦Ó±`¦³´|»ó¤lªº°Ê§@¡A·íµM¤]·|¦]»ó¶ë¦Ó¦³¥´©IÁn¡C¦Ü©ó©I§l¹Dªº¹L±Ó¤ÏÀ³©ÎªÌ»¡¬O®ð³Ý¡A©¹©¹¬O¦b3~4·³º¥º¥²£¥Í©úÅã¯gª¬¡C©Ò¿×ªº¡u¹L±Ó¶i¦æ¦±¡v«K¬O«ü¹L±Ó¯gª¬ªº¶¥¬qÅܤƩʡA¦]¦¹·s¥Í¨à¦³¥´©IÁn¬Æ¦Ü©I§l¦³³Ý»ïÁn¡A¨Ã¤£·|°¨¤W¦Ò¼{¬O®ð³Ý¡CµM¦Ó­Y¬O¤ÏÂЦ³³Ý»ïÁn¡A¯gª¬¦n¤£®e©öªv¦n¤F¦ý¨S¦h¤[¤S¦³¥t¥~¤@¦¸ªº¯gª¬¡A«K­n¦Ò¼{¬O¥®¨à©Ê®ð³Ý¡C­Y¥H®ð³Ýªº¤è¦VªvÀø¤´¥¼¨£§ïµ½¡A§ó­n§ä¨ä¥Lªº­ì¦]¡A¦p­G­¹¹D°f¬y©Î¥ý¤Ñ©Ê¤ßŦ¦åºÞªººc³y©Î¨«¦V²§±`¡A³o¨Ç³£»Ý­n¶i¤@¨BÀˬd¤~¯à°÷½T©w¡C¹ï©ó¤j¤pªB¤Í¦Ó¨¥¡A®ð³Ý³Ì±`¨£ªºÁ{§Éªí¼x¬°ºC©Ê«y¹Â¡A¦Ó¥B¦­±ß¯gª¬¸û©úÅã¡A¤£¤@©w­n¦³³Ý»ïÁn¡C¥´©IÁn¥D­n­n¨Ó¦Û©ó»óµÄ¤Î³ïÀY¡A³Ý»ïÁn«hµo¦Û©ó®ðºÞ¡A¨âªÌ³£¥i¯à¦bºÎı®É©úÅã¡A¦ý¥NªíªºÁ{§É·N¸q¥ç¤£¦P¡C

ÁöµM®ð³Ý¬O¤@ºØ¦h°ò¦]¿ò¶Çªº¯e¯f¡A¦ý¨Ã¤£¬O¤@¥X¥Í«K·|®ð³Ý¡A©M«á¤ÑÀô¹Òªº¼vÅTµ´¹ï¦³³s±aÃö«Y¡C¤@¯ë«D¹L±Ó­ì»¤µoªº®ð³ÝºÙ¬°¤º¦]«¬®ð³Ý¡A¤]´N¬O¥i¯à·|¦]·P«_©Î¤G¤â·Ïµ¥«D¹L±Ó­ìªº¦]¯À¦Ó»¤µo¡A©â¦åÀˬd«o´ú¤£¨ì¹L±Ó¤ÏÀ³¡A¦ýÁ{§Éªº¯gª¬ªº½T¬O®ð³Ýªºªí²{¡C¥t¤@ºØ«h¬°¥~¦]«¬®ð³Ý¡A¤]´N¬O·|¦]±µÄ²¨ì¹L±Ó­ì¦Ó»¤µo®ð³Ýªº¯gª¬¡C¥Ñ¦¹¥i¤F¸Ñ®ð³Ýªº¶EÂ_¨Ã«D¾a¥ô¦ó©â¦å©Î¢æ¥úÀˬd¡A³Ì­«­nªº¤Ï¦Ó¬O¯f¥v¤Î¨­Åé²z¾ÇÀˬd¡C¤@¯ë¦Ó¨¥¤º¦]«¬®ð³Ý¬ù¦û¤Q¤À¤§¤@ªº¤ñ¨Ò¡A¤£¹Lµ´¤j³¡¤À³£¬O¥ý¤ÑªºÅé½è¥[«á¤ÑªºÀô¹Ò³y¦¨¡A¨âªÌ¦bªvÀø¤W¤Î¥Í¬¡·ÓÅ@¤W¨ÃµL¤£¦P¡C®ð³ÝÁöµM»P¿ò¶Ç°ò¦]¦³Ãö¡A¦ý¨Ã«D¤÷¥À¥ô¤@¤è¦³®ð³Ý¤~·|¿ò¶Ç¡AÀ³¸Ó»¡¹L±ÓÅé½èªº¿ò¶Ç¡A¦Óªí²{¦b©I§l¹Dªº¹L±Ó¤ÏÀ³«K¬O®ð³Ý¡C¨Ò¦pª¨ª¨ÁöµM¨S¦³®ð³Ý¦ý«o¦³»ó¤l¹L±Óªº¯gª¬¡A¦Ó¤pÄ_Ä_¥i¯à¿ò¶Ç¨ì¹L±ÓÅé½è¦Óªí²{¦b®ðºÞ¡A¦Ó¦¨®ð³Ýªº¯gª¬¡C

    ¬JµM®ð³Ý·|¦]±µÄ²¥~¦bªº¨ë¿Eª«©Î¹L±Ó­ì»¤µo¡A¦]¦¹ªvÀøµ´¤£¥u¯à¾aÃĪ«¡A¤]»Ý­nÀô¹Òªº°t¦X¡A¥u­n´î¤Ö¹L±Ó­ìªº±µÄ²´N¥i¥H´î¤Öµo§@ªº¾÷·|¡C¨ä¹ê¦³¾÷·|§ó¤F¸Ñ®ð³Ý¯f¡A°Ñ»P®ð³Ýªº½Ã±Ð¬¡°Ê¡A¤]«D±`­«­n¡C³Ì±`¹J¨ìªº«K¬O¹ï®ð³Ý¯f¤@ª¾¥b¸Ñ¦Ó¥¼¯à±µ¨üªø´Á¥B§¹¾ãªºªvÀø¡C¨Ò¦pªvÀø®ð³Ý³Ì­«­nªºÃÄ«K¬O¡y§l¤J«¬Ãþ©T¾J¡z¡A¤£¹L¤@¯ë¤H¥u­nÅ¥¨ì¡yÃþ©T¾J¡z3­Ó¦r²ö¤£°hÁפTªÙ¡A¤@¤è­±®`©ÈÃþ©T¾Jªº°Æ§@¥Î¡A¥t¤@¤è­±¤S¥H¬°¯gª¬§ïµ½¤F¨Ï¦Û°Ê°±ÃÄ¡A©Èªø´Á¨Ï¥Î·|¶Ë¨x¶ËµÇ¡C¨ä¹ê¹ï¯e¯f¥»¨­¤£¤F¸Ñ¡A¥H¤Î¹ïÃĪ«ªº»~¸Ñ¦Ó¥¼¯à°t¦XÂåÅñ¡A¤Ï¦Ó·|¨Ï®ð³Ý¯gª¬±±¨î¤£Ã­©w¡A§ó·|¤ÏÂЬݯf©Î¦YÃÄ¡C¦bÁקK¹L±Ó­ì¤è­±¡A¤é±`¥Í¬¡¤WÀ³ª`·N°£Àã¡A±±¨î¬Û¹ïÀã«×¥ª¢´¢¯¢H¨ì¢µ¢¯¢H¤§¶¡¡A¦]¬°¹L±Ó­ì¦p¹Ð蟎©ÎÅðµß³Ì³ßÅw¼éÀ㪺Àô¹Ò¡A¤×¨ä¥xÆW§ó¬OÄÝ©ó¼éÀ㪢¼öªº®ü®q«¬®ð­Ô¡A§ó¾A¦X¹L±Ó­ì´þªø¡A­°§CÀã«×¤£¶È¥Í¬¡µÎ¾A¤]¥i´î¤Ö¹L±Ó­ì¡C§É³æ¡BªEÀY®M¡A³Q³æµ¥Âæ³¹L±Ó­ìªºª««~³Ì¦n¨â¬P´Á´N´«¬~¤@¦¸¡A¬~«á¯M°®©ÎÅΰ®¡C¥t¥~¤G¤âµÒÁö«D¹L±Ó­ì¦ý¬O¥þ¥@¬É¤½»{©ö»¤µo®ð³Ýªº¨ë¿Eª«¡A©Ò¥HÀ³ÁקK§l¤J¡C¦Ü©ó¦b¶¼­¹¤è­±­º­«Àç¾i§¡¿Å¡A¤d¸U¤£»Ý¦]®`©È¹L±Ó¦Ó­­¨î¶¼­¹¡A¦~¬ö¶V¤jªº¤pªB¤Í¸z­G¹D§ó¦¨¼ô¡A§ó¤£·|¦]¦Y¨ì¬YºØ­¹ª«¦Ó»¤µo®ð³Ý¡C¦Ü©ó2·³¥H¤Uªº¤pªB¤Í´Nª`·N¤£­nÄá¨ú°íªGÃþ¡A³JÃþµ¥¹L±Óªº­¹«~¡A«Ý¸z­G¹DÀH¦~ÄÖ¼Wªø¦Ó§ó¦¨¼ô«á¦A²K¥[¡C

    ®ð³Ýªº¤pªB¤Í¤j¬ù¤K¦¨·|¦X¨Ö¦³¹L±Ó©Ê»óª¢¡A±`¨£ªº¯gª¬«K¬O¦­¤W¥´¼QÀ¡¡B´|»ó¤l¡B¬y»ó¤ôµ¥¡C»ó®÷¤£·|ìì¡A«K©¹¤º§l¡A¤[¦Ó¤[¤§«K®e©ö¦X¨Ö¦³»óÄuª¢¡A¦Ó¦³»óÄuª¢­Y¤£ªvÀø¦n¤S·|Åý®ð³Ý¤£©ö±±¨î¡A¦]¦¹ªvÀø¤W­n¦P®Éª`·N³o¤T¤è­±ªº°ÝÃD¡C¤£¹L¥´©I¬O§_´N¥i¹w´ú¬O§_¦³®ð³Ý­Ë¬O­n¤£¥²¤Ó´dÆ[¡A¤Ï¦Ó¬O¦Ò¼{¨ì¬O§_¦³¹L±Ó©Ê»óª¢©Î¦X¨Ö»óÄuª¢ªº¯gª¬¡C¥t¥~¡A»ó¤¤»JÅs¦±¡B¹L­Dµ¥µ¥¤]³£·|¥´©I¡A©Ò¥H­Ë¤£¥²¥u­n¤pbaby¤@¦³¥´©IÁn«K¾á¤ß·P«_¤F©Î±N¨Ó·|®ð³Ý¡C¥´©I¬O¤@ºØÁ{§Éªí¼x¡AÀ³­n´M§ä¦óºØ¯e¯f¤Þ°_¡CÁöµM¦³¬ã¨sµo²{¥´©I»P®ð³Ý¥i¯à¦³Ãö¡A¦ý¤]¤£¥²¦]¤pªB¤Í·|¥´©I«K¾á¤ß±N¨Ó¦³®ð³Ý¡C²¦³º®ð³Ý¤]¬O¤@ºØ¹L±Ó©Ê¯e¯f¡A©¹©¹·|¦X¨Ö¨ä¥L¹L±Ó¯gª¬¡C½T©w¬O®ð³Ý«h§ó»Ý­nªø´Á°t¦X±M¬ìÂå®v±±¨î¯f±¡¡A´N¯f²z¾ÇªºÆ[ÂI¤£¯à»¡®ð³Ý¥i®Úªv¡A¦ýµ´¤j³¡¤À³£¥i¥H±±¨î¨ì¤£»Ý¥ÎÃĤ]¯f±¡Ã­©w¡A³Ì»ÝÅU§Òªº¤Ï¦Ó¥¼¯à¤F¸Ñ®ð³Ýªº¥»½è¦Ó¬qÄòªvÀø¡A©¹©¹¨Ï®ð³Ý¯gª¬¤£Ã­©w¡C

ºK¿ý¦Û¡¨ ¶ý¶ýÄ_Ä_12¤ë¸¹¡¨


¡@

¡@

¡@

²§¦ì©Ê¥Ö½§ª¢

ªø©°¨àµ£¹L±Ó®ð³Ý­·Àã¬ì¥DªvÂå®v  ¸­°ê°¶

 

²§¦ì©Ê¥Ö½§ª¢¬O¤@ºØºC©Ê¡A¦Ó¥B·|¤ÏÂеo¥Í¡A©_ÄoµL¤ñªº¥Ö½§ª¢¤ÏÀ³¡C¥¦¬O¤@ºØ¥Ö½§ªº¹L±Ó¤ÏÀ³¡AµM¦Ó¥H¬ì¾ÇªºÆ[ÂI¡A¤S¥i¤À¬°¹L±Ó©Ê(¥~¦]©Ê)ªº¤Î«D¹L±Ó©Ê(¤º¦]©Ê)ªº§ÎºA¡C«eªÌ¤j¬ù¦ô70-85%¡A¥D­n¬O»P¥~¦bªº¹L±Ó­ì¨Ó»¤µo¯e¯fªº¯gª¬¡A¦Ó«áªÌ¬J¦W¬°¤º¦]©Ê¡A¤]´N¬O§ä¤£¥X¯S©wªº¤Þ°_¹L±Óªº­ì¦]¡A³o³¡¤Àªº¯f¤H¤j¬ù¦ô15-30%¡A¦ýµL½×¨º¤@ºØ«¬ºA¡AÁ{§É¯gª¬­Ë¬O¬Û¦Pªº¡C

±Nªñ9¦¨ªº²§¦ì©Ê¥Ö½§ª¢¦b5·³¥H«e«K¶}©l²£¥Í¯gª¬¡AÀHµÛ¦~¬öªº¼Wªø¡A¯gª¬º¥º¥§ïµ½¡CµM¦Ó¥~¦]«¬ªº²§¦ì©Ê¥Ö½§ª¢¡A±N¨Ó¦³3~6¦¨ªº¾÷²v·|µo®i¦¨©I§l¹Dªº±Ó·P©Î®ð³Ý¡A¦Ó¤º¦]«¬ªº²§¦ì©Ê¥Ö½§ª¢¦ý¸û¤£·|¦³¦¹ºtÅÜ¡C

 

²§¦ì©Ê¥Ö½§ª¢ªº»¤µo¦]¤l

³y¦¨²§¦ì©Ê¥Ö½§ª¢¯gª¬ªº­ì¦]¨ä¹ê»P°ò¦]¡BÀô¹Ò¤Î§K¬Ì¨t²Î³£¦³³s±aÃö«Y¡A³Ì±`¨£ªº»¤µo¦]¤l²ö¹L©ó­¹ª«¡A³J¡B¤û¥¤¡Bªá¥Í¡B¤j¨§¡B³Á¡B³½¤Î°íªG¬O³Ì±`¨£ªº¤CÃþ­¹ª«¡A¦ÓªÅ®ð¤¤ªº¹L±Ó­ì¨Ã¤£¬O¥u»P®ð³Ý¦³Ãö¡A´î¤Ö«Ç¤º¹Ð蟎ªº¦s¦b¤]¥i´î»´¯gª¬¡A¦Ü©ó°Êª«ªº¥Ö½§»PÁ­½¸µ¥¹L±Ó­ì»P²§¦ì©Ê¥Ö½§ª¢ªº¦]ªGÃö«Y«h»Ý§ó¦hªº¬ì¾ÇÃÒ¾Ú¡A¨ä¥L¤@¨ÇÀô¹Ò¤¤«D¹L±Ó±Ó­ìªº¨ë¿E¦]¤l¤]·|»¤µo²§¦ì©Ê¥Ö½§ª¢¡C¨Ò¦pªw¼ö¤ô¡B¥Îµæ¥Ê¥¬¨ê¬~¨­Åé¡AÁö¦³µu¼È¦³¤îÄoªº·Pı¡A¦ý½T·|¾A±o¨ä¤Ï¡C¬y¦½¤]¬O¤@ºØ¨ë¿E¦]¤l¡A©Ò¥H·íµM«Øij¬ï´Ö½è¡B³z®ðªº¦çªA´î¤Ö³Q¨ë¿Eªº¾÷·|¡C¤ß²z¦]¯À¤]¤£¯à©¿²¤¡A¦³²§¦ì©Ê¥Ö½§ª¢ªº¤pªB¤Í¡A¦]¬°Äo¦ÓºÎ¤£¦n¡A¦]¬°Äo¦Ó¦b±ß¤W¤£¦Ûıªº·kÄo¡A³o¨Ç¤£¶ÈÅý²§¦ì©Ê¥Ö½§ª¢§ó´c¤Æ¡A¤]¦]ºÎ±o¤£¦wí¦Ó¼vÅT¤é±`ªº¦æ¬°¡CµJ¼{¤ÎÀ£¤Oªº½T·|¨Ï¨­Åé¤Àªc§ó¦hªºµoª¢©Î¤Þ°_Äo·Pªºª«½è¡C

 

²§¦ì©Ê¥Ö½§ª¢ªº³B¸m

­n§¹¥þ±±¨î²§¦ì©Ê¥Ö½§ª¢»Ý­n¦h­±¦Vªº³B¸m¡A¥]¬A¥Ö½§«OÀã¡AÃĪ«ªvÀø¥H¤Î¥h°£»¤µo´c¤Æªº¨ë¿Eª«¡C

 

¥Ö½§«OÀã

²§¦ì©Ê¥Ö½§ª¢ªº¯f¤H¥Ö½§°Ï¯Ê¥F¤F¤@¼h«Ì»Ù¡A§ó®e©ö³y¦¨¤ô¤Àªº¬y¥¢¡A§ó©ö³y¦¨¥Ö½§·L²ÓªºµõÁ_¡A¤]¬O³y¦¨¹L±Ó­ì©Î¨ë¿Eª«©ö«I¤J¤§³B¡C¨ä¹ê¥i¥Î·L·Åªº¤ô®ûªw20¤ÀÄÁ¡A¤§«á¤£­n¥Î¤OÀ¿°®¡A¦Ó¬O»´·L©ç°®¡A¦A¶î©Ù«OÀã¨Å²G¡A¥i«O«ù¥Ö½§ªº¤ô¤À¤]¥i­×´_¥Ö½§ªº¨¤½è¼h¡C°µ¦n«OÀã¤]¥i¼W¥[¥~¥ÎÃþ©T¾JÃÄ»I§l¦¬ªº®ÄªG¡C¹ï©ó·¥ÄY­«ªº³¡¦ì¥i¨Ï¥ÎÀ㯽¥¬Âл\«ùÄò«OÀã¡A¨Ã¶î¤W«OÀã¨Å²G¡C

 

Ãþ©T¾JÃÄ»I

    ¨ä¹êÃþ©T¾J¤@ª½¬O«D±`­«­nªº§Üµo¨¥ÃĪ«¡A¥u¬O­I¤W¤FÃþ©T¾Jªº²±¦W¤§²Ö¡A¦Ó¨Ï¤j²³»Dª¾¦âÅÜ¡CÃþ©T¾JÃÄ»I°£¤FªvÀø«æ©Ê´Áªº¥Ö½§¯gª¬¡A¦³¨Ç·sªº¬ã¨s¤]«Ø¤@¬P´Á¨â¦¸¶î©Ù¦b¦nµoÀã¯lªº³¡¦ì¤]¥i¹F¨ìªø´Á±±¨îªº¥Øªº¡CÃþ©T¾JÃÄ»I¤@±j«×¥i¤À¤C­Óµ¥¯Å¡A°£¤F¦³¨Ç³¡¦ì¤wºC©Ê­aÅ~¤Æ¥i¥Î¸û±jªº§½³¡Ãþ©T¾JÃÄ»I¡Aªø´Á¦Ó¨¥ÁÙ¬O­n¾a«OÀã¤Î§C±j«×ªºÃþ©T¾JÃÄ»I¨Óºû«ùªvÀø¡C

 

µL¥i±ÏÃĪºÄo   

    ²³æªº»¡Â²³æªº»¡¥u­n±±¨î¥Ö½§ªºµoª¢´N¥i±±¨î¾iªº·Pı¡A¤£¹LªÌ¥u¬O¯È¤W½Í§L¡C¯f¤H©¹©¹´N¬OÄo¦Ó¤£¦Û¥Dªº·k§ì¦Ó¨Ï²§¦ì©Ê¥Ö½§ª¢§ó´c¤Æ¡C§Ü²Õ´Ói¬O³Ì±`¥Îªº¤îÄoÃĪ«¡A¤£¹L²Õ´Ói¥u¬O³y¦¨¥Ö½§Äoªº¤p³¡¥÷¦]¯À¡A¦]¦¹¨Ï¥Î§Ü²Õ´Ói¨Ã¤£¤@©w¦³®Ä±±¨îÄoªº·Pı¡A¦³®É¤Ï¦Ó¬O§Q¥Î¨äÂíÀRªº°Æ§@¥Î¨Ó¹F¨ì¤îÄoªº®ÄªG¡C¦Ó·s¤@¥Nªºªø®Ä§Ü²Õ´Ói¨Ã¤£¤@©w´N¤ñ¸û¦³®Ä¡C¥Ñ©óÄo·P©¹©¹¦b±ß¤W¸û©úÅã¡A©Ò¥H¦bºÎ«e¥i¿ï¥Î©ö³y¦¨¶ÝºÎªº²Ä¤@¥N§Ü²Õ´ÓiªA¥Î¡C¦Ü©ó®ÄªG¤´¤£¨ÎªÌ¡A¥i¨Ï¥Î¦pdoxepinªº»´·L§Ü¼~Æ{¾¯¦P®É¤]¦³§Ü²Õ´Óiªº®ÄªG¡C

 

ÁקK±µÄ²¹L±Ó­ì

Àô¹Òªº±±¨î¨ÓÁקKªÅ®ð¤¤ªº¹L±Ó­ì¤]¬O¥þ¤è¦ìªvÀø²§¦ì©Ê¥Ö½§ª¢­«­nªº¤@Àô¡A³o¨Ç§ïµ½¹L±Ó­ìªº¤è¦¡³£¬O¦Ñ¥Í±`½Í¡C³\¦h¯f¤H¤]®Ú¾Ú«Øij´«¤F¨¾蟎¹ì¨ã¡A¥Î¤F°£Àã¾÷¡BªÅ®ð²M²b¾÷µ¥µ¥¡A¤]¾¨¶q¤£¥Î¥¬»s«~ªº®a¹¢¡A¦ý¯gª¬«o¤£¨£§ïµ½¡C¦ý¾Ú²Î­p¡A¥u¦³10%ªº¯f¤H·|§¹¥þ¨Ì·Ó«Øij¨ÓÁקK¹L±Ó­ì¡A²¦³º­n«ùÄò´î¤Ö¹L±Ó­ì¡A¤£¶Èªá¿ú¶O®É¡A¦P®É§ïÅܤF§Ú­Ìªº¥Í¬¡«¬ºA¡A¦ý½T¦³«Ü¦h¬ã¨sÃÒ¾ÚÅã¥Ü¨ä»P²§¦ì©Ê¥Ö½§ª¢¦³³s±aÃö«Y¡A§ä¥X»¤µo¦]¤l¥u¬O­Ó°_ÂI¡A«ùÄòªº½Ã¥Í±Ð¨|§ó»Ý¥[§â«l¡C

 

¥Ö½§·P¬V

    ²§¦ì©Ê¥Ö½§ª¢ªº¥Ö½§¤W±`·|¦³ª÷¶À¦â¸²µå²yµß·P¬V¡A¦Óª÷¶À¦â¸²µå²yµß·|²£¥Í¶W§Ü­ì§ó©ö»P¥Ö½§²Ó­Mµ²¦X¦Ó³y¦¨¯gª¬´c¤Æ¡C¥²­n®É©Î¥Ö½§¦³²Óµß·P¬V®ÉÀ³°t¦X¨Ï¥Î¹ï§Üª÷¶À¦â¸²µå²yµßªº§Ü¥Í¯À¡A§½³¡·P¬V¤]¥i¥Î§Ü¥Í¯ÀÃÄ»I¶î©Ù¡C¥t¥~²§¦ì©Ê¥Ö½§ª¢ªº¥Ö½§¤]·|¨ü¯f¬r¦p疱¯l¯f¬rªº·P¬V¡C¦Ó³y¦¨Äjº©©Ê©_Äoªº¤p¤ôªw¡A³o¨Ç¤p¤ôªw¬Æ¦Ü·|¥X¼g³o¨Ç¤p¤ôªw¬Æ¦Ü·|¥X¦å¡Aµ²¯m¡C¦³®É¤]·|³Q»~»{¬°¬Oª÷¶À¦â¸²µå²yµßªº·P¬V¡C­YÃhºÃ¬°疱¯l¯f¬r·P¬V¡A¥i¼È°±§½³¡Ãþ©T¾JÃÄ»I¡A¨Ã¶}©l¥Î§Ü¯f¬rÃĪ«¡C

 

·sªºÀÆ¥ú

    ªø´Á¥H¨Ó¹ï©ó²§¦ì©Ê¥Ö½§ª¢¨S¦³§ó¦³®Ä¡A§ó·sªºªvÀø¤è¦¡¡CÃø±o¦b«e´X¦~¸g¥Ñ¦h¦~ªºÁ{§É¸ÕÅçµ²ªG¡A²×©ó¦³·sªº«DÃþ©T¾J¡A±MªùªvÀø²§¦ì©Ê¥Ö½§ª¢ªºÃÄ»I¤W¥«¡A¤@¬°¡y´¶¯S¥Ö¡z¡A¤@¬°¡yÂå¥ß§´¡z¡C³oÃþÃÄ»I¦Ü¤Ö¦w¥þ¡A¨Ã¤£·|¦pÃþ©T¾JÃÄ»I³y¦¨¥Ö½§ÅÜÁ¡©Î¥þ¨­§l¦¬¡A¦Ó¥B¦³¹êÃÒÅã¥Ü¨äÁ{§É®ÄªG¡C³ø§iÅã¥Ü¨Ï¥Î¤T¤Ñªº´¶¯S¥Ö«K¥i´î¤ÖÄo·P¡A¥u¬O­è¥Î®É¥Ö½§¦³µy·L¨`¼ö·P¡A¤@¬P´Á«K·|®ø¥¢¡A¤d¸U¤£­n¦]¦¹¦Ó°±¤î¥ÎÃÄ¡C

 

   ¹ï©ó²§¦ì©Ê¥Ö½§ª¢¡A«OÀã¬Oµ´¹ïªº»Ý­n¡A¹ïÃþ©T¾JÃÄ»I¤£¥²¦]¤£ª¾¦Ó®£·W¡A¦Ó¬O§óÁA¸Ñ³oÃþªºÃĪ«¡C¹ï©ó·sªºÃĪ«¤£¥u´Á«Ý¡A§ó­nÁA¸Ñ¤ÎÆ[¹î¡A¦ý¤]§O§Ñ¤F¿í´`¶Ç²Îªº«ØijªvÀø¡C

ºK¿ý¦Û¡¨°·±d¥@¬É¡¨

 


¡@

²¾°£«Ç¤ºªº¹L±Ó­ì

ªø©°¨àµ£Âå°| ¨àµ£¹L±Ó®ð³Ý­·Àã¬ì    ¸­°ê°¶Âå®v

±`Å¥»¡¤pªB¤Í¹ï®a¹Ð¹L±Ó¡A¦Ó©Ò¿×ªº®a¹Ð¨Ã«D«ü±q«Ç¥~­¸¶i«Î¤ºªº¦Ç¹Ð¡A¦Ó¬O«ü·½¦Û©ó®a¤¤ªº¥Î«~²æ¸¨©Î¤À¸Ñ«á©Ò²£¥Íªº·¥·L²Óªº¹Ð®J¡C®a¹Ðªº¦¨¤À¥]¬A¤H©ÎÃdª«ªº¥Ö½§²æ¸¨ªº¥Ö®h¡AÅðµß¡AÁôÂéó§É³æ¡B§É¹Ô¤¤ªº¹Ð蟎µ¥¡A¨ä¤¤ªº¹Ð蟎§ó¬O³y¦¨¥xÆW¨àµ£¹L±Ó¯gª¬¥]¬A®ð³Ý¡B¹L±Ó©Ê»óª¢µ¥ªº­º­n¦]¯À¡CªvÀø¹L±Ó¯g¤£¥u¬O¾aÃĪ«ªº§@¥Î¡AÀô¹Òªº±±¨îµ´¹ï¬O«D±`­«­nªº¤@Àô¡A¥²¶·¬Û»²¬Û¦¨¤~¯à¦³®Ä±±¨î¯gª¬¡C´î¤Ö¹L±Ó­ìªº¨ë¿Eªº¾÷·|¡A¦ÛµM´î¤Ö¹L±Ó¯gª¬ªº²£¥Í¡C

»Ý­n¥ÎªÅ®ð²M²b¾÷©Î¬O°£Àã¾÷¡H

¹Ð蟎³Ì³ßÅw¼éÀã·Å·xªºÀô¹Ò¡A­n¥h°£¹Ð蟎À³¿ï¾Ü°£Àã¾÷¡C±N«Ç¤ºªºÀã«×±±¨î¦b¬Û¹ïÀã«×50%¦Ü60%¤§¶¡¡A¬J¤£·|¤Ó°®Àê¦Ó·P¨ì¤£¾A¡A¤S¥i´î¤Ö¹Ð蟎¤ÎÅðµßªº¦s¦b¡C¥Ñ©ó¹Ð蟎ªº­«¶q¸û¯»¹Ð¥Ö®h¬°­«¡A°£«D²M±½©Ð¶¡¡A§_«h¤@¯ë¦b«Ç¤ºÀR¤îªºªÅ®ð¤¤¹Ð蟎¨Ã¤£·|¨ì³B­¸´­¡A¦]¦¹ªÅ®ð²M²b¾÷¨Ã¤£¯à®É®Éµo´§¨ä¥h°£¹Ð蟎ªº¥\¥Î¡C¤£¹L¨ä¹ï¥h°£¤G¤â·Ï¡A²§¨ý©ÎÃdª«¥Ö®hªº¹L±Ó­ìµ¥·|¤Þ°_®ð³Ýªº¨ë¿Eª«¬O¦³À°§Uªº¡C

¨Ï¥Î¼ö¤ô¬~¦ç¡H

¹Ð蟎¥H¤Hªº¥Ö®h¬°­¹¡A¦]¦¹³Q³æ¡AªEÀY®M¡A§É¹Ôµ¥»P¤HÅ鱵IJ¦hªº¦a¤è¦ÛµM¹Ð蟎ªº¼Æ¶q«K¦h¡C¦]¬°¥Î¤@¯ë§N¤ô¬~¦ç¨ÃµLªk®ø°£¹Ð蟎¡A©Ò¥H«Øij¨C¹j¤@¦Ü¤G¶g¥i¥Î¬ùÄá¤ó60«×ªº¼ö¤ô²M¬~§É³æ¡BªEÀY®M¡CµM¦Ó¦b¥xÆWªº¬~¦ç¾÷«Ü¤Ö¥i¥Hª½±µ±±¨î¬~¦ç·Å«×¡A¦]¦¹¬~«á¦Ü¤Ö¥Î¯M°®¾÷¯M°®¤G¤Q¤ÀÄÁ©Î¬O¦b¶§¥ú¤U´½°®¥ç¥i¹F¨ì±þ¦º¹Ð蟎ªº¥Øªº¡C

¨Ï¥Î¨¾蟎§É¸n¡H

§É¹Ô¤£©ö²M¬~¡A¦Ó§É¹Ô²`¼h¤]·|ÁôÂäj¶qªº¹L±Ó­ì¡A¨¾蟎§É¸n¡AªEÀY®Mµ¥¤´¬O¤@­Ó¦³®Ä¥B²³æªº¤èªk¨Ó´î¤Ö¹Ð蟎ªºÄÆ´­»P±µÄ²¡A¥u¬O¥þ®M¶R¤U¨Ó¥i¬O¤@¤ñ¤£¤pªº­t¾á¡CÀHµÛ¨¾蟎§ÜµßªºÆ[©À¤é¯q²`­È¤H¤ß¡A³oÃþªº°Ó«~«K¤j¶q¥R¥¸©ó¼s§i¤¤¡A¥u¬O¬O§_¯uªº¨ã¦³©Ò¼Ðº]ªº¨¾蟎®ÄªG¡A©óÁʶR®É§óÀ³ÂÔ·V¤ñ¸û¡A­n½T©w¦³«~µP¥B«HÅA¨Îªº¼t°Ó¡C­Y«Ç¥~ªÅ¶¡³\¥i¥ç¥i¦b¶§¥ú¤UÃnÅΧɹԡC

µ²½×

ÁöµM®É®É¨è¨èª`·N®a¤¤Àô¹Ò±±¨î¹ï©ó¤u§@¦£¸Lªº®aªø¬O«D±`¨¯­Wªº¡A¦ý¤F¸Ñ¹L±Ó­ì¡A°µ¦nÀô¹Ò±±¨î¨ÓÁקK¹L±Ó­ì±µÄ²½T¬OªvÀø¹L±Ó©Ê¯e¯f¤Î®ð³Ýªº²Ä¤@¨B¡C°£¤FÀô¹Ò±±¨î¥~¡A§ó­n»P¨àµ£¹L±Ó¬ìÂå®v¤@¦P°Q½×ÃĪ«ªº¨Ï¥Î¤ÎªvÀøªº¤è¦V¡CªvÀø¹L±Ó¯e¯f¬O»Ý­n®É¶¡»P­@¤ßªº¡A¥þ®a°Ê­û¤@¦P²M²z¦Û¤vªº©~®aÀô¹Ò¡A¤]Åý¥þ®a¤H©I§lªº§ó¦n¡A§ó°·±d¡C


¡@

¡@

®Ú¾Úªø©°¨àµ£Âå°|91¦~ªº¬ã¨s³ø§iÅã¥Ü¡A¥x¥_¥«°ê¤p¨àµ£ªº®ð³Ý²±¦æ²v¤w¼W¥[¨ì19.8%¡A¬Û¸û©ó30¦~«eªº¼Æ¾Ú¡A¨¬¨¬¼W¥[¤F15­¿¡C·íµM¨Ã«D©Ò¦³©I§l®ÉÅ¥¨ì¦³«¦«¦ªº³Ý»ïÁn«K¬O®ð³Ý¡A¦]¬°³¡¤Àªº®ðºÞª¢©ÎªÍª¢¤]·|¦³Ãþ¦ü±o¯gª¬¡A¤]¤£¬O¦p¤@¯ëªº¨èªO¦L¶H¤@©w­n³Ý¨ì©I§l§xÃø®É¤~ºâ¬O®ð³Ý¡C¬Û¤Ï¦a¡A®ð³Ý³Ì±`¨£ªº¯gª¬­Ë¬O¤ÏÂÐ¥BºC©Êªº«y¹Â¡C¤@¯ë©Ò¿×¡§·P«_¡¨¬O«ü©I§l¹Dªº¯f¬r·P¬V¡A§Y¨Ï¤£ªvÀø¦b¤@¨â¶g¤º¤]·|¦ÛµM²¬Â¡¡C¦ý­Y¬O¨C¦¸¡§·P«_¡¨ªº¯gª¬«ùÄò¼Æ¶g¡A¹j¨S¦h¤[©Î¤Ñ®ð¤@Âà²D«K¤S¡§·P«_¡¨¤F¡A©Î¬O¬¡°Ê«á«K®e©ö«y¹Â¥B¦­±ß«y±o¸û©úÅã¡A³o¨Ã¤£¥Nªí¤pªB¤Í©è§Ü¤O®t¡A¨ä¹ê«K­n¦Ò¼{®ð³Ýªº¥i¯à©Ê¡C
®ð³Ýªº¶EÂ_¨Ã«D¾a¯Ý³¡X¥ú¡B©â¦å¡BªÍ¥\¯à¡B©ÎÀË´ú¹L±Ó­ì¨Ó½T©w¡AºI¦Ü¥Ø«e¨ÃµL³æ¤@ÀËÅç´N¯à¶EÂ_¬O§_¬O®ð³Ý¡C¤]´N¬O§Y¨Ï©Ò¦³ªºÀˬd³£¥¿±`¡A¤]¤£¯à»¡¤£¬O®ð³Ý¡A¦]¬°®ð³Ý³Ì­«­nªº¶EÂ_¨Ì¾Ú¬O¾a¯gª¬ªí²{ªº¯f¥v¨Ó¨M©w¡AÀËÅç¥u¬OÀ°§U½T©w¶EÂ_®ð³Ýªº¤u¨ã¡C¹ï©ó¤G·³¥H¤UªºÀ¦¥®¨à¡A³\¦hÀËÅ綵¥Øê©ó¦~¬ö¤Ó¤pµLªk°t¦X¡A¦]¦¹­n¶EÂ_®ð³Ý§ó¬O¤£©ö¡C¤@¯ë¦Ó¨¥¡A­Y¬O¤@¦~¤º¦³¤T¦¸¥H¤Wªº¡u²Ó¤ä®ðºÞª¢¡v©Î¤ÏÂгݻï«K­n¦Ò¼{¥®¨à©Ê®ð³Ýªº¥i¯à¡C¦P®É¤]­n¦Ò¼{¨ì¨ä¥L·|²£¥Í«¦«¦Ánªº¯e¯f¡A¦p­G­¹¹D°f¬y¡B¤ßŦ¦åºÞµ²ºc²§±`µ¥µ¥¡A³o³¡¥÷§ó­n¸g¥Ñ±M·~ªº¹L±Ó¬ìÂå®v¨Ó§PÂ_¡C
®ð³Ý¦nµo©ó¨C¦~9¡B10¤ëªº¤J¬î®É¤À¤Î3¡B4¤ëªº±ö«B©u¸`¡C¤Þ°_®ð³Ýªº­ì¦]·¥½ÆÂø¡A°£¤F¿ò¶Çªº¦]¯À¥~¡A¹L±Ó­ì¥ç¬O­«­nªº­ì¦]¤§¤@¡C¦]¦¹ªvÀø®ð³Ý°£¤FÃĪ«¥~¡AÀô¹Òªº±±¨î¥ç¬Û·í­«­n¡C¤]´N¬O©~®aÀô¹ÒºÉ¶q°®²b¡A¼éÀã®É­n¶}°£Àã¾÷¡A±±¨î«Ç¤º¬Û¹ïÀã«×©ó55%¥ª¥k¡A¤G¤â·Ï§ó¬O­nÁקK¡C®ð³Ý¥Ø«e³Ì­«­nªºªvÀø¤è¦¡«K¬O¡§§l¤J¾¯«¬Ãþ©T¾J¡¨¡A¤d¸U¤£­n¤@Å¥¨£¡§Ãþ©T¾J¡¨¦Ó®`©È¡A¾á¤ß¨ä°Æ§@¥Î¥H­PÂ_Äò¥ÎÃÄ¡A·|¨Ï®ð³Ý±±¨î§ó¤£©ö¡A²¦³º¡§§l¤J¾¯«¬Ãþ©T¾J¡¨»P¡§¤fªAÃþ©T¾J¡¨¦b¾¯¶q¤W®t²§·¥¤j¤£¥i¬Û´£¨Ã½×¡C¹ï©ó2·³¥H¤Uªº¥®¨à©Ê®ð³Ý¡A®aªø¤£»Ý¯S§O¶i¸É¡A§¡¿ÅªºÀç¾i¡A¿í±qÂåÅñ«ö®É§lÃÄ¡Aµ´¤j³¡¤À³£¥i§K©ó®ð³Ýªº·Ð´o¡C

ºK¿ý¦Û¡¨ ¥©³s´¼Ä_Ä_ª©¡¨


¡@

®ð³ÝªvÀøªº²{ª¬»PÁͶÕ

ªL¤fªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý§K¬Ì­·Àã¬ì

¸­°ê°¶¥DªvÂå®v

®ð³ÝÄÝ©ó¤@ºØºC©Ê®ð¹Dª¢¯g¡A«æ©Êµo§@®É·|¦³³Ý»ï¡B©I§l§xÃø¡B¯Ý´e¥H¤Î«y¹Âµ¥¯gª¬¡A¦ý³Ì±`¨£ªºÁ{§Éªí²{¬O¤Ï¦Ó¬OºC©Ê¤Î¤ÏÂЫy¹Â¡C®ð³ÝÃĪ«ªºªvÀø¥Øªº§Y¦b©ó«ì´_¨Ã¥BÁקK®ð³Ý¯gª¬ªº²£¥Í©M©I§l¹D®ð¬yªý¶ë¡A¥i¤À¬°«æ©Êµo§@®Éªº½w¸ÑÃĪ«¤Îªø´Á¨Ï¥Îªº±±¨îÃĪ«¨â¤jÃþ¡G

¡P         ½w¸ÑÃĪ«¡]«æ±ÏÃĪ«¡^¡G¥Hµu®Ä«¬¤ä®ðºÞÂX±i¾¯¬°¥D¡AÃĪ«§@¥Î§Ö®ÄªG¨Î¡A¦b®ð³Ý«æ©Êµo§@®É¡A¥i¥H¨³³t½w¸Ñ¤ä®ðºÞ¦¬ÁY¤Î©I§l§xÃø¡B«y¹Â¡B©M³Ý»ïµ¥¯gª¬¡C¦¹ÃþÃĪ«¥H³t®Ä«¬§l¤J¦¡£]2¥æ·P¯«¸g¿³¾Ä¾¯¬°¥D¡B¨ä¥L¥]§t¤fªA©Îª`®g¯ùÆP»s¾¯¡B§l¤J¦¡§Ü¤AñQÁxÆP¾¯¡]ipratropium¡^µ¥¡C

¡P         ±±¨îÃĪ«¡]¹w¨¾ÃĪ«¡^¡G¥H§Üµoª¢ÃĪ«¬°¥D¡A¥Î©óªø´Á±±¨î®ð³Ý¯f±¡¡A¹w¨¾®ð³Ý´c¤Æ¥H¤Î«O¾i®ðºÞ¡A¥²¶·¨C¤é«ùÄò¨Ï¥Î¡C§Üµoª¢ÃĪ«¤¤³Ì­«­n¬°§l¤J©ÊÃþ©T¾J¡AÃþ©T¾J¥H§l¤J¾¹§l¤J«áª½±µ§@¥Î¦b©I§l¹D¡A¥þ¨­©Êªº°Æ§@¥Î«D±`¤Ö¡A¬O¥Ø«e¬°¤î³Ì¦³®Äªº§Ü®ð³ÝÃĪ«¡C±±¨îÃĪ«ÁÙ¥]¬Aªø®Ä«¬¤ä®ðºÞÂX±i¾¯¡B¤fªA½wÄÀ«¬¯ùÆP»s¾¯¡B¥Õ¤T²m¯À«ú§Ü¾¯¡]leukotriene¡^µ¥¡A¥i»²§U§l¤J©ÊÃþ©T¾J¦@¦P¨Ï¥Î¥[±jÀø®Ä¡A´î¤Ö°Æ§@¥Îªº²£¥Í¡C¨ä¤¤¯ùÆP¡]Theophylline¡^ªº»ù®æ«K©y¦ý°Æ§@¥Î¸û¦h¡F¥Õ¤T²m¯À«ú§Ü¾¯¬O·s¤@Ãþªº¤fªA®ð³ÝÃĪ«¡A§Üµoª¢®ÄªG¤ñÃþ©T¾J®z¡A¥D­n¥Î©óªvÀø»´¤¤«×®ð³Ý¡C¦Ü©óªø®Ä«¬¤ä®ðºÞÂX±i¾¯¨Ã¤£«Øij³æ¿W¨Ï¥Î¡A¦X¨Ö§l¤J©ÊÃþ©T¾J¥iµo´§§ó¤jªºÀø®Ä¡C

 

®ð³Ý±±¨îÁͶաЦX¨Ö¦¡Àøªk

¥Ø«e¥xÆWªvÀø®ð³Ýªº¤è¦¡³q±`±Ä¶¥±è¦¡Àøªk¡A±N®ð³Ý¨ÌÄY­««×¤À¬°¥|­Ó¶¥¬q¡A²Ä¤@¶¥¦Û²Ä¥|¶¥¨Ì§Ç¬°¶¡·²µo§@©Ê®ð³Ý¡B»´«×«ùÄò©Ê®ð³Ý¡B¤¤«×«ùÄò©Ê®ð³Ý¥H¤Î­««×«ùÄò©Ê®ð³Ý¡A¨C¤@¶¥¬q«Øij³B¸mªºÃĪ«ºØÃþ»P¾¯¶q¤]·|ÀH¤§½Õ¾ã¡C·í¯f±w¦b¬Y­Ó¶¥¬q®É®ð³Ý±±¨î¤£¦n¡A§Y¥i¤É¶¥¶i¤J¤U¤@¶¥¡A¤Ï¤§¡A­Y®ð³Ý±o¨ì±±¨î¨Ã¥Bºû«ù¦Ü¤Ö¤T­Ó¤ë¥H¤W¡A´N¥i¥H­°¶¥¨ì¤U¤@¶¥¡A³vº¥´î¤ÖÃĪ«ºØÃþ©Î¾¯¶q¡C

ªñ¦~¨Ó®ð³Ý±±¨î¤§ÁͶդw´Â¦V¦X¨Ö¦¡Àøªk¡A©Ò¿×¦X¨Ö¦¡Àøªk«üªº¬O¦X¨Ö¨Ï¥Îªø®Ä§l¤J«¬£]2¥æ·P¿³¾Ä¾¯»P§C¾¯¶q§l¤J«¬Ãþ©T¾J¡A¨ã¦³«ù¤[©Ê®ðºÞÂX±i»P§Üµoª¢ªº¥[¦¨ªvÀø®ÄªG¡A¦bªø´Á°lÂܯf¤HªºªÍ¥\¯à©Î®p³t­È¬Ò¦³©úÅã§ïµ½¡C

 

¦X¨Ö¦¡Àøªk¥i´î¤ÖÃþ©T¾J¥Î¶q

¦X¨Ö¦¡Àøªkªº³Ì¤j¦n³B¡A§Y¦b©ó¥i¥H´î¤ÖÃþ©T¾Jªº¨Ï¥Î¾¯¶q¡C¾¨ºÞ§l¤J©ÊÃþ©T¾Jªº°Æ§@¥Î·¥¤Ö¡A¦ý¤´¦³³\¦h¤H¹ïÃþ©T¾J·P¨ì¼~¼{¡A¦Ó¦b¯fªp¸û¬°ÄY­«ªº®ð³Ý±wªÌ¡A¶i¶¥ªvÀø®É©Ò¨Ï¥ÎªºÃþ©T¾J¾¯¶q¤ñ¸û°ª¡A¬Û¹ï¨Ó»¡²£¥Í°Æ§@¥Îªº¾÷·|¤]¸û¤j¡C®Ú¾ÚÁ{§É¬ã¨s³ø§iÅã¥Ü¡A§C¾¯¶qªº§l¤J¦¡Ãþ©T¾J¥[¤Wªø®Ä«¬ÂX±i¾¯ªºÀø®Ä¡A¤ñ³æ¿W¨Ï¥Î°ª¾¯¶qªº§l¤J¦¡Ãþ©T¾J§ó¬°ÅãµÛ¡A¥ç§Y¦X¨Ö¦¡Àøªk§ïµ½®ð³Ýªº®ÄªGÀu©ó¤GºØÃÄ­Ó§O¨Ï¥Î¡C¦]¦¹¦b¥Ø«e®ð³Ý¶EÀø«ü¤Þ¤¤¡A¦X¨Ö¦¡Àøªk¤w¬O¤¤¡B­««×®ð³Ý±±¨îªº«Øij­º¿ïÃĪ«³B¤è¡A¦Ü©ó»´«×®ð³Ýªº±±¨î¡A«h¤´¥H§l¤J©ÊÃþ©T¾J¬°¥D¡C

 

®ð³ÝªvÀø·sÀÆ¥ú

®ð³Ý¬O¤@ºØ¹L±Ó¤ÏÀ³¡A¤j³¡¤À®ð³Ý¯f±wÅ餺ªºIgE§ÜÅé¼Æ¶q·|¤É°ª¡A§ÜIgE§ÜÅéÀøªk(Anti-immunoglobulin E)§Y¬O°w¹ï¹L¦hªºIgE§ÜÅé§@¬°ªvÀø¼Ðªº¡A§Q¥Î¤H¤u¦X¦¨ªº§ÜIgE§ÜÅé¥Hª`®g¤è¦¡¥´¤J¥Ö¤U¡A±NÅ餺´åÂ÷ªºIgE§ÜÅé«ú§Ü¦í¡AIgE§ÜÅé«K¤£·|©MªÎ¤j²Ó­Mµ²¦X²£¥Í¶i¤@¨Bªºµoª¢¤ÏÀ³¡A¦b®ð³Ý¯gª¬ªº¤ÏÀ³¤W´å«K²×¤î¦í¡C³oºØÀøªk¥iÂkÃþ¬°§K¬ÌÀøªkªº¤@ºØ¡A³Ìªñ5¡B6¦~¨Ó°ê¥~¤w¦³¤£¤ÖÁ{§É¬ã¨s³ø§i¡A¹êÅçµo²{®ð³Ý±wªÌ¡]¥]§t¦¨¤H»P¨àµ£®ð³Ý±wªÌ¡^¸g¥Ö¤Uª`®gªvÀø«á¡AÅ餺IgE§ÜÅ骺§t¶q¦b¤@¤Ñ¤§¤º§YÅãµÛ¤U­°¡A¸g¹L¼Æ­Ó¤ë«áªº°lÂÜÆ[¹î¡A¤]µo²{¨ì±wªÌªº®ð³Ý¯gª¬Àò±o§ïµ½¡C §ÜIgE§ÜÅéÀøªk¦b¤µ¦~¡]2003¦~¡^3¤ë¤wÀò±o¬ü°êFDA®Ö­ã³q¹L¡A¥i¹w´Á¦¹ÀøªkÀ³¥Î©óÁ{§ÉªvÀø±N¬O«ü¤é¥i«Ý¡C¸û¬°¥i±¤ªº¬O¡A°ê¤º¹ï©ó§ÜIgE§ÜÅéÀøªkªº¬ã¨s¸}¨B¸ûºC¡A¥Ø«e©|µL©M°ê¥~¦P¨BªºÁ{§É¹êÅç¡A°ê¤º®ð³Ý±wªÌ¥i¯àÁٻݦAµ¥¤@µ¥¡C¦Ó¦b·sªºªvÀø¥¼¦¨¼ô«e¡A«e­z¦X¨ÖªvÀøÀ³¬O²{¶¥¬qªvÀø®ð³Ý³Ì­«­n¥B³Ì¨Îªº¤è¦¡¡C

 

®ð³Ý½Ã±Ð¤´»Ý¥[±j

¨ì¥Ø«e¬°¤î¡AÃþ©T¾J¬OªvÀø®ð³Ý§Üµoª¢ÃĪ«¤¤³Ì¦³®Äªº¿ï¾Ü¡C¦ý¤@¯ë¥Á²³¦]¬°¹ïÃþ©T¾Jªº¤£¤F¸Ñ»P¿ù»~ªº¨èª©¦L¶H¡A¦Ó®`©È¨Ï¥ÎÃþ©T¾J¡C®ð³ÝªvÀø³q±`»Ý­n¼Æ¤ë¬Æ¦Ü¼Æ¦~¡A³¡¤À±wªÌ¦]¬°¾á¤ßÃþ©T¾J·|¦³°Æ§@¥Î¡A¨Ï¥ÎÃþ©T¾J¤@¬q®É¶¡¯gª¬§ïµ½«á§Y¦Û¦æ½Õ¾ã¾¯¶q¬Æ¦Ü°±ÃÄ¡A¤Ï¦Óªýê¤F®ð³ÝªºªvÀø¡C¦]¦¹¡AÁٻݦA¥[±j±Ð¨|®ð³Ý±wªÌ¤Î¨ä®aÄÝ¡A¹ï©ó§l¤J©ÊÃþ©T¾J©ê«ù¥¿­±ªººA«×¡A¥u­n¿í·ÓÂåÅñ¥¿½T¨Ï¥Î¡AÃþ©T¾JªvÀø®ð³Ýªº®ÄªGµ´¹ï¬O§Q¦h©ó¹ú¡C¦¹¥~¡A®ð³ÝÃĪ«ªº§l¤J§Þ¥©¤]¶·¯S§Oª`·N¬O§_¥¿½T¡A¤×¨ä¬O¹ï©ó¨àµ£±wªÌ¡C®Ú¾Ú½Õ¬d¡A¥_¥«®ð³Ý¾Çµ£¦Ü¤Ö¦³¥b¼Æ¥H¤W¨Ï¥Î§l¤J©Ê®ð³ÝÃĪ«ªº¤è¦¡¤£¥¿½T¡A¨Ï±o¹w´ÁªvÀøªº®ÄªG¥´§é¦©¡C

¦p¦ó¨Ï®ð³Ý¥ÎÃĵo´§³Ì¨Î¥\®Ä¡A®ð³Ý½Ã±Ð§êºt¬Û·í­«­nªº¨¤¦â¡CÂå®v°£¤F¿í·Ó®ð³Ý¶EÀø«ü¤Þ¡A¨î©w¨C¦ì±wªÌªº­Ó¤HªvÀø­p¹º¡A«ü¾É±wªÌ¨Ì¾Ú¤£¦P¯gª¬©ÎºÊ´úµ²ªG½Õ¾ã¨Ï¥Î¤£¦PªºÃĪ«»P¾¯¶q¨Ó¶i¦æªvÀø¤§¥~¡A¤]À³Åý¨C¦ì¯f±w±µ¨ü§¹¾ãªº®ð³Ý±Ð¨|¡A±Ð¾É¯f±w¦p¦óÁקK¹L±Ó­ì¡A«ü¾É¯f±w¥¿½T¨Ï¥Î§l¤JÃĪ«ªº¤è¦¡¥H¤Î¨Ï¥Î®É¾÷¡AÅý±wªÌ¹ï®ð³ÝÃĪ«¤Î§l¤J¾¹¨ã§ó¥[ÁA¸Ñ¡A¥H¤Î±wªÌ¥»¨­»P¨ä®aÄݦb¤é±`¥Í¬¡¤W¦p¦ó³B²z®ð³Ý°ÝÃD¡C¹ï©ó®ð³ÝªºªvÀø»P¹w¨¾¡AÂå®vªº³d¥ô¤£¶È¤î©ó¶}ÃĪvÀø¦Ó¤w¡A§ó§Æ±æ¯à°÷³z¹L½Ã±Ð¡A¥þ¤è¦ìªº·ÓÅU®ð³Ý¯f±w¡C


¡@

¡@

­^­Ûªì©]

ªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý­·Àã¬ì ¸­°ê°¶Âå®v

 

    ¤Q¦h­Ó¤p®Éªº­¸¦æ¡A°£¤F¬¡°Ê¥²»Ý­­¨î©ó¤T¸U­ù°ªªÅ¤¤ªºÅK³¾¤º¡A¤ß±¡­Ë¨S¦³¦]¦¹¦Ó»·ÃG¡A­Ë°¸º¸³Q¶Ã¬yÅͱo¤ßªiÀúºy¡A³s¸¨¦a«á¤]¨S¦³½ñ¹êªº·Pı¡C¨Ó±µ¾÷ªº¤H¦­¤w¦w±Æ¦n¡A¥u¤£¹L¤£¬O·Q¹³¤¤ªº­^°ê²Ô¤h¡A¦Ó¬O¨­µÛµu­m¾ÞµÛ±aµÛµÄ½Õªº­^»yªº­D¤p¤l¡A¤@¸ôÅX¨®¥Ñ§Æ´µÃ¹¾÷³õ¦Ü«n¦w´¶¹y¤pÂí¡C¤@¼Ëªº¤Ó¶§¡A¥u¬O¨B½Õ¤]¤ñ¸ûºC¨Ç¡A±ß¤W¤KÂI¦h¤´²²ÅÊ©ó¦a¥­½u¤W¡A¹ê¦b¤£´±¬Û«H¦Û¤v¤w½ñ¤W¤@­Ó¸¹ºÙ¤é¤£¸¨ªº°ê®a¡C

    ²Ä¤@¦¸¨«¶iÂå°|±JªÙ¯U¹iªº¨«´Y¡A¤ì½è¦aªO³Q«p­«ªº¦æ§õÀ£±o¨Ì§r§@ÅT¡A¨¾¤õªù¼h¼hªºªý¹j§ó§Î¤o¨BÃø²¾¡AªÅ®ð¤¤Äjº©µÛ¥j¦Ñ«Ø¿v¯S¦³ªº¾`¨ý¡CÂ÷¶}ª«½è¨ú¦V¥Í¬¡«K§Qªº¥x¥_¡A¦í¶i³o¤@¶¡¨S¦³¹q¸Ü¡B¦¬­µ¾÷¤Î¹qµø¾÷ªº³æ¨­±JªÙ¡C¤@±i®Ñ®à¡B¤@­Ó¦çÃo¡B¤@®u³æ¤H§É«Øºc¤F¤@¤H¥@¬É¡C²¦³º¦Û¤v¤w¤£¬O¤p¯d¾Ç¥ÍÃhµÛ¦n©_»P¤£ª¾·Tªº½Ä«l¥h²`³y¨D¾Ç¡A¤]¤£¬O°Ñ¥[®È¦æ¹Î©Î¦Û¥Ñ¦æ¦í¶i¤­¬P¯Å¤j¶º©±¡A³p»»¦Û¦bªº½à´º½ñ«C¡A¦Ó¬O¥¼¨Ó¤@¦~¤º¦b²§¦a¿W³Bªº¶i­×¥Í²P¡A­IµÛ°l¨D·sª¾»P·s§Þ³Nªº¨Ï©R¡C¦b³o«Ê³¬ªº©Ð¶¡¤¤¡A­n¾Ç²ßªº¬O¥Í¬¡¡A­n¹ê¦æªº¬O¤Ï¬Ù¡C

    Áö¨S¦³®É®tªº§xÂZ¡AµM¦Ó«äºü©|¥¼¨H¾ý­Ë¤£¯à»´©ö¤J¯v¡CÁö¬O²±®L¡A©]±ß«h¨G²DµS¦p¥xÆWªº²`¬î¡C±Àµ¡¦V¥~ÀôÅU¶g¾D¡AµL¼ô±xªºÀO­i¿O°{Ã{¡A¤]¨S¦³©I¼Sªº¾÷¨®¤ÞÀºÁn¡A¥u¦³®A®AÂÎÁn¤Î¸s¸¿°g±¦©ó©ü¶À¸ô¿Oªº¸I¼²Án¡C­ì¥H¬°³Á·í³Ò©Î«K§Q°Ó©±À³¥|³B¥i´M¡A¼öª¯¡Bº~³ùÁ`¥iªG¸¡¡A¨S·Q¨ì­n¶R¦YªºªF¦èÁÙ­n¹B®ð»P®É¾÷¡AÀ\ÆU¨Ã«D³B³B¥i±o¡A©±®a¤]¦­¦­¥´¨Ë¡C¥u±o¥ô¥ÑÄȸzñFñFÁn¦A¦ñ¦X©]±ßªºÁn­µ¨Ó¬q¤p©]¦±¡C

    ·í¤[¤F³Q¨þÅ@ºD¤Î³Q¦£¸Lªº¤u§@À£±oµL·v¤Ï¬ÙªºÂå¥Í¡AÃø±o¯à¦³¾÷·|§NÀR¡C¶Â©]ùØ¡A¤@¹õ¹õ»X¤Ó©_ªº¼v¹³§óÂA©úªº¬y¹L²´«e¡C¦Ç¦â¬O¤ÑªÅ°ß¤@ªºÃC¦â¡AÃú®ðÄjº©ªº³£¥«¦p­^¤å¯ëÅý¤HºN¤£µÛÀYºü¡AµLªk¾A¤Áªºªí¹F¨ä¯u¥¿ªº®e»ª¡A³s¯ºÁn³£·|§N¾®ªº®ð­Ô¹ï¤@­Ó¨Ó¦Û¨È¼ö±aªº¤HÁ`¬O¥Rº¡­t­±ªºÁr´ú¡C·Q¹³¦Û¤v±N¦b¤U³·¥B³±§Nªº­^°ê¥V¤é¿W¦Û¤@¤H¦b³o¤pªÅ¶¡¤¤¡A¹LµÛ©t»÷¦Ó¹çÀRªº¥Í¬¡¡A¦Õ¯`ÅT°_³ìªv·Å´µ¹yªº·s¥@¬ö¿ûµ^Án¡A¤f°ã·Å¼öªº©@°Ø¡A¤£¹L¥¼ª¾«h¦h©ó®öº©¡CÂå¥ÍÁ`³Q¼ÐÅÒ¬°°ª¶Qªº¦æ·~¡A¹LµÛª÷¦r¶ð³»¯Åªº¥Í¬¡¡C¤H¨Ó¤H©¹ªºÂå°|¤¤¤Ö¤@¦ì©Î¦h¤@¦ìÂå®v¨ä¹êµL¶Ë¤j¶®¡A¤j®aªº¸}¨B¨ÌµM«æ«P¡A¯fµß«hÀH®É¦ø¾÷¦Ó°Ê¡A·Q­n¤Ï§ðªø¤[¥H¨Ó©~©ó¦H¶Õªº¦a¦ì¡CµJ«æªº¶ý¶ý©êµÛµo¿N«y¹Âªº¤pªB¤Íµ¥«ÝµÛ´X¤ÀÄÁªº¬Ý¶Eªº®É¶¡¡A¥u­n¬Ý¤FÂå¥Í«K¦w¤ßªº»âÃĦ^®a¡Aªü·A«h¦b²M²z¤pªB¤Í¹Ã¦RªºÂ©ª«¡Cª¢¼öªº¥xÆW¨Ì¬O¦³¤H±¡¾aÃö«Yªº¤p®q¡A¸ôÃäÅu¿Ë¤Áªº©Û©I¬O¹C¤l³Ì·Å·xªº¨É¨ü¡Fµó¨¤ªº¦Ñ¼Ú¤Ú®á©ìµÛ§Fܼªº¨­Å餴¦uµÛ¤éÁͨS¸¨ªº¥Ì¥J©±¡Aº¡¨¬¤p«Ä¥Î¤@¤¸¨â¤¸¶R¨ÓªºÅå³ß¡F®aªù«e¶À©ü¥«³õªºµæ³c¤£Á×­·«Bªº¬°¥Í¬¡¥´«÷¡A±Ã±oªº¬OÃÇÀY¤p§Q¡FÁöµM³o¨Ç¤p¤Hª«¾Ç¾ú¤@©w¤£°ª¡A¦çµÛ¥¼¥²¥úÂA¡A³\¦h¤H§ó§Æ±æ®â°ö¤U¤@¥N¦¨¬°Âå¥Í¡A¥X¤HÀY¦a¡AµM¦Ó¥L­Ì¥»¨­¤£ª¾¤£Ä±µo´²¥Xªº¥Í©R¤¸¯À§ó³Ó¥P¤¦§®ÃÄÅý¤H¦³¥Í¦sªº­ì°Ê¤O¡C²³æªº¥Í¬¡¯à¦w³h¼Ö¹D¡AÂå¥Í¨Ã¤£¤@©w­n¦³°ª¯Åªº¨É¨ü¤~²Å¦X¨­¤À¡C±q«eªº¥xÆW¤H¯à¦bª«½è³h¥Fªº§x¹Ò¤¤¥Í¦s¡A²{¦bªº§Ú¤]­n¯à¦b²§¶m­®«Ç¤¤¥Í¬¡¡A¾ÌÂǪº«K¬O®Äªk¤Î¾Ç²ß¤p¤Hª«¦p¯ó®Ú¯ëªº¥Í©R¤O¡A¹y®ÉÅåı¦Û¤vªº¯Ü®z¡A¤]·PÃh¦Û¤vªº©¯¹B¡C½ö¦b§É¤W¤~µo²{¤Ö¤F§É´Ö³Q¡C

    ²Ä¤G¤Ñ²M¦­³º³Qµ¡¥~ªºÄXÄX¸s³¾§n¿ô¡A°¸¦³¨ä¥L«Ç¤Í¨«¹Lªº¸}¨BÁnÂIºó¡A¦pªG¨¬¤£¥X¤á¡A¨S¦³¤Hª¾¾å©Ð¶¡¤º¦³¨S¦³¤H¦s¦b¡C°£¤F­n¦V¶i­×³æ¦ì³ø¨ì¤§¥~¡A§ó­n¹³³¥¥~¨D¥Í¯ë¥h±´¯Á¤Î¸Ñ¨M­¹¦ç¦í¦æªº¥Í¬¡¥²»Ý°ÝÃD¡A¶}©l¥Í©R¤¤¥t¤@¶¥¬qªº¾úÀI¡C


¡@

¡@

AAAAI 60¶g¦~¼y---¤¦¦ò¬ö¦æ

 

ªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý­·Àã¬ì ¸­°ê°¶Âå®v

 

­¸¶V¤Ó¥­¬v¦A¾î¸ó¸¨ÁF¤s«á¡A­¸¾÷­°¸¨¦b¸¹ºÙ¬O¥þ¬ü«e¤­¤jªº¤¦¦ò°ê»Ú¾÷³õ¡C¤µ¦~AAAAI (American Academy of Allergy, Asthma and Immunology) 60¶g¦~ªº¦~·|«K¿ï¾Ü¦b¬ìù©Ô¦h¦{ªº¤s«°Á|¦æ¡C¾Ú»¡¤j·|¶}©l«e¤¦¦ò¤s«°¤´¬O¦B¤Ñ³·¦a¡A´N¦b¤j·|¶}©l·í¤é©ñ´¸¡A¥u¤£¹L¿n³·µS¦b¡Aªì¬K¤T¤ëÁcªá¤´¥¼¿ô¡C¥ÑGINA²Õ´¥D¾ÉªºInternational Conference on Pediatric Asthma©ó²Ä¤@¤Ñµn³õ¡A³o­ÓijÃD¤]§l¤Þ¤F¥@¬É¦U¦aªº±M®aÅ¥²³À½Ãz·|³õ¡C

 

®ð³Ý²±¦æ²v¦~¦~Ãk¤É¬O­È±o§ó²`¤Jªº±´°Q¡A¥þ¥@¬É¤]¬°®ð³Ýªá¶O¤F¬Û·í¦hªº¸g¶O¤Î¤H¤O¡C¤¤«n¬ü¬wªºÂå®v¤]´£¥X¥L­ÌÁ{§É¤WªºªvÀø®ð³Ýªº±¡§Î¡C¨Ò¦pªü®Ú§Ê¦]±M·~¹L±Ó±M¬ìÂå®v¯Ê¥F©Î®ð³Ý¤§ªvÀø¸gÅ礣¨¬¡A©¹©¹¤ÏÂЪº³Ý»ï¥H¬°¬O¤@¯ë·P«_¦Ó¥¼¯à¤Î¦­±µ¨üªvÀø¡C©Ò¦³¤p¨à¬ìÂå®v¤]¦Õ¼ô¯à¸Ô¤F¸Ñ³Ý»ï¤£¤@©w¬O®ð³Ý¡A¤]´N¬O¦³³Ý»ïÁn¨Ã¤£»Ý­n¥ß§Y¨Ï¥ÎÃþ©T¾J¡C¬Û¹ïªº¨Ï¥ÎÃþ©T¾JªvÀøÁٮɱ`¦³®ð³Ý¯gª¬®É¡A§ó»Ý¦Ò¼{¨ä¥L¯e¯fªº¥i¯à¡A¦p­G­¹¹D°f¬y¡AºC©Ê»óÄuª¢©Î¨ä¥L©I§l¹D¯e¯f¡A¦Ó«D¤@ª½¥[­«ªvÀø®ð³ÝªºÃĪ«¡A³o¤]¬O¨C¦ì¨à¬ìÂå®vÂÔ°O©ó¤ßªº·Ç«h¡C®ð³Ý¯uªº¨º»ò¦h¡AÁÙ¬OÂå®v±N¯f¤H¼ÐÅÒ¬°®ð³Ý¨ÓªvÀø¡H¬O­È±o²`«ä

ªº¡C

 

¤j³°ªº½Õ¬dÅã¥Ü³º¦³¤E¦¨¤Kªº®ð³Ý¤pªB¤Í¦X¨Ö¨Ï¥Î§Ü¥Í¯ÀªvÀø¡Aªñ¤C¦¨·|¨Ï¥Î¤¤ÃĪvÀø¡A¬Ý¨ì¼Æ¾Ú¥uı±o³Y²§¡AÁöµMªvÀø·Ç«h¤¤»¡©ú°£«D»óÄuª¢©Î¦X¨Ö²Óµß·P¬Vªº¥i¯à¤~»Ý¨Ï¥Î§Ü¥Í¯À¡A¦ý¬O¦U¦aªvÀø¤ô·Ç¤£¤@©Î³\¦]¦a¦Ó¨î©y¡A¦Ó¤j³°¤]¦Û­q¤@®M§ó²³æ¤À¯ÅªºªvÀø¼Ð·Ç¡CÁöµMÂå®v¤j¥iªí¥Ü¬O¿í´`·Ç«hªvÀø®ð³Ý¡A¤£¦Û¥~©ó¥@¬É¼é¬y¡AµM¦Ó¦b¥xÆW¹ê»Úªº±¡§Î¤S¬O¦p¦ó©O¡HªvÀøªº·Ç«hÁö¤w«Ø¥ß¡A¦ý¹ê»ÚÁ{§ÉÂå®v¬O§_³£·Ó·Ç«h¬I¦æ¡HµM¦Ó·Ç«h´N¾A¦X¥þ¥@¬É¨C¤@­Ó¦a°Ï¡H³o¤£¬O­n¦³°ê»ÚÆ[¡A¸¨¹ê¥»¤g¤Æªº³¯µÄÀݽաA¦Ó­n«Ø¥ß©Î­×¥¿·Ç«h¬O­n¦³¬ì¾Ç¹êÅçÃÒ¾Ú¤ä«ù¨Ó¨î©w¡C

 

¤£¥u¥xÆW¤H®`©È¡u¬ü°ê¥P¤¦¡v¡A§Y¨Ï¬O¥ý¶iªº¬ü°ê¤´¹ï§l¤J©ÊÃþ©T¾J¨Ï¥ÎªººÃ¼{¤´³y¦¨®£·W¡A§Y¨Ï³\¦h¬ì¾ÇÃÒ¾ÚÃÒ¹ê§l¤J©ÊÃþ©T¾J¨Ã¤£·|¼vÅT¨­°ª¡A¦¨ªø¤Î°©½è±K«×¡C¦ý¬O¤j³¡¤À®aªø®Ú²`¸¦©T¤Î¤@ª¾¥b¸Ñ¤U±µ¨ü¤F³\¦h¥H³_¶Ç³_ªº¸ê°T¡A¤Ï¦Ó¨Ï®ð³ÝªºªvÀø¾D¹Jªýê¡A³o´N»Ý­n¾a±M®a§ó¥Î¤ß¥h±Ð¨|¥Á²³¡C

 

¥HGINAªºÆ[ÂI¡A§Æ±æ¯à­q¥X¤@®M©ñ½Ñ¥|®ü±µ¥i¦æªº·Ç«h¡A¥xÆW±µ¨üÂåÀø¸ê°T¤ÎÂåÃĪvÀøªº¶i¨B¨ä¹êºâ¬O¥ý¶iªº¡A¤ñ¤§¾l¸gÀÙ¸¨«áªº°ê®a§Ú­Ìªº¤pªB¤Í¯àªá·¥¤Öªºªá¶O´N¯à±µ¨ü¥ý¶iªºªvÀø¡A¥u¥i±¤¤´¥¼¯à±Nªá¶O¤ÎªvÀø¦¨®Ä¹F¨ì³Ì¨Î¤§®Ä¯q¡C¤F¸Ñ¨ä¥L°ê®aªvÀø±¡§Î¥u·P¨ì¥xÆWªº®ð³ÝÂåÀø¨ä¹ê¦³¤@©wªº¤ô·Ç¡A·|ij¤¤¤Þ¥Î¥xÆW¨àµ£®ð³Ý²±¦æ²vªº¸ê®Æ¤´¬O¤Q¦h¦~«eªº¼Æ¾Ú¡A¥uªí¥Ü¥@¬É¹ï¥xÆWªº¤F¸ÑÁÙ¤Ó¤Ö¡A²¦³º¤´¦³¤@¸s±M®aºë­^¤´ÀqÀq¦b¬°¥xÆW¨àµ£®ð³Ý§V¤O¡C

 

·sªº¹L±Ó§K¬Ì¾÷Âà³°Äò¶i¦æ¤¤¡A¤]³\¤@¤p¨BÆJªºµo²{«K¯à¸ÑÄÀ©Ò¦³ªº°²³]»PÃøÃD¡A¦¨¥\ªº¤j·|¤£¥u¬OµwÅ餽Ãöªº³]³Æ¡AÁ¿ÃDªº³]­p¡AºtÁ¿ªÌªºª¾¦W«×¤]¶·¬Û¤¬°t¦X¡CÁöµM®È³~³Ò¹y¡A¦ý¬OÂ×´I¦ÓºëªöªººtÁ¿¦­¤w±N¯h¾Î§Ñ«o¡A¥u©È¤Ö»â²¤¤F¤@¨Ç¤j®vªº­·ªö¡C

 

·íÂå¥ÍÁÙ¦bª§½×®ð³Ýªº·sªvÀø·Ç«h¡A©ÎÃļtÁÙ¦b±Mª`·sÃÄ«~ªº¥þ²y¥«³õ¦û¦³²v®É¡AÁÙ¦³³\¦h¤¤ªF°ê®aªº¤pªB¤Í¤´¥Í¬¡¦b¾Ôª§ªº³±¼v¤¤¡C¥L­Ì¤£­n®ð³Ý¡A¦ý¥L­Ì¥i¯à¨S¦³¸gÀ٤䴩±µ¨ü·sªºªvÀø¡AµM¦Ó¥L­Ì§ó·¥¤O©IÆ~¤£­n¾Ôª§¡C·|¤¤·P©Êªº¨q¥X¤@±i¤¤ªF¤pªB¤Í¹ïµÛ¤ÆµÛªá±mªº¤p¤¡ÅS¥XÅå³Yªºªí±¡¡A¨Ã¤£¬O¤p¤¡¥¼¯à±aµ¹¥L­ÌÅw¼Ö¡A¦Ó¬O¥L­Ì±q¥¼¬Ý¹L©Ò¿×ªº¤p¤¡¡C¦Ó·í¬ü°êÁ`²Î¥¿·Q¬°®Â½Ã¥¿¸q¦Ó®v¥X¦³¦W®É¡A¦b·|¤¤ªº¤Ï¾Ô¤H¹D«Å¨¥Ä¹±o¤F§ó¦hªº´xÁn¡C

 

µù°O¡GInternational conference on pediatric asthma¥u¬O¾ã­Ó·|ij´Á¶¡ªº¤@¤p¸`½Òµ{¡A©|¦³¦Ê³õ¥H¤W±q°ò¦¨ìÁ{§Éªº½Òµ{¡AÂ×´I§§Áï¤@¦p¼h¼hÅ|»Aªº¸¨ÁF¤s¯ß

¡@

 


¡@

Survey of the Clinical Practice of Physicians in the Management of Asthma in Taiwan

Kuo-Wei Yeh M.D. 1, Li-Chi Chiang PhD.2, Sue-Hsien Chen. M.S.N.3, and

Jing-Long Huang M.D.1

 

Published in Asia Pacific Journal of Allergy and Immunology 2006

ABSTRACT

Asthma is a common problem with a prevalence rate increasing every year. However, not all asthmatic patients receive appropriate treatment, partly due to the disease entity or patients¡¦ compliance, and partly due to physicians¡¦ knowledge and disposition in terms of treatment. This study was designed to investigate the current status of asthma treatment among clinicians in different practice settings, particularly regarding the acceptance of and adherence to asthma treatment guidelines and asthma patient education. Questionnaires were distributed by randomized sampling to doctors throughout the entire country. The questionnaire had six parts, measuring the following: 1) the use of different kinds of medication in the treatment of asthma; 2) adherence to asthma treatment guidelines; 3) the use of inhaled corticosteroids as part of management; 4) the use of peak flow meters in monitoring asthma; 5) relative efficiency in treating asthma; and 6) the use of a referral system, from general practitioners to specialists. There were 531 respondents out of 1000 questionnaires distributed. The results revealed the following: 1) 20.2% of physicians use oral corticosteroids for maintenance therapy; 2) 31.8% of physicians do not follow asthma treatment guidelines; 3) 77.2% of physicians use inhaled corticosteroids for maintenance therapy (physicians in medical centers and regional hospitals use inhaled corticosteroids more frequently than private practitioners); 4) 51% of doctors do not use peak flow meters to monitor asthma symptoms because of prohibitive costs; 5) approximately 80% of clinicians have confidence in dealing with asthma problems; and 6) 29.2% of general practitioners do not refer patients to asthma specialists unless there is poor control or a need for further evaluation. Adherence to asthma treatment guidelines is poor, and such guidelines need to be popularized or simplified. There are still many discrepancies among doctors at different levels of hospitals. Re-education and review of asthma knowledge is necessary to keep clinical practitioners at the forefront of standard practice.


Allergens and Allergic Diseases in Children

KUO-WEI YEH M.D.

Publishe in Acta Paediatrica Taiwan 2006

ABSTRACT

   The prevalence of allergic diseases is increasing gradually. Exposure to allergens is one of the trigger factors for symptoms in sensitized individuals. House dust mites and cockroach are the two most common indoor aeroallergens in Taiwan. There are wide differences in the numbers in different locations and in different seasons of these allergens. Sensitization to food allergens is prominent in young infants and can predict further aeroallergen sensitization. However, whether early exposure to allergens might develop or prevent allergic diseases in later childhood requires further research. Up to the present, allergen avoidance has demonstrated no prominent clinical efficacy in the improvement of allergic symptoms, although it is able to reduce allergen load in the environment. In a clinical regard, allergen avoidance should still be included as a part of treatment plans and be well explained to patients.

 


Survey of asthma care in Taiwan: a comparison of asthma specialists and general practitioners

Kuo-Wei Yeh; Sue-Hsien Chen; Li-Chi Chiang; Li-Chen Chen; and

Jing-Long Huang

 

Published in Ann Allergy Asthma Immunol. 2006;96:593¡V599.

 

Background: Asthma is a common disease in Taiwan. The promotion of quality care for asthmatic patients should focus not only on new treatment remedies but also on patient adherence to treatment and a continuous education program integrated into

treatment plans. One reason for patients¡¦ poor response to treatment is the lack of asthma knowledge on the part of physicians in terms of attitudes toward treatment.

Objective: To investigate the current status of asthma treatment among asthma specialists and general practitioners and their relative acceptance of and adherence to treatment guidelines.

Methods: One thousand questionnaires were distributed to physicians throughout Taiwan using a randomized sampling procedure. The questionnaire asked about the use of different kinds of medications, including inhaled corticosteroids, to treat asthma; adherence to asthma treatment guidelines; the use of a peak flow meter for monitoring asthma status; and self-efficacy in the treatment of asthma.

Results: A total of 526 questionnaires were returned. Of these, 90.4% of specialists and 63.2% of general practitioners would follow the guidelines for patient care (P< .002). It was significant that 79.8% of specialists but only 41.9% of general practitioners would instruct patients to use a peak flow meter to monitor symptoms (P < .001). Asthma specialists also seemed to be significantly more competent than general practitioners regarding asthma knowledge, instruction of inhalation techniques, use of peak flow meters to monitor symptoms, and making an action plan.

Conclusions: To minimize the knowledge gap between specialists and general practitioners regarding asthma treatment, recognized treatment guidelines need to be popularized or simplified. Furthermore, the continuing education of general practitioners in asthma knowledge and management skills is important.


¡@

 

¡@

¡@
¡@
¡@